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Chapter 1: General introduction to endocrine and metabolic features of 
familial longevity: the Leiden Longevity Study 
Maarten P. Rozing1,3, P. Eline Slagboom2,3, Rudi G.J. Westendorp1,3, Diana van Heemst1,3, on 
behalf of the Leiden Longevity Study (LLS) Group  
From the  1Department of Gerontology and Geriatrics, 2Department of Medical Statistics, section 
Molecular Epidemiology, Department of Medical Statistics, Leiden University Medical Center, 





World life expectancy has rapidly increased over the last two centuries, from roughly 25 years to 
about 65 years for males and 70 years for females 1. Before 1950, the improvement in life 
expectancy was achieved through reductions in mortality at younger ages 2. However, in the 
second half of the 20th century this improvement was mainly due to a gain in life-expectancy at 
older ages 3. Unfortunately, not all of the gained years of life are spent in good health. Currently 
extensive research in both model organisms and humans focuses at identifying the genetically 
determined pathways and mechanisms of healthy longevity. Understanding the role of these 
pathways and mechanisms in longevity might eventually reveal targets for interventions to 
prevent aging-related loss of function and disease4.  
 
Various attempts have been made to identify genetic markers of the regulatory pathways that 
underlie human longevity. As yet, the results of these studies are hindered by an increase of 
genome diversity when extrapolating results from experimental models to men, hampered by the 
critical dependency on the environmental conditions in which the genes are expressed, and biased 
by the absence of a valid control group when studying exceptionally long-lived individuals. In 
search for the biology of healthy longevity, and to circumvent the methodological problems 
mentioned above, we set off to study the phenotypes of exceptionally long-lived families in the 
Leiden Longevity Study. Substantial evidence supports the familial clustering of exceptional 
longevity. The existence of families showing aggregation of this long-lived phenotype implies a 
genetic basis 5-7.  In this overview, we report on the endocrine and metabolic characteristics that 
appear to be pertinent for familial healthy longevity.  
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Leiden Longevity Study  
Studies into determinants of human longevity commonly compare age groups of unrelated 
individuals. These so-called cross-sectional designs are particularly prone to confounding as cases 
and controls originate from different birth cohorts. An alternative design is to study multiple 
generations from long-lived families. This study design has been applied to both centenarians or 
nonagenarians and their middle aged offspring, i.e. the New England Centenarian Study 8 and the 
Ashkenazi Jewish Centenarian Study 9, and more recently to nonagenarian sibling pairs and their 
middle aged offspring, Leiden Longevity Study 10.  
 
The study design of the Leiden Longevity Study is depicted in figure 1. Families were eligible for 
participation if two or more long-lived siblings were alive who met the age criteria of 89 years or 
over for males and 91 years or over for females. Along with the long-lived siblings, their 
offspring and partners thereof were enrolled. In total 944 long-lived siblings participated with a 
mean age of 93 years (ranging from 89 to103 years), 1671 offspring (mean age of 59 years, range: 
34-80 years) and 744 partners (mean age 59 years, range: 30-79 years).  
 
Figure 1. Study design 
of the Leiden 
Longevity Study. Black 
symbols denote 
siblings eligible for 
inclusion based on 










Our study design allowed for three approaches to identify longevity-associated phenotypes and 
underlying genotypes. First, we compared the group of familial nonagenarians with a group of 
sporadic nonagenarians (not selected on having nonagenarian siblings) from the Leiden 85-plus 
Study to distinguish between markers for familial longevity and markers for sporadic longevity. 
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Secondly, the offspring from long-lived individuals were compared to their middle aged partners 
as controls from the general population. Postulating that longevity-enabling genes are transmitted 
across generations, the offspring of long-lived nonagenarians represent cases predisposed for 
longevity, while their partners provided an appropriate control group. Finally, we calculated a 
family mortality history score which describes the mortality of the parents of the nonagenarian 
siblings compared to their birth cohort 11. We thereby reasoned that in nonagenarian siblings from 
parents with a lower family mortality history score, indicating a lower than average mortality, 
traits related to longevity would be more pronounced than in nonagenarian siblings from parents 
with a higher family mortality history score.  
 
The Leiden 85 Plus Study 
In the Leiden 85-plus Study, a prospective, population-based study of all individuals 85 years old 
(birth cohort 1912–1914) living in Leiden, the Netherlands, 599 subjects were enrolled between 
September 1997 and September 1999. Of the Leiden 85-plus cohort, 275 subjects survived to the 
age of 90 years.  
 
Outline of this thesis 
The first part of this thesis, part A, discusses the endocrine and metabolic characteristics of long-
lived families as observed in the Longevity Study. In chapter two we investigate two critical 
indicators of aging retardation. We compare the (late life) risk of mortality of nonagenarian 
siblings with that of sporadic nonagenarians as population based controls. Further, we determine 
the prevalence of morbidity in their offspring as compared to their partners. The following three 
chapters address the role of insulin sensitivity and glucose regulation in familial longevity. In 
chapter three we firstly compare the prevalence of metabolic syndrome and its individual risk 
components between offspring of nonagenarian siblings and their partners. Secondly, we explore 
differences in glucose metabolism between offspring and partners by performing an oral glucose 
tolerance test. To compare tissue specific insulin action between offspring of long-lived siblings 
and controls, a double tracer, 2-step hyperinsulinaemic euglycaemic clamp was performed. 
Results of this experiment are given in chapter four. In chapter five we investigate the relation 
between low grade inflammation and glucose regulation in the two groups. Closely related to 
insulin sensitivity, is the IGF-1 signaling pathway. In chapter six and seven hallmark phenotypes 
of the IGF-1 signaling pathway (height and serum IGF-1 axis parameters) are presented for 
middle aged offspring and the nonagenarian siblings respectively. Another endocrine system 
implicated in modulating the aging process is the hypothalamo–pituitary–thyroid axis. This topic 
is treated in chapter eight to ten. Chapter eight and nine include the study of serum thyroid 
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hormone parameters in middle-aged offspring and nonagenarian siblings. Chapter ten explores a 
mutual relation between peripheral thyroid hormones and immune function in the Leiden 85-plus 
Study. Chapter eleven gives an overview of the main findings presented in this thesis and 
discusses their relation to the current state of the field of longevity research.  
 
The second part of this thesis, part B, includes a critical appraisal of the definition of the rate of 
senescence.  Classic inference from the Gompertz law of aging has lead to the conclusion that the 
rate of senescence is unaffected by environmental conditions. In chapter twelve we propose an 
alternative method for assessment of the rate of senescence. In chapter thirteen we will 
empirically test this novel approach in a population of renal patients, a population known to 
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Chapter 2: Nonagenarian siblings and their offspring display lower risk of 
mortality and morbidity than sporadic nonagenarians: The Leiden 
Longevity Study 
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Abstract 
The aim of this study was to assess the risk of mortality of nonagenarian siblings compared to 
sporadic nonagenarians and to asses the prevalence of morbidity in the offspring compared to the 
partners thereof. We recruited 991 nonagenarian siblings derived from 420 Caucasian families, 
1365 of their offspring and 621 of the partners thereof. In the Leiden 85-plus Study, 599 subjects 
aged 85 years were included of which 275 attained the age of 90 years (sporadic nonagenarians). 
All nonagenarians siblings (2.7 ± 1.4 years, mean ± SD) and sporadic nonagenarians (3.0 ± 1.5 
years) were followed for mortality. Information on medical history and medication use was 
collected for offspring and their partners. Nonagenarian siblings displayed a 41% lower risk of 
mortality (p<0.001) compared to sporadic nonagenarians. Compared to their partners, the 
offspring of nonagenarian siblings displayed a lower prevalence of myocardial infarction (2.4% 
vs. 4.1%, p=0.03), hypertension (23.0% vs. 27.5%, p=0.01), diabetes mellitus (4.4% vs. 7.6%, 
p=0.004) and use of cardio-vascular medication (23.0% vs. 28.9%, p=0.003).  
The lower mortality rate of nonagenarian siblings and lower prevalence of morbidity in their 
middle-aged offspring reinforce the notion that resilience against disease and death have similar 
underlying biology that is determined by genetic or familial factors.  
Mortality and morbidity 
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Introduction 
In Western societies, life expectancy has increased dramatically over the last century, but striking 
inter-individual differences in life expectancy remain 1. Moreover, although rare examples of 
exceptional healthy longevity do exist, generally not all of the years that have been gained are 
spent in good health. Ample evidence has shown that healthy longevity is determined by a mix of 
genetic, environmental and chance elements. An increasing effort is currently being put in 
identifying the genetically determined pathways and mechanisms of healthy longevity in humans, 
as these might provide targets for specific interventions aimed at preservation of disease-free 
longevity.  
 
The contribution of genetic factors to healthy longevity has been estimated to be rather modest 
(approximately 20-30%), but was shown to become increasingly important 2 and specific 3 at 
advanced ages. Studies aimed at understanding the genetics of human longevity have thus far 
preferentially studied the elite of exceptional longevity, such as centenarians or the even more 
elite "supercentenarians" that survive 110-plus years. In these studies, it was shown that 
compared to offspring of parents who had died at average age, offspring of centenarians displayed 
a lower prevalence 4 and incidence 5 of in particular cardiovascular disease (including 
hypertension and diabetes mellitus), as well as a later onset of these diseases 6 translating in a 
lower mortality risk 7. Centenarians were also shown to have a healthier lifestyle compared to 
control groups, and may have transmitted part of these habits to their offspring 8. These results 
raise the question how much of the enhanced survival and health in elite cases of exceptional 
longevity is determined by either genetic or lifestyle factors. Comparable to the risk of developing 
common and rare diseases, such as breast cancer or hypercholesterolemia, the odds of exceptional 
longevity also runs in families 9. 
 
We aim at identifying genetic determinants of healthy longevity in nonagenarians siblings 
enriched for heritable influences on morbidity and mortality. Therefore, we designed the Leiden 
Longevity Study in which we specifically recruited families based on proband siblings that both 
exhibit exceptional longevity 9 instead of the recruitment of families based on sporadic proband 
cases of exceptional longevity 10, 11. Here, we compare the mortality risk of 991 nonagenarian 
siblings to that of 275 sporadic nonagenarians. Next, we assess disease prevalence in the 
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Materials and methods 
Leiden Longevity Study 
In the Leiden Longevity Study, 420 families were recruited consisting of long-lived Caucasian 
siblings together with their offspring and the partners thereof 9. In the Netherlands, there is no 
central registry of longevity. In 2002, only 0.5% the Dutch population was aged 89 years or older 
for males and 91 years or older for females. Long-living siblings fulfilling these age-criteria are 
even more rare and estimated to represent far less than 0.1% of the Dutch population. To recruit 
as much as possible long-living siblings within a fixed time window (July 2002-May 2006), we 
used the following strategy. A randomly chosen 80% (398 out of 496) of the municipalities in the 
Netherlands were approached and asked for the following information: names and addresses of all 
inhabitants aged 89 years or older for males and 91 years or older for females, as well as the 
names and birth dates of their parents. We received the requested information from 375 of the 398 
municipalities. Next, by matching the inhabitants thus identified on the names and birth dates of 
both of their parents by means of a computer algorithm, we identified 2193 potential 
nonagenarian siblings. Approximately 1650 nonagenarian siblings were contacted and 991 
nonagenarian siblings derived from 420 families of Caucasian descent agreed to participate and 
donate a blood sample (participation rate: app. 60%). Within the same time window, for each 
nonagenarian included in the Leiden Longevity Study, we also approached the offspring and the 
partners thereof for case control studies. Of the electable offspring cohort (n=2847), 1705 agreed 
to participate and donate a blood sample (participation rate: 60%) and of the app.1306 partners 
thereof, 760 agreed to participate and donate a blood sample (participation rate: app. 58%). There 
were no selection criteria on health or demographic characteristics. For all subjects, blood 
samples were taken at baseline for extraction of DNA, RNA and the determination of non-fasted 
serum and plasma parameters. Between November 2006 and May 2008, we collected additional 
information and biomaterials from the generation of offspring and partners, including self-
reported information on life style, bodily measures, socio-economic status, perceived health, 
physical activity, number of children and dietary intake. Information on medical history was 
requested from the participants’ treating physicians and information on medication use was 
requested from the participants’ pharmacist. The Medical Ethical Committee of the Leiden 
University Medical Centre approved the study and informed consent was obtained from all 
subjects. 
 
The Leiden 85-plus Study 
In the Leiden 85-Plus Study, a prospective, population-based study of all individuals aged 85 
years (birth cohort 1912-1914) and living in Leiden, the Netherlands, 599 subjects were enrolled 
between September 1997 and September 1999 12. Of the Leiden 85-plus cohort, 275 subjects 
Mortality and morbidity 
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survived to the age of 90 years. The Medical Ethical Committee of the Leiden University Medical 
Centre approved the study and informed consent was obtained from all subjects. 
  
Statistical analysis 
Distributions of continuous variables were examined for normality and logarithmically 
transformed, when appropriate. Geometric means (with 95% confidence intervals (CI)) are 
reported for transformed variables. All differences between offspring and partner categories were 
assessed with the use of linear regression, adjusted for sex, age, and correlation of sibling data 
using robust standard errors. Mortality analyses were performed with a sex-adjusted, left censored 
Cox proportional hazards model, to correct for late entry into the data set according to age. The 
Statistical Package for the Social Sciences (SPSS) program for Windows, version 14.0, and 
STATA version 10.0 were used for data analysis. 
 
Results 
Enrolment and baseline characteristics of participants 
We previously recruited 420 families, consisting of 991 long-lived Caucasian siblings together 
with their offspring and the partners thereof in the Leiden Longevity Study. For 2465 of the 
offspring and their partners, non-fasted serum samples taken at baseline were available for the 
determination of endocrine and metabolic parameters. Between November 2006 and May 2008, 
for 2235 of the offspring and their partners, information on medical history was obtained from the 
participants’ treating physicians (response: 90.7%). For 2255 of the offspring and their partners, 
information on the use of medication was obtained from the participants’ pharmacist (response: 
91.5%). For the present study, for a total of 1986 of the offspring and their partners, information 
on medical history and information on medication use were available (inclusion: 80.4%). Based 
on self-reported information from questionnaires, the offspring and partners did not differ for any 
major indicators of lifestyle, including current smoking (13.7% versus 15.6%, p=0.24), self-
reported body mass index (BMI) (25.4 versus 25.6, p=0.26) and level of education (low level; 
43.0 % versus 45.9 %, p=0.16; moderate level: 22.5 % versus 22.9 %, p=0.87; high level: 34.5 % 
versus 31.2 %; p=0.10). 
 
Mortality characteristics of the long-lived siblings 
After a mean (± standard deviation (SD)) follow-up of 2.65 (± 1.37) years, 43.1% of the 
nonagenarians with the familial longevity phenotype from the Leiden Longevity Study had died, 
while after a mean (SD) follow-up of 3.04 (± 1.51) years, 62.2 % of the nonagenarians with the 
sporadic longevity phenotype had died. At old age, the nonagenarian siblings displayed a 0.59 
Chapter 2  
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(95% Confidence Interval (CI): 0.45-0.71, p<0.001, table 1 and figure 1) lower mortality risk 
compared to sporadic nonagenarians. 
 
Table 1. Old age mortality in familial nonagenarians compared to sporadic nonagenarians 
  




Demographics   
  Age, median (IQR)* 90 (90.0-90.0) 93.4 (91.5-94.9) 
  Females, No. (%) 199 (72.4%) 619 (62.5%) 
   
Mortality   
  HR (95% CI)† 1 (ref) 0.59 (0.46-0.71) 
*Age is presented as median with interquartile range.  
†Mortality risk is presented as hazard ratio (HR) with 95% confidence interval (CI). 
  
Disease, medication use and anthropometric and metabolic characteristics in offspring and 
partners 
In the group of 1986 subjects (table 2), a significantly lower disease prevalence was observed in 
the offspring compared to their partners for myocardial infarction (2.4% vs. 4.1%, p=0.03), 
hypertension (23.0% vs. 27.5%, p=0.01), diabetes mellitus (4.4% vs. 7.6%, p=0.004) and use of 
cardio-vascular medication (23.0% vs. 28.9%, p=0.003), including glucose lowering agents, anti-
hypertensives and lipid lowering agents, but not anti-platelet agents (table 2).  
 
Discussion 
The majority of studies into human longevity have thus far focused on centenarians. Here, we 
show that selection for nonagenarian siblings leads to the inclusion of families that exhibit lower 
mortality rate at high ages and a better preservation of health at middle age compared to groups of 
age- and sex-matched controls. This observation indicates that resilience against disease and 
death may have similar underlying biological mechanisms that are influenced by genetic/familial 
factors.  
Mortality and morbidity 
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Table 2. Comparison of demographics, prevalence of disease and medication use between offspring 
and partners for males and females combined (n=1986) 
 
 Offspring 
(n = 1365) 
Partners 
(n = 621) 
P-value 
Demographics    
   Age – yr 59.19 (54.97 - 64.02) 58.88 (54.31 - 63.63) 0.06 
   Females – no. (%) 732 (53.6) 354 (57.0) 0.16 
    
Prevalence of disease    
   Myocardial infarction – no. (%) 32 (2.4) 25 (4.1) 0.03 
   Stroke – no. (%) 47 (3.5) 19 (3.1) 0.87 
   Hypertension – no. (%) 307 (22.9) 168 (27.6) 0.009 
   Diabetes mellitus – no. (%) 59 (4.4) 46 (7.6) 0.004 
   Malignancies – no. (%) 115 (8.5) 44 (7.2) 0.43 
   Chronic obstructive pulmonary disease – no. (%) 49 (3.6) 25 (4.1) 0.50 
   Rheumatoid arthritis – no. (%) 21 (1.6) 4 (0.7) 0.06 
    
Medication use    
   Cardiovascular medication – no. (%) 316 (23.2) 180 (29.0) 0.004 
      -Glucose lowering agents – no.(%)  23 (1.7) 22 (3.5) 0.02 
      -Antihypertensive agents – no. (%)  223 (16.3) 142 (22.9) <0.001 
      -Lipid lowering agents – no. (%) 107 (7.8) 69 (11.1) 0.01 
      -Acetylsalicylic acid – no. (%) 69 (5.1) 37 (6.0) 0.22 
   Thyroid medication – no. (%) 37 (2.7) 15 (2.4) 0.62 
   Growth hormone – no. (%) 0 (0.0) 0 (0.0) - 
P-values were calculated using a linear regression model, adjusted for age and sex. Age is presented as 
median with interquartile range. Diabetes mellitus is defined as reported by the general practitioner. 
Glucose lowering agents are defined as insulins and analogues, oral blood glucose lowering drugs. 
Antihypertensive agents are defined as diuretics, beta blocking agents, calcium channel blockers, agents 
acting on the renin-angiotensin system. Lipid lowering agents are defined as fibrates, niacin, bile acid 
sequestrants, HMG-COA reductase inhibitors. Thyroid medication is defined as thyroid hormones, anti-
thyroid preparations, iodine therapy. 
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Previously 9, we showed that standardized mortality ratios compared with the general Dutch 
population were app. 30% lower for all first degree family members of the proband siblings from 
the first 100 families that were included in the Leiden Longevity Study. Here, we extend those 
findings by showing that the survival benefit observed earlier is maintained up to the highest age 
categories (89-104 years) in the complete cohort of nonagenarian siblings (derived from 420 
families) as compared to the survival of sporadic nonagenarians from the Leiden 85-plus Study 
using prospective survival analysis. This result is in line with that of another study, showing that 
the survival advantage of siblings of centenarians persists into the highest age categories 2, 13. In 
the first phase of life siblings share many environmental factors, including socioeconomic status, 
life styles and region of residence, but these are likely to diverge as they grow older. Because the 
influence of genetic factors has been shown to become increasingly important at advanced ages, 
the observation that the survival advantage extends up to the highest age category (89-104 years 
in the nonagenarian siblings), strongly suggests that genetic factors could play a role in longevity 
in these families. 
 
 
Figure 1. Cumulative mortality 
from age 90 through age 95 
among familial nonagenarians 
(n=991) and sporadic 
nonagenarians (n=275) for 
males and females combined. 
Solid line indicates familial 






Previous studies have shown that the offspring of centenarians as well as offspring from one or 
two parents who survived to the age of 85 years have a lower prevalence of diseases when 
compared to control subjects from the same birth cohort whose parents died at younger ages 6. 
However, when comparing offspring from one or two parents who survived to ‘old’ age to 
offspring of parents who died at ‘young’ age, significant differences were observed in major 
cardiovascular risk factors between these groups, including years of education and current 
smoking, which complicates disentangling the precise contribution of genetic, behavioral and 
Mortality and morbidity 
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lifestyle factors to the observed longevity phenotype.14 Likewise, centenarians were also shown to 
generally avoid bad lifestyle habits, and their offspring may have copied their behavior 8.  
 
As a strategy to minimize the potential confounding effects of differences in (adult) environment, 
we 9 have deliberately chosen to compare offspring from long-lived cases  to their partners. 
Although the amount of cohabitation may have been variable, the lack of differences between 
these two groups in major indicators of lifestyle, including estimates for body mass index, current 
smoking, and prevalence of COPD, a smoking related disease, may be explained by the shared 
adult environment of the couples.  
 
The decreased prevalence of myocardial infarctions, diabetes mellitus and hypertension in the 
offspring of nonagenarian siblings as compared to their partners is thus more likely to be due to 
genetic influences rather than environmental differences between the two groups. This result is in 
line with those of another study, in which significant lower prevalence was observed for diabetes 
mellitus and myocardial infarction in 180 offspring from Ashkenazi Jewish centenarians as 
compared to 75 of their partners in the absence of differences in BMI and percentage of body fat 
between these two groups 10.  
 
In conclusion, by recruiting nonagenarian siblings in the Leiden Longevity Study the current 
study was enriched for subjects with a familial predisposition for longevity. Early features of 
healthy longevity appear already at middle age in these families, setting the stage for further 
analyses on how to live healthier for longer. Future research in this study population will focus on 
unraveling the genetic determinants and biochemical pathways and mechanisms that contribute to 
healthy longevity, as these might provide targets for specific interventions aimed at preservation 
of disease-free longevity in the population at large.  
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The involvement of the insulin/IGF-1 signaling pathway in the regulation of lifespan has been 
demonstrated in numerous model organisms. It has been suggested that insulin sensitivity is at 
play in human longevity as well. The aim of this study was to explore measures of glucose 
metabolism in families with exceptional longevity. Therefore, we performed an oral glucose 
tolerance test in a group of 121 offspring of nonagenarian siblings, who were enriched for 
familial factors promoting longevity, in comparison to a group of 113 of their partners. All 
subjects were non-diabetics and body composition was similar between the two groups. The 
group of offspring had a lower prevalence of metabolic syndrome (p=0.031), similar body 
composition and lower mean fasting blood glucose levels (4.99 vs. 5.16 mmol/L; P = 0.010), 
lower mean fasting insulin levels (5.81 vs. 6.75 mU/L; P = 0.039), a higher mean homeostasis 
model assessment of insulin sensitivity (HOMA of 0.78 vs. 0.65, P = 0.018) and a more favorable 
glucose tolerance (mean area under the curve for glucose (13.2 vs. 14.3; P = 0.007) when 
compared to the group of their partners.  No significant differences were observed between the 
group of offspring and their partners in beta cell function (insulinogenic index of 13.6 vs. 12.5; 
P = 0.38). Our findings imply that a preserved glucose tolerance and insulin action is already 
present at middle-age in offspring of familial nonagenarians. 
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Introduction 
Healthy longevity is determined by a mix of genetic, environmental and chance elements. An 
increasing effort is currently being put in identifying the genetically determined pathways and 
mechanisms of healthy longevity in humans, as these might provide targets for specific 
interventions aimed at preservation of disease-free longevity. Of the genetically determined 
pathways that have been implicated in longevity in model organisms, the evolutionary conserved 
insulin/insulin-like growth factor-1 signaling (IIS) pathway clearly stands out in current literature. 
Mutations in the insulin/IGF-1 signaling pathway have been associated with longevity in a variety 
of model organisms, including nematodes, flies, and rodents 1-9. In mammals, a hallmark 
phenotype shared by many of the long-lived mutants 10, including those with genetically induced 
insulin-like growth factor-1 (IGF-1) resistance is their preserved insulin sensitivity and/or their 
low fasting blood glucose concentrations. Strikingly, preserved insulin sensitivity/glucoregulation 
is also intimately associated with the dietary restriction mediated decreased mortality recently 
observed in non-human primates 11.  
 
Recently, we found that the offspring of familial nonagenarians showed a lower prevalence of 
myocardial infarction, hypertension and diabetes, suggesting that they are protected against the 
combination of cardio-vascular risk factors that constitute the metabolic syndrome12. Current 
estimates suggest that the population-attributable fraction for the metabolic syndrome is 
approximately 6-7% for all-cause mortality, 12-17% for cardiovascular disease, and 30-52% for 
diabetes 13. It is unclear which of the risk factors that constitute the metabolic syndrome 
contributes most strongly to these effects, although it had been suggested that either body mass 
index (BMI) or insulin sensitivity might play such a major role 13, 14.  
Previous reports have shown that the offspring of centenarians had a moderately lower prevalence 
of metabolic syndrome 15. Moreover, it has been reported that centenarians showed a preserved 
insulin sensitivity, comparable to that of healthy young subjects 16. 
However, comparative cross-sectional studies involving long-lived subjects are hampered by the 
lack of proper controls, making it difficult to disentangle the precise contribution of genetic and 
lifestyle factors to the observed phenotype. We designed the Leiden Longevity Study in order to 
identify genetic determinants of healthy longevity in nonagenarian siblings and their offspring, 
which are enriched for heritable influences on morbidity and mortality 17. In the Leiden Longevity 
Study, we included 420 families based on proband siblings that both exhibit exceptional 
longevity. We also included the middle-aged offspring of the nonagenarian siblings and the 
partners thereof. Recently, we found that compared to their partners, the offspring of 
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nonagenarian siblings had  a lower prevalence of myocardial infarction, hypertension and 
diabetes 18 as well as lower non-fasting serum glucose levels 19. As the offspring and their 
partners by and large share the same environment, it is unlikely that the observed differences 
between offspring and partners were confounded by environmental factors. For example, the 
prevalence of Chronic Obstructive Pulmonary Disease (COPD), which is almost entirely caused 
by behavioral factors, was similar among both groups.  
The purpose of this study is twofold. First, to compare the prevalence of metabolic syndrome and 
its individual risk components between offspring of nonagenarian siblings and their partners. 
Secondly, to further explore the differences in glucose metabolism between offspring of 
nonagenarian siblings and their partners. For the latter, oral glucose tolerance was compared 
between a group of offspring of nonagenarian siblings and their partners, after exclusion of 
diabetes patients. 
 
Materials and methods 
The Leiden Longevity Study 
The recruitment of 420 families in the Leiden Longevity Study has been described before 17. 
Families were recruited if at least two long lived siblings were alive and fulfilled the age-criterion 
of 89 years or older for males and 91 year or older for females. There were no selection criteria 
on health or demographic characteristics. For 2465 of the offspring of long-lived siblings and 
their partners, non-fasting serum samples were taken at baseline for the determination of 
endocrine and metabolic parameters. Additional information was collected from the generation of 
offspring and partners, including self-reported information on life style, information on medical 
history from the participants’ treating physicians and information on medication use from the 
participants’ pharmacists.  
 
For the present study, a subgroup of 190 middle-age couples, living in close proximity to the 
Research Center (traveling distance less than 45 minutes by car) were invited to come fasted to 
the research Center. Of these, 137 middle-aged couples, each consisting of an offspring of a 
nonagenarian sibling and the partner thereof, agreed to participate.  Of the 137 offspring, two 
participants were excluded because of current use of glucose lowering agents, nine participants 
because of a previous history of diabetes mellitus and five because of unreliable oral glucose 
tolerance test results. Of the 137 partners, six participants were excluded because of current use of 
glucose lowering agents, seven because of a previous history of diabetes mellitus, ten because of 
unreliable oral glucose tolerance test results and one because of non-compliance to the fasting 
Glucose tolerance and metabolic syndrome 
31 
state. The Medical Ethical Committee of the Leiden University Medical Centre approved the 
study and informed consent was obtained from all subjects. 
 
Anthropometric measurements 
Waist circumference was measured halfway between the lower costal margin and the iliac crest 
with subjects in standing position. Hip circumference was measured at the level of the great 
trochanters. Body composition was determined by a bioelectrical impedance analysis. Measures 
of blood pressure, heart rate and temperature were taken at two occasions and averaged for 
analysis. Glucose tolerance was assessed by a two hour oral glucose tolerance test, conducted 
with a standard loading dose of 75g glucose/300 ml water, and venous blood samples drawn at 
time points of zero, 30, 60 and 120 minutes after glucose loading. Data on frequency, intensity 
and duration of exercise were obtained using the International Physical Activity Questionnaire 
(Ipaq).20 Data were available for only 85 offspring (70.2%) and 80 partners (70.8%). 
 
Biochemical analysis 
All serum measurements were performed with fully automated equipment. For insulin the 
Immulite 2500 from DPC (Los Angeles, CA, USA) was applied. The coefficient of variation 
(CV) for this measurement was below 8%. For glucose, total cholesterol, high-density lipoprotein 
(HDL)-cholesterol, triglycerides, the Hitachi Modular P 800 from Roche, Almere, the 
Netherlands was applied. CV’s of these measurements were below 5 %. For low-density 
lipoprotein (LDL)-cholesterol the Friedewald formula was applied.  
 
Definitions 
Metabolic syndrome was defined according to the criteria of the Third Report of the National 
Cholesterol Education Program:21 Waist > 102 cm (males), waist > 88 cm (females), Triglyceride 
≥ 1.69 mmol/L, HDL cholesterol <1.04 mmol/L (men) or < 1.29 mmol/L (women), Fasting 
glucose ≥ 6.1 mmol, Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 85 or 
treated hypertensive. 
 
Areas under the curves obtained in the oral glucose tolerance test were calculated by the trapezoid 
rule; the homeostasis model assessment (HOMA) of insulin sensitivity was calculated by dividing 
22.5 by the product of the fasting plasma insulin level (in mU/L) and the fasting plasma glucose 
level (in mmol/L) 22. Insulinogenic index was calculated as the ∆ 30, 0 minutes insulin (mU/L) divided 






Distributions of continuous variables were examined for normality and logarithmically 
transformed when appropriate and used in all calculations. Geometric means (with 95% 
confidence intervals (CI)) are reported for transformed variables (serum insulin levels, area under 
the curve for insulin and insulinogenic index). Differences between offspring and partner 
categories were assessed with the use of linear mixed models or with logistic regression, adjusted 
for age and body mass index and correlation of sibling relationship. Differences in age between 
the group of offspring and partners were tested using a Mann-Whitney rank sum test. Differences 
in smoking behavior and sex distribution between the group of offspring and partners were 
calculated using a Chi-square test. The Statistical Package for the Social Sciences (SPSS) 
program for Windows, version 16.0 or STATA, version 10.1 were used for data analysis.  
 
Results 
Table 1 displays the baseline characteristics of the study populations after exclusion of diabetic 
participants (see methods section). In total 121 offspring and 113 partners were included in the 
study. The offspring group was slightly yet non-significantly older than the group of partners 
(median age of 63.9 years and 62.2 respectively; p = 0.33).  Current smoking status was not 
different between the two groups: 11 current smokers (9.2%) in the offspring group versus 12 
current smokers (10.6%) in the partners group (p = 0.83). Body mass index and the percentage of 
body fat were similar between the offspring group and partner group. In the group of offspring we 
observed a lower proportion of subjects using lipid lowering agents than in the group of partners. 
Estimated mean fasting total cholesterol and fasting LDL cholesterol levels were higher in the 
group of offspring than in the group of partners. However, exclusion of subjects using lipid 
lowering agents, diminished the difference in mean fasting total cholesterol and fasting LDL 
levels between offspring and partners. Furthermore, we found that the group of offspring had 
lower levels of fasting glucose, fasting insulin, a lower proportion of subjects using 
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Table 1. Baseline Characteristics of Offspring and Partners  
 
Data are presented as estimated mean value with 95% confidence interval. Results were adjusted for age 
and sex (except age). * Analyses after exclusion of subjects using lipid-lowering agents. P values for 
antihypertensive medication and lipid lowering agents were calculated using a logistic regression model 
adjusted for age and sex. Data on physical activity were available for 85 offspring and 80 partners. HDL: 
high-density lipoprotein; LDL: low-density lipoprotein. 
 
 
 Offspring Partners P-value 
Number participants (N, %) 121 (51.7%) 113 (48.3%)  
Females (N, %) 62 (51.2%) 59 (52.2%)  
Age (year) 63.9 (58.9 – 67.9) 62.2 (58.9 – 67.6) 0.33 
Physical activity (Met-S/ week) 712.6 (569.9 – 891.1) 768.4 (610.5 – 967.2) 0.64 
Smoking 11 (9.2%) 12 (10.6%) 0.83 
Fat percentage 31.0 (29.7 – 32.4) 30.5 (29.1 – 31.9) 0.49 
Body Mass Index (kg/m2)  26.2 (25.5 – 26.9) 26.4 (25.7 – 27.2) 0.62 
Waist (cm.)  97.7 (95.8 – 99.6) 99.2 (97.3 – 101.2) 0.18 
Lipid lowering agents (N, %) 7 (5.8%) 20 (17.7%) 0.004 
Total cholesterol (mmol/L)  5.54 (5.37 – 5.72) 5.14 (4.96 – 5.32) 0.001 
Total cholesterol (mmol/L)* 5.58 (5.41 – 5.75) 5.35 (5.16 – 5.56) 0.067 
Triglycerides (mmol/L) 1.25 (1.15 – 1.36) 1.28 (1.17 – 1.39) 0.74 
Triglycerides (mmol/L)* 1.25 (1.14 – 1.36) 1.27 (1.16 – 1.39) 0.77 
HDL cholesterol (mmol/L)  1.55 (1.48 – 1.63) 1.48 (1.40 – 1.56) 0.17 
HDL cholesterol (mmol/L)* 1.56 (1.48 – 1.64) 1.49 (1.40 – 1.56) 0.19 
LDL cholesterol (mmol/L) 3.37 (3.21 – 3.54) 3.03 (2.86 – 3.20) 0.002 
LDL cholesterol (mmol/L)* 3.40 (3.25 – 3.56) 3.24 (3.06 – 3.41) 0.14 
Fasting glucose (mmol/L) 4.99 (4.89 – 5.08) 5.17 (5.08 – 5.27) 0.006 
Fasting insulin (U/L) 5.61 (4.93 – 6.37) 6.65 (5.84 – 7.59) 0.034 
Antihypertensive medication (N, %) 26 (21.5%) 38 (33.6%) 0.016 
Systolic blood pressure (mm Hg) 138.9 (135.4 – 142.5) 144.5 (140.9 – 148.2) 0.030 
Diastolic blood pressure (mm Hg) 82.9 (81.1 – 84.7) 83.6 (81.7 – 85.5) 0.57 
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Table 2. Number of non-diabetic participants who fulfill metabolic syndrome criteria for offspring 
and partners 
* Waist > 102 cm (males), waist > 88 cm (females), † Triglyceride ≥ 1.69 mmol/L, ‡ HDL cholesterol 
<1.04 mmol/L (men) or < 1.29 mmol/L (women), § Fasting glucose ≥ 6.1 mmol/L,   
¶ Systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥ 85 or treated hypertensive. HDL: 
high-density lipoprotein. 
 
Table 2 shows the prevalence of metabolic syndrome and its individual components for the group 
of offspring and the group of partners. The group of offspring showed a lower prevalence of 
metabolic syndrome than the group of partners (p=0.031). Moreover, in the group of offspring a 
lower proportion of subjects fulfilled the criteria for the glucose component (p=0.019) and the 
HDL component (p=0.017) when compared to the group of partners. In contrast, no differences 
were observed between offspring and partners for obesity related criteria, including waist and 
triglycerides. Figure 1 displays the number of metabolic syndrome components for offspring and 
partners.  
 
Figure 1. Distribution of number of 
metabolic syndrome components 








To determine possible differences in peripheral glucose metabolism and insulin sensitivity 






Metabolic syndrome 25 (20.7%) 36 (31.9%) 0.031 
   Waist* 68 (56.2%) 70 (61.9%) 0.40 
   Triglyceride† 29 (24.0%) 29 (25.7%) 0.73 
   HDL cholesterol‡ 16 (13.2%) 27 (23.9%) 0.017 
   Fasting glucose§ 1 (0.8%) 10 (8.8%) 0.019 
   Blood pressure¶ 83 (68.6%) 86 (76.1%) 0.050 
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test. Results of the oral glucose tolerance test are depicted in figure 2, in which all analyses were 
adjusted for BMI. 
 
Figure 2. Results of oral glucose tolerance test for offspring and partners. Figure 2A depicts serum 
glucose concentrations (mmol/L) for offspring (open circles) and partners (closed circles) for both sexes 
combined at 0. 30. 60 and 120 minutes (min.). Figure 2B depicts log serum insulin concentrations (mU/L) 
for offspring (open circles) and partners (closed circles) for both sexes combined at 0. 30. 60 and 120 
minutes (min.). Data were adjusted for sex, age and body mass index.  * denotes P value < 0.05. ** denotes 
P value < 0.01. 
  
Results of the oral glucose tolerance test are presented in table 3 for the group of offspring and 
the group of partners. In the group of offspring as compared to the group of partners, fasting 
glucose levels were lower (4.99 mmol/L versus 5.16 mmol/L, P = 0.010) and the area under the 
curve for glucose was comparatively smaller (13.2 vs. 14.3; P = 0.007). Likewise, fasting insulin 
levels were lower in the group of offspring compared to the group of partners (5.81 mU/L vs. 
6.75 mU/L; P = 0.039). The area under curve for insulin was non-significantly lower among the 
offspring group versus the partner group (92.1 vs.100.7; P = 0.18). Insulin sensitivity as assessed 
by the homeostasis model was higher among the group of offspring in comparison to the group of 
partners (0.78 vs. 0.65; P = 0.018). No differences were observed between the two groups for the 
insulinogenic index, an approximate measure for the pancreatic β-cell function: 13.6 in the 
offspring group versus 12.5 in the partner group (P = 0.38). These differences between the 
offspring and partner groups were most pronounced in females, while for males a trend towards 
these differences was observed (table 3). All analyses above were adjusted for age and body mass 
index (and in case of all, for sex). Results were not materially different when analyses were 
further adjusted for waist hip ratio, percentage of fat mass, current smoking and physical exercise 




Table 3. Results of Oral Glucose Tolerance Test for Offspring and Partners.  
Data are presented as means with 95% confidence intervals. Results were adjusted for age and body mass 
index, and in the case of all for age and sex. HOMA: homeostasis model assessment. 
 
Discussion 
The purpose of this study was to explore measures metabolic syndrome and differences in 
glucose metabolism among the middle-aged offspring of nonagenarian siblings which are 
enriched for heritable influences on longevity, as compared to the control group of their middle-
aged partners. We found that the group of offspring had a lower prevalence of metabolic 
syndrome as compared to the group of partners. When considering the individual components of 
the metabolic syndrome, the group of offspring showed a lower fraction of subjects fulfilling the 
 Offspring Partners P-value 
All (n) 121 (100%)  113 (100%)   
   Fasting glucose (mmol/L) 4.99 (4.90 – 5.08) 5.16 (5.07 – 5.26) 0.010 
   Area under the curve glucose  13.2 (12.6 – 13.8) 14.3 (13.7 – 14.9) 0.007 
   Fasting insulin levels (mU/L) 5.81 (5.20 - 6.51) 6.75 (6.02 - 7.57) 0.039 
   Area under the curve insulin 92.1 (83.2 - 102.0) 100.7 (90.6 - 111.8) 0.18 
   HOMA-insulin sensitivity 0.78 (0.69 – 0.88) 0.65 (0.58 – 0.74) 0.018 
   Insulinogenic index 13.6 (11.8 – 15.7) 12.5 (10.8 – 14.5) 0.38 
    
Females (n) 62 (51.2%) 59 (52.2%)  
   Fasting glucose (mmol/L) 4.88 (4.76 -  5.01) 5.13 (5.00 - 5.25) 0.007 
   Area under the curve glucose  13.2 (12.4 – 14.0) 14.2 (13.4 – 15.1) 0.069 
   Fasting insulin levels (mU/L) 5.34 (4.55 - 6.28) 7.27 (6.18 - 8.55) 0.007 
   Area under the curve insulin 92.7  (81.1 - 106.1) 107.0 (93.3 - 122.5) 0.13 
   HOMA-insulin sensitivity 0.87 (0.73 – 1.03) 0.61 (0.51 – 0.72) 0.003 
   Insulinogenic index 13.6 (11.5 – 16.2) 13.0 (10.9 – 15.5) 0.73 
    
Males (n) 59 (48.8%) 54 (47.8%)  
   Fasting glucose (mmol/L) 5.09 (4.95 - 5.24) 5.19 (5.04 - 5.34) 0.34 
   Area under the curve glucose  13.3 (12.4 – 14.2) 14.3 (13.4 – 15.3) 0.10 
   Fasting insulin levels (mU/L)  6.42 (5.56 - 7.41) 6.32 (5.44 - 7.34) 0.89 
   Area under the curve insulin 92.4 (79.6 - 107.3) 94.7 (80.8 - 111.0) 0.82 
   HOMA-insulin sensitivity 0.69 (0.59 – 0.81) 0.69 (0.59 – 0.81) 0.97 
    Insulinogenic index 14.4 (11.2 – 18.3) 12.8 (9.84 – 16.6) 0.46 
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criteria for the HDL component and the glucose component but not of obesity related criteria, 
including waist and triglycerides, centralizing the role of glucose metabolism in our findings.  
With respect to glucose metabolism, we found that the group of offspring had lower fasting blood 
glucose concentrations and higher HOMA insulin sensitivity when compared to the group of 
partners thereof. In addition, offspring had a more favorable glucose tolerance than their partners. 
However, beta cell function as measured by the insulinogenic index was similar between the two 
groups. 
 
These data are in accordance with earlier studies showing that the offspring of exceptionally long-
lived individuals are protected against the combination of cardio-vascular risk factors that 
constitute the metabolic syndrome 15. However, while it was shown that offspring of 
exceptionally long-lived individuals are healthier in many parameters, this has not previously 
been shown for glucose tolerance. Data from mammalian models show an association in diverse 
mutants (including those with mutations causing growth hormone/IGF-1 resistance) between 
enhanced lifespan and preserved insulin sensitivity i.e enhanced insulin action. Taken together, 
these findings suggest that in humans as in mammals decreased insulin signaling is not associated 
with exceptional longevity as it is in non-mammalian models. 
 
These findings are a crucial extension of our initial observations of lower non-fasted blood 
glucose levels and the lower prevalence of diabetes in offspring of nonagenarian siblings 
compared to their partners 18, 19. Moreover our findings add to the previous observations of a 
preserved glucose tolerance and insulin action in healthy centenarians 16 by demonstrating that a 
beneficial glucose metabolism is already present at middle-age in offspring of familial 
nonagenarians.  
 
The lower prevalence of metabolic syndrome and better glucose handling in the offspring of 
nonagenarian siblings which we observed in the current study might have contributed to the lower 
prevalence of cardiovascular disease which we reported in an earlier study 18.  Prior research has 
demonstrated advantageous cardiovascular risk profiles in middle-aged individuals with long-
lived parents compared with those whose parents died younger 23, 24, although in this study 
significant differences in lifestyle existed between the groups that were compared, including years 
of education and current smoking, which complicates disentangling the precise contribution of 
genetic and lifestyle factors to the observed longevity phenotype. As a strategy to minimize the 
potential confounding effects of differences in environment, we and others have deliberately 
chosen to compare offspring from long-lived cases to their partners 23, 25.  
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In line with previous findings 26, 27, our data suggest that differences in metabolic syndrome and 
glucose tolerance may result not only from environmental factors but also from genetic factors, 
which are transmitted in families. The lack of difference in the insulinogenic index between the 
offspring and their partners makes pancreatic β-cell function unlikely to account for the beneficial 
glucose tolerance in the offspring. As the offspring and their partners by and large share the same 
environment, it is unlikely that the observed differences between offspring and partners are fully 
explained by environmental conditions. For example, current smoking behavior and levels of 
physical activity were similar in both groups. Likewise, body mass index, an important risk factor 
for the development of insulin resistance was similar among the two groups. In order to identify 
mechanisms which may be involved in the better glucose handling we are planning to perform 
clamp studies in a representative subset of offspring and the partners thereof. 
In conclusion, we observed a lower prevalence of metabolic syndrome and a favorable glucose 
tolerance among the offspring of nonagenarian siblings when compared to their partners. The 
favorable glucose tolerance could not be explained for by differences in body mass index and 
pancreatic β-cell function. Our findings imply that the preserved glucose tolerance and insulin 
action is already present at middle-age in offspring from familial nonagenarians.  
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Chapter 4: Familial longevity is marked by enhanced insulin sensitivity 
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A key question in aging research is whether the extreme effects of altered insulin signaling on 
lifespan observed in model organisms can be translated to humans. We aimed to compare the 
relation between insulin and glucose and tissue specific insulin action between subjects from 
long-lived families and controls. Non-fasted serum data were analyzed in 1838 subjects and a two 
step hyperinsulinemic-euglycemic clamp was performed in 24 subjects, comprising offspring 
from long-lived siblings and their partners. Clamp participants were aged 52-72 years, healthy, 
non-smoking, non-obese, and groups were similar with regard to sex distribution, age, exercise, 
BMI, waist circumference, fat mass, and fasting glucose and insulin levels. Higher glucose 
infusion rate was required to maintain euglycemia during high dose insulin infusion (p = 0.036) in 
offspring from long-lived siblings, reflecting higher whole body insulin sensitivity. After 
adjustment for sex, age and fat mass, the insulin-mediated glucose disposal rate was higher in 
offspring than in controls (42.5 ± 2.7 vs. 33.2 ± 2.7 µmol/kg*min, mean ± SE, p=0.025). The 
capacity of insulin to suppress endogenous glucose production and lipolysis did not differ 
between groups (all p > 0.05). Furthermore, glucose disposal rate was significantly correlated 
with the mean age of death of the parents. In conclusion, subjects from long-lived families are 
marked by enhanced insulin sensitivity and mimic the phenotype found in mammalian models 
with genetic disruption of IGF-1/insulin signal transduction. These observations allow for 




A key question in aging research is whether the extreme effects of altered insulin signaling on 
lifespan observed in model organisms can be translated to humans. The insulin/IGF-1 system, 
which is highly conserved among (in)vertebrate species, adapts metabolism, growth and 
differentiation under various environmental conditions, including nutrient availability1. An 
ancestral gene encodes just one insulin/IGF-1 receptor tyrosine kinase in invertebrates 2, while 
three distinct receptors have evolved in vertebrates to mediate the metabolic and mitogenic effects 
of insulin, IGF-1 and IGF-2: the insulin receptor, the IGF-1 receptor and the insulin related 
receptor1. In addition, the IGF-2 receptor is thought to have evolved primarily as a clearance 
receptor 3. In mammals, the production of IGF-1 is controlled by growth hormone to mediate its 
effects on growth and development. Extreme effects of IGF and insulin signaling on longevity 
were shown in invertebrates (reviewed in 4).  In mammals, enhanced insulin sensitivity is 
prominent in hypopituitary (GH deficient) and GH receptor deleted mice, suggesting that insulin 
sensitivity is a hallmark phenotype of mammalian longevity, at least in these model organisms 5. 
 
In humans, insulin sensitivity declines progressively with age, which significantly contributes to 
the increased incidence of type 2 diabetes mellitus and cardiovascular disease in older people 6, 7. 
A previous study suggested that glucose tolerance and insulin action are preserved in 
centenarians8. We designed the Leiden Longevity Study to examine the underlying biomolecular 
mechanisms of longevity in humans9. To this end we have recruited 421 long-lived families 
consisting of multiple nonagenarian siblings and their offspring (aged 33-81 years) from the 
Dutch population. The partners of the offspring (aged 30-80 years) were included as controls. 
Recently, we showed that the offspring from these families had lower mortality and lower 
prevalence of major age-related diseases, including diabetes10. Random and fasting glucose levels 
were also lower and we showed that glucose tolerance was better in the non-diabetic offspring 
when compared to controls. Offspring and controls did not differ with respect to age, sex 
distribution, body mass index, and lifestyle indices such as the level of physical activity 11.  
 
To test whether the biomolecular mechanisms underlying familial longevity in humans resemble 
those of long-lived animal models in terms of insulin action (i.e. whether it is characterized by 
enhanced insulin sensitivity), here we further explored the relation between insulin and glucose in 
the two groups. To this end, we first compared the relationship between glucose and insulin levels 
as determined in random non-fasted serum samples (n=1838), which include the physiological 
variation in insulin levels in response to everyday challenges, such as meals. Next, we performed 
a double tracer, 2-step hyperinsulinemic euglycemic clamp in two subgroups comprising 12 
healthy offspring from long-lived siblings and 12 partners as control subjects. This gold standard 
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technique allowed us to assess whole-body insulin sensitivity and distinguish between the effects 
of insulin on glucose disposal rate, endogenous glucose production and lipolysis.  
 
Materials and methods 
Subjects 
The Leiden Longevity Study comprises 421 families, as described more extensively elsewhere9. 
Families were recruited if at least two long-lived siblings were alive and fulfilled the age-criterion 
of 89 years or older for males and 91 year or older for females. As no proper controls exist for 
this age group, for further studies the offspring of these long-lived nonagenarians were included. 
This generation carries on average 50% of the genetic advantage of their long-lived parent and 
was shown to have a 35% lower mortality rate compared with their birth cohort. Their partners, 
with whom most have had a relationship for decades, were included as population-based controls. 
Nonfasted serum samples and BMI were available for 1930 subjects. After exclusion of subjects 
with non-fasted glucose levels above 11 mmol/L (indicative of possible diabetes), history of 
diabetes or use of glucose lowering medication, non-fasted serum samples of 1838 subjects were 
available for the current study. 
 
For the hyperinsulinemic euglycemic clamp study, we aimed to include twelve couples, each 
consisting of an offspring from long-lived siblings and his or her current partner as control 
subject. Subjects were selected from the database based on the following inclusion criteria: 
middle-age (50-75 years), residence in close proximity of the research center (less than 45 
minutes by car) and normal body mass index (BMI) (22 kg/m2 < BMI < 30 kg/m2). Eligible 
subjects were screened for the following exclusion criteria: fasting plasma glucose > 6.9 mmol/L 
12, presence of endocrine, renal, hepatic or other significant chronic disease, use of medication 
known to influence lipolysis, glucose metabolism or GH-secretion, recent weight changes or 
attempts to loose weight (> three kg weight change within last three months), smoking, extensive 
sporting activities (> 10 hours/week) and inaccessible peripheral veins for intravenous catheter 
insertion, as assessed by clinical examination and routine laboratory tests. During the screening 
interview, information on age (of death) of the parents was obtained.  
In total, 87 subjects were approached, of which 17 subjects did not fulfill the inclusion criteria 
(19%), 44 subjects refused participation (51%) and 26 subjects agreed to participate in the study 
(30%). Two subjects (one offspring, one control) did not complete the study due to medical 
technical reasons. One of the partners of an offspring also had a long-lived parent with a long-
lived sibling and was therefore included in the offspring group. In total, the group consisted of 24 
subjects, comprising 8 couples and 8 unrelated subjects (4 offspring, 4 controls). The Medical 
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Ethical Committee of the Leiden University Medical Center approved the study and written 
informed consent was obtained from all subjects.  
 
Clinical protocol. 
All clamp studies started at 8:00 AM after an overnight fast. Anthropometric measurements 
(height, weight, waist and hip circumference) and blood pressure measurements were performed 
according to standard methods. Body composition was measured using bioelectrical impedance 
analysis (BIA). In a larger sample of the Leiden Longevity Study, body composition as measured 
with BIA was highly correlated with dual energy X-ray absorptiometry (DEXA) measurements. 
(Ling et al, unpublished) Metabolic studies were performed as described previously13. Subjects 
were requested to lie down on a bed in a semirecumbent position. A polyethylene catheter was 
inserted into an antecubital vein for infusion of test substances. Another catheter was inserted into 
a contralateral dorsal hand vein for blood sampling; this hand was kept in a heated box (60 ˚C) 
throughout the study day to obtain arterialised venous blood samples. Basal samples were taken 
for measurement of glucose, insulin, total cholesterol, high-density lipoprotein (HDL-) 
cholesterol, triglycerides, free fatty acids (FFA), glycerol, and background enrichment of [6,6-
2H2]-glucose and [
2H5]-glycerol. At 08:30 AM (t = 0 min), an adjusted primed (17.6 µmol/kg) 
continuous (0.22 µmol/kg per minute) infusion of [6,6-2H2]-glucose (enrichment 99.9%; 
Cambridge Isotopes, Cambridge, Mass) was started and continued throughout the study. At 09:00 
AM (t=30 min), a primed (1.6 µmol/kg), continuous (0.11 µmol/kg per minute) infusion of [2H5]-
glycerol (Cambridge Isotopes) was started and continued throughout the study. At the end of the 
basal period (t = 90 min), three blood samples were taken at 10 min-intervals for the 
determination of glucose, insulin, glycerol, triglycerides, FFA’s and enrichment of [6,6-2H2]-
glucose and [2H5]-glycerol. Subsequently, a primed continuous infusion of human recombinant 
insulin (Actrapid, Novo Nordisk Pharma BV, Alphen aan de Rijn, The Netherlands; 10 mU/m2 
per minute) was started (t = 120 min) for 2 hours. This low dose insulin infusion was used to 
determine differences in insulin sensitivity of the liver and whole-body lipolysis. Exogenous 
glucose 20% enriched with 3% [6,6-2H2]-glucose was infused at a variable rate to maintain the 
plasma glucose level at 5.0 mmol/L. From t = 210 to t = 240 minutes blood samples were taken at 
10 minute intervals for the determination of [6,6-2H2]-glucose and [
2H5]-glycerol-specific 
activities, glucose, insulin, glycerol, triglycerides and FFA. Next, at t=240, a primed continuous 
infusion of insulin was started at 40 mU/m2 per minute. This second high dose of insulin infusion 
was used to determine whole-body glucose disposal. From t = 330 to t = 360 minutes, blood 
samples were taken at 10 minute intervals for the determination of [6,6-2H2]-glucose and [
2H5]-
glycerol-specific activities, glucose, insulin, glycerol, triglycerides and FFA. Plasma samples 
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were put on ice immediately after withdrawal, and all samples were centrifuged at 1610 x g at 4 
˚C for 20 minutes and stored at -80 ˚C until assay. 
 
Assays 
All serum measurements were performed with fully automated equipment. 
For glucose, cholesterol, HDL-cholesterol, triglycerides and FFA, the Modular P2 analyzer was 
used from Roche (Almere, the Netherlands). Insulin was measured using the Immulite 2500 from 
DPC (Los Angeles, CA, USA). CVs for these measurements were all below 9%.   
[6,6-2H2]-glucose and [
2H5]-glycerol were determined in a single analytical run using gas 
chromatography-mass spectrometry as described previously13. LDL-cholesterol was calculated 
using the Friedewald formula (11).  In case insulin and glycerol values were below threshold for 




An isotopic steady state was achieved during the steady-state and during the last 30 minutes of 
the hyperinsulinemic clamp periods. Therefore, steady-state equations were used to calculate 
tracer infusion rates, according to the modified Steele’s steady state equations 14, 15. The rates of 
appearance (Ra) and disappearance (Rd) for glucose and glycerol were calculated by dividing the 
tracer infusion rate by the tracer-to-tracee ratio.  Glucose disposal rates were expressed in 
µmol/kg body weight per minute. Endogenous glucose production (EGP) during the basal steady 
state and during the hyperinsulinemic state was calculated as the difference between the rates of 
glucose appearance and glucose infusion.  
 
Statistical analyses 
A piece wise change-point model was used to model the relation between glucose and ln(insulin) 
for the two groups (n=1838). Within each group, the expected glucose level for a person at a 
certain level of ln(insulin) were modeled using the formula: predicted 
glucose = α1 + β1 * ln(insulin), for ln(insulin) < gamma and α2 + β2 * ln(insulin), for 
gamma < ln(insulin), with restrictions on α1 and α2 such that the function is continuous in the 
transition point gamma, i.e., (α1 + β1 * gamma) = (α2 + β2 * gamma). Because transition points 
were similar between groups, group differences in slopes before (difbeta1) and after (difbeta2) the 
transition point (gamma) were modeled using the formula: predicted glucose_ = ALPHA+ 
difalpha*partner + (BETA1+difbeta1*partner) * (lnInsuline-gamma)*((lnInsuline-gamma)<0) +   
(BETA2+difbeta2*partner) * (lnInsuline-gamma)*((lnInsuline-gamma)>0). The model was fitted 
using software for nonlinear regression models.  Data are presented as mean with standard 
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deviation (baseline characteristics) or mean with standard error (SE) to assess differences 
between groups. Differences in outcomes between groups as well as the associations of glucose 
disposal rate (GDR) with age of parents were calculated using a linear regression model with 
correction for age, sex and fat mass. Statistical significance was set a p < 0.05. All analyses were 
performed using SPSS version 17.0. 
Results  

























Table 1. Baseline characteristics of baseline cohort 
    
  Offspring (n=1273) Controls (n=565) 
Female gender, n ( %) 692 (54.4) 329 (58.2) 
Age (yr) 59.4 (6.4) 58.7 (7.4) 
BMI (kg/m2) 25.3 (3.4) 25.5 (3.6) 
Glucose (mmol/L) 5.7 (1.1) 5.9 (1.2) 
Ln Insulin (mU/L) 2.7 (0.8) 2.8 (0.8) 
   
Continuous data are presented as means with S.D 
      
Figure 1. Relation between non-fasted insulin and 
glucose values in baseline cohort of the Leiden 




Table 1 shows the baseline characteristic of the baseline cohort (n=1838). Baseline 
characteristics were similar between the offspring and controls. Figure 1 shows the non-fasted 
serum insulin  versus glucose levels for the two groups . For both groups, a biphasic positive 
association was observed between levels of glucose and ln(insulin). Initially slopes were similar 
between groups (0.38 in offspring vs. 0.32 in partners, p=0.73); diverged from ln(insulin)= 2.37 
(corresponding to 10.7 mU/L insulin) onwards, after which slopes were significantly steeper in 
the partners (0.73 in offspring vs. 0.95 in partners, p=0.02). 
  
Baseline characteristics of the hyperinsulinemic-euglycemic clamp study. 
Next, we performed a hyperinsulinemic euglycemic clamp in 24 subjects. Table 2 shows the 
baseline characteristics of the study groups. The group of offspring from long-lived siblings did 
not differ from the control group with respect to any of the baseline characteristics, although the 























Table 2. Baseline characteristics of clamp group 
    
  Offspring (n=12) Controls (n=12) 
Female gender (%) 50.0 50.0 
Age (yr) 62.7 (2.4) 61.2 (5.5) 
Systolic blood pressure (mmHg) 142.5 (20.6) 143.2 (25.0) 
Diastolic blood pressure (mmHg) 86.8 (10.7) 86.2 (11.1) 
Weight (kg) 79.3 (10.3) 80.1 (9.7) 
BMI (kg/m2) 26.0 (2.0) 26.1 (2.3) 
Fat mass (%) 33.0 (7.3) 30.9 (9.7) 
Lean mass (kg) 53.6 (11.5) 53.8 (12.2) 
Waist circumference (cm) 93.0 (10.8) 93.6 (7.7) 
Waist/Hip ratio  0.90 (0.1) 0.89 (0.1) 
Total cholesterol (mmol/L) 6.1 (1.0) 5.9 (0.8) 
HDL-cholesterol (mmol/L) 1.7 (0.4) 1.7 (0.4) 
LDL-cholesterol (mmol/L) 3.9 (0.9) 3.8 (0.7) 
Mean age parents (yr) 88.3 (4.0) 76.6 (8.2) 
Age oldest parent (yr) 97.0 (3.8) 82.3 (10.5) 
      
Continuous data are presented as means with S.D 






Figure 2. A. 
Glucose levels and 
B. glucose infusion 
rates during the 
clamp study. 





groups during the 
last 30 minutes of 
high dose insulin 
infusion (corrected 




Familial longevity associates with higher whole-body glucose metabolism 
A two-step hyperinsulinemic clamp was performed using a low (10 mU/m2/min) and a high (40 
mU/m2/min) insulin dose in the first and second clamp step, respectively. Mean insulin levels 
during the last 30 minutes of the clamp periods were similar between groups, both during low 
dose insulin infusion (11.0 ± 1.0 mU/L in offspring vs. 11.2 ± 1.0 mU/L in controls, p = 0.89 ) 
and during high dose insulin infusion (42.5 ± 2.2  mU/L in offspring vs 38.9 ± 2.2 mU/L in 
controls p = 0.25). Throughout the entire clamp glucose levels remained stable and were similar 
between groups (figure 2a). Figure 2b shows the glucose infusion rates during the clamp. During 
high dose insulin infusion, offspring had significantly higher glucose infusion rates (p = 0.036) 
compared to controls, despite a slightly higher age and fat mass in the offspring. 
 
Familial longevity is characterized by enhanced peripheral insulin sensitivity, but not hepatic 
insulin sensitivity 
Next, we assessed whether the higher glucose infusion rate required to maintain euglycemia in 
offspring was accounted for by increased glucose disposal or by enhanced insulin-mediated 
suppression of endogenous glucose production (table 3, figure 3). At low dose insulin infusion 
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(10 mU/m2/min), the groups did not differ with respect to endogenous glucose production. At 
high dose insulin infusion (40 mU/m2/min), the mean glucose disposal rate was higher in 
offspring than in controls (42.5 ± 2.7 vs. 33.2 ± 2.7 µmol/kg/min, p=0.025). To determine the 
insulin sensitivity of adipose tissue, we assessed the capacity of insulin to suppress the rate of 
glycerol appearance (Ra). At baseline and during both clamp conditions, the Ra of glycerol was 




Table 3. Glucose and fat metabolism in offspring enriched for longevity and controls  under different clamp conditions          
                        
   
  Basal steady 
state       
 Insulin 
(10mU/m2/min)                                                  
  Insulin  
(40 mU/m2/min)   
  Offspring  Controls  p-value   Offspring  Controls  p-value   Offspring  Controls  p-value 
Plasma Glucose (mmol/L) 6.1 (0.1)  5.9 (0.1)  0.27   5.6 (0.1)  5.6 (0.1)  0.69    5.5 (0.1)  5.4 (0.1)  0.64  
Plasma Insulin (mU/L) 5.4 (1.1) 4.7 (1.1) 0.68   10.8 (1.1) 11.5 (1.1) 0.66   41.9 (2.2) 39.5 (2.2) 0.45 
Glucose Rd (µmol/kg/min) 12.9 (0.3) 12.6 (0.3) 0.43   15.5 (1.0) 14.3 (1.0) 0.57   42.5 (2.7) 33.2 (2.7) 0.025 
Clamp EGP (µmol/kg/min) 12.7 (0.3) 12.4 (0.3) 0.57   7.8 (0.3) 7.9 (0.3) 0.85   1.8 (0.3) 2.1 (0.3) 0.36 
Glycerol Ra (µmol/kg/min) 2.1 (0.2) 2.4 (0.2) 0.34   0.9 (0.1) 1.0 (0.1) 0.36   0.6 (0.1) 0.7 (0.1) 0.52 
FFA (mmol/L) 0.60 (0.1)  0.76 (0.1) 0.07    0.14 (0.03) 0.21 (0.03)  0.08     <0.05 (0.005) <0.05 (0.005)  0.94 
Triglycerides (mmol/L)  1.17 (0.2) 1.0 (0.2)  0.49   1.0 (0.2)  0.9 (1.2)  0.52     0.91 (0.2) 0.74 (0.2)  0.49  
             
Glucose Rd = Rate of disappearance of glucose   EGP = Endogenous Glucose Production   Glycerol Ra = Rate of appearance of glycerol   FFA = free fatty acids  




Figure 3. Glucose and fat metabolism in offspring and controls under different clamp conditions; A. 
glucose disposal rate (Rd), B. endogenous glucose production (EGP), C. rate of appearance of glycerol 
(Ra). Results are means with standard error, after adjustment for age, sex and fat mass (%). 
 
Insulin sensitivity correlates positively with the age at death of the subjects’ parents  
The presented results suggest a relation between familial longevity and glucose disposal rate. To 
explore if this association was specific for offspring of long-lived siblings only or of a more 
general nature, we assessed the relationship between parental age (at death or censorship) with the 
glucose disposal rate under high dose insulin infusion in all subjects (figure 4, table 4).  
After adjustment for sex, age and fat mass, we found a positive correlation between the mean age 
of the parents and glucose disposal rate (p = 0.007), and between the age of the oldest parent and 
the glucose disposal rate (p = 0.034). To exclude the possibility that these results were driven by 
the high age of parental death in the offspring group, we repeated the analyses for the control 
group only, and results did not change materially (table 4). Also, excluding subjects with parents 
who were still alive at date of censorship did not change results (data not shown). 
 
Figure 4. A Relation between mean age of both parents (at death or censorship) and glucose disposal 
rate; B. Relation between age of oldest parent only (at death or censorship) and glucose disposal rate. 
Grey circles represent the offspring, black squares represent controls. 
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Table 4. Relation between parental age and glucose disposal rate 
 
β represents increase in glucose disposal rate (µmol/kg/min) per year increase in age of death of the 
parent(s).  
S.E. = standard error. When parents were still alive, current age was used. 
multivariate: adjusted for age, sex and fat mass. p-value obtained using linear regression analysis. 
 
Discussion 
Here, we show that familial longevity in humans is characterized by enhanced peripheral insulin 
sensitivity, i.e. compared to a control group with similar distribution of age, sex and body 
composition, healthy offspring of long-lived siblings had a higher insulin-mediated glucose 
disposal rate. In contrast, the capacity of insulin to suppress endogenous glucose production or 
lipolysis did not differ between the groups. Interestingly, the glucose disposal rate during 
hyperinsulinemia was positively correlated with the age at death of the parents of the entire 
group, suggesting that longevity genes are involved in the control of insulin action in the general 
population.  
 
This is the first study to show that subjects genetically predisposed for healthy longevity have 
higher whole-body insulin sensitivity when compared to a control group similar in age, sex and 
body composition and lifestyle indices such as smoking, socio-economic status and physical 
activity. A previous study showed preserved whole-body insulin sensitivity in healthy 
centenarians, but different to our study, these data could not be compared to a control group of 
similar age and body mass index8. Moreover, here we document that it is insulin action on 
glucose metabolism, and glucose disposal in particular, that distinguishes offspring of long-lived 
siblings from controls. Insulin action on lipolysis did not differ between the groups. These data 
  all subjects (n=24)     
controls only 
(n=12)     
  β S.E. p-value   β S.E. p-value   
                  
1. mean age of both parents                 
Crude 0.52 0.2 0.045   0.65 0.4 0.11   
Multivariate 0.65 0.2 0.007   0.69 0.2 0.022   
                  
2. age of oldest parent only                 
Crude 0.33 0.2 0.12   0.33 0.3 0.30   
Multivariate 0.43 0.2 0.034   0.37 0.3 0.19   
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suggest that glucose metabolism is involved in the control of aging in humans, as has recently 
been demonstrated for Caenorhabditis elegans 16. 
The importance of preservation of insulin action on glucose disposal is in line with previous 
studies on the pathophysiology of type 2 diabetes mellitus. Muscle insulin resistance is being 
regarded as one of the earliest steps in the pathophysiology of diabetes mellitus17, 18, and can be 
found already several decades before onset of the disease 19, 20. Insufficient suppression of hepatic 
glucose production, on the other hand, is seen as a consequence of fat accumulation in the liver 21, 
and is regarded a later phenomenon in the trajectory towards onset of diabetes18. Virtually all of 
this is mediated by increased fat mass, overweight and reduced physical exercise explaining for 
the epidemic of diabetes associated with increased disabilities and decreased life expectancy. It 
should be emphasized that the phenomena that we describe here are independent of fat mass and 
exercise and are likely to reflect a different and evolutionary conserved biomolecular mechanism 
of longevity. 
 
Several possible explanations exist for the link between preserved insulin sensitivity and familial 
longevity. Insulin resistance and compensatory hyperinsulinemia are risk factors for a variety of 
(age related) diseases, including obesity, type 2 diabetes 22 and cardiovascular disease 23. 
Furthermore, insulin resistance shows familial clustering 24, 25 and is more prominent in non-
diabetic offspring of patients with diabetes type 2 26. Thus, the present data are in keeping with 
our previous observation of a reduced prevalence of type 2 diabetes and myocardial infarction 
among offspring of long-lived siblings comprising the entire Leiden Longevity Study cohort (4). 
Less age related morbidity and associated mortality could readily explain why the offspring of 
long-lived siblings have a propensity to live longer9.  
 
Alternatively or in addition, in middle-aged individuals, insulin sensitivity may be a hallmark of a 
different physiological state associated with increased life expectancy. Interestingly, enhanced 
insulin sensitivity in the offspring of long-lived siblings co-occurs with other phenotypic features, 
including lower levels of active thyroid hormone 27, a different spectrum of cellular responses to 
oxidative stress in vitro 28 and larger LDL particle sizes 29. The co-occurrence of multiple 
beneficial features is reminiscent of the phenotype seen in genetically modified long-lived 
mammals as well as in calorie-restricted mammals 30. In long-lived mammalian models, including 
hypopituitary (GH deficient) dwarf- and GH receptor knock out mice, enhanced insulin 
sensitivity often co-occurs with enhanced protection against oxidative damage 31, 32. Conversely, 
it has recently been shown that mitochondrial superoxide production is a common feature of 
many different in vitro and in vivo models of insulin resistance 33. Pathways implicated in 
mediating longevity phenotypes in genetically modified long-lived mammals as well as in 
    Insulin sensitivity 
 57 
calorie-restricted mammals include modulation of FOXO, AMPK, Sirtuins and mTOR 34.  
Interestingly, genetic variants of FOXO3A have been been linked to human longevity in seven 
different cohorts, including Hawaiians of Japanese descent, Italians, Ashkenazi Jews, 
Californians, New Englanders, Germans and Chinese (reviewed in 4). Given the complexity of 
pathways and the generally small but possibly additive effects observed for individual genetic 
variants 35, stronger effects will possibly be observed when entire genetic pathways will be 
analysed 36. 
 
The strict selection criteria for the clamp study participants may have diminished the 
experimental contrast between the groups and masked even greater differences in insulin action. 
The groups were comparable for age, gender, environmental conditions and lifestyle indices, and 
type 2 diabetes and/or any other chronic disease were reasons to exclude individuals from 
participation (whether it concerned offspring or control). Since the prevalence of age-related 
pathology, including diabetes and cardiovascular disease associated with insulin resistance, is 
higher in controls10, inclusion of all cohort members (irrespective of the presence of chronic 
disease) would probably have revealed an even more explicit difference in insulin action between 
offspring and controls but would have hampered causal inference.  
 
The insulin levels during the hyperinsulinemic clamp study were comparable to insulin levels in 
the non-fasted, randomly obtained serum samples in the larger baseline cohort of the Leiden 
Longevity Study. Likewise, the different response to insulin in offspring under experimental high 
insulin clamp conditions was reflected by a comparable difference in the relationship between 
randomly taken non-fasted insulin and glucose levels in the higher range of insulin levels. This 
suggests that the differences in insulin sensitivity found between offspring and controls under 
controlled, experimental conditions may reflect everyday physiological conditions. 
 
 In conclusion, familial longevity in humans is marked by an increased capacity of insulin to 
stimulate glucose disposal, which confirms observations in mammalian models of longevity. 
Moreover, the age at death of the parents predicts the glucose disposal rate in response to insulin 
infusion in their offspring, suggesting that longevity genes are involved in the control of insulin 
action in man. Taken together, our data suggest that genetic predisposition for longevity is 
associated with altered insulin sensitivity in man as it is in model organisms. Our future research 
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Earlier we showed that the offspring from exceptionally long-lived families have a more 
favorable glucose metabolism when compared to controls. As chronic low-grade inflammation 
has been regarded as a strong risk factor for insulin resistance, we evaluated if and to what extent 
the favorable glucose metabolism in offspring from long-lived families could be explained by 
differences in subclinical inflammation, as estimated from circulating levels of C-reactive protein. 
We found no difference between the two groups in C-reactive protein levels or in the distribution 
of C-reactive protein haplotypes. However, among controls higher levels of C-reactive protein 
were related to higher glucose levels, whereas among offspring levels of C-reactive protein were 
unrelated to glucose levels. The current study suggests that the favorable glucose metabolism in 
offspring from long-lived families allows tight regulation of glucose levels despite elevated 
markers of low-grade inflammation. This finding indicates a robust insulin sensitivity which may 
render subjects from long-lived families resilient against the effects of low-grade inflammation 
and concomitant morbidity.  
 
   C-reactive protein and glucose regulation 
 65 
Introduction 
The association between chronic subclinical inflammation and insulin resistance has been well 
established 1. Insulin resistance in turn is regarded a strong risk factor for type 2 diabetes, 
hypertension and cardiovascular disease 2;3. Levels of C-reactive protein (CRP), a marker of 
systemic inflammation, are elevated in subjects with impaired glucose tolerance as well as in 
overt diabetes 4;5 and increased levels of CRP are predictive for development of diabetes 6;7 
Observational studies have shown a relation between elevated levels of CRP and elevated glucose 
levels in subjects without diabetes as well 8-10.  
 
In the Leiden Longevity Study we have recruited exceptionally long-lived families based on 
proband siblings that both exhibit exceptional longevity. We also included the middle-aged 
offspring of the long-lived siblings and their partners as population based controls. Earlier we 
have shown that the offspring from these long-lived families have a lower prevalence of type 2 
diabetes when compared to controls 11. Moreover, we demonstrated that after exclusion of 
diabetic patients the offspring from long-lived families had relatively lower fasted and non-fasted 
glucose levels as well as a higher glucose tolerance 12;13. The differences in glucose metabolism 
between offspring from long-lived families and controls could not be explained by differences in 
body composition or life style, such as smoking or physical activity.  
 
In the current study, we sought to evaluate whether and to what extent the observed differences in 
glucose metabolism between the offspring from long-lived families and controls can be explained 
by differences in subclinical inflammation, as estimated from circulating levels of CRP. 
Therefore we examined high-sensitivity C-reactive protein (hsCRP) serum levels as well as CRP 
genotypes and their influence on glucose regulation in the offspring from exceptionally long-lived 
families and controls.  
   
Materials and methods 
The Leiden Longevity Study 
The recruitment of 421 families in the Leiden Longevity Study has been described before.14 A 
short outline is provided here. Families were recruited if at least two long lived siblings were 
alive and fulfilled the age-criterion of 89 years or older for males and 91 year or older for 
females. There were no selection criteria on health or demographic characteristics. For 2415 
offspring of long-lived siblings and their partners as population controls, non-fasting serum 
samples were taken at baseline for the determination of endocrine and metabolic parameters. 
Additional information was collected from the generation of offspring and controls, including 
self-reported information on life style, information on medical history from the participants’ 
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treating physicians and information on medication use from the participants’ pharmacists. 
Subjects with hsCRP levels higher than 10.0 mg/L were excluded from the study (68 offspring 
(4.6%) and 31 controls (4.9%)) as were subjects with diabetes (65 offspring (4.4%) and 53 
controls (8.3%)). Subjects were regarded as having diabetes if they had non-fasted glucose levels 
>11.0 mmol/L, a previous medical history of diabetes and/or used glucose lowering agents. In 84 
subjects (61 offspring and 23 controls) data on hsCRP and/or glucose were not available. 
 
CRP genotypes 
Three single nucleotide polymorphisms (SNPs) were selected that associate with serum CRP 
levels: rs1205 (positioned in 3’UTR, alleles C/T), Rs1800947 (positioned in Codon 184, alleles 
G/C) and Rs1417938 (positioned in intron 1, alleles T/A). Genotyping of the SNPs was 
performed using Sequenom MassARRAY iPLEX®Gold. The high iPLEX primer design was 
performed by entering the sequences encompassing each polymorphism into SpectroDESIGNER 
provided by Sequenom®, Inc. (CA, USA). The high plex reaction protocol was used 
(www.sequenom.com/iplex). The average genotype call rate for genotyped SNPs was 96.3% and 
the average concordance rate was 99.7% among 4% duplicated control samples. All SNPs were in 
Hardy-Weinberg equilibrium (P≥0.05)  
 
Plasma parameters 
All serum measurements were performed with fully automated equipment. For insulin the 
Immulite 2500 from DPC (Los Angeles, CA, USA) was applied. For insulin the coefficient of 
variation was below 8%. For glucose and CRP, the Hitachi Modular P 800 from Roche, Almere, 
the Netherlands was applied. CV’s of these measurements were below 5 %.  
 
Statistical analysis 
The program haploview was used to estimate allele frequencies, test the consistency of genotype 
frequencies at each SNP locus with Hardy-Weinberg equilibrium and estimate and plot pair wise 
LD between the examined SNPs. Haplotypes and haplotype frequencies were estimated using the 
SNPHAP software. The posterior probabilities of haplotypes <95% were excluded from the 
analyses (61 offspring and 24 controls). 
 
Distributions of continuous variables were examined for normality and serum insulin levels and 
hsCRP levels were logarithmically transformed prior to analyses. Differences in age between the 
groups of offspring and controls were tested using a Mann-Whitney rank sum test. Differences in 
sex distribution between the groups of offspring and controls were calculated using a Chi-square 
test. Geometric means (with 95% confidence intervals (CI)) are reported for transformed 
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variables. Associations between serum levels as well as associations between CRP haplotypes and 
serum levels were tested using a linear mixed model with a random sibship effect to model 
correlation of sibling data. Age, sex, body mass index and use of lipid lowering agents were 
regarded as potential confounders in this association and were included in the analyses. The 
Statistical Package for the Social Sciences (SPSS) program for Windows, version 16.0 was used 
for data analysis.  
 
Results 
The principal features of the study groups, both without diabetes, are displayed in table 1. The 
proportion of males was slightly higher in the group of offspring than in the group of controls. 
Body mass index was similar between the two groups (P=0.57). Non-fasted glucose levels were 
lower in the group of offspring when compared to the group of controls (P=0.001), while non-
fasted insulin levels did not differ (P=0.16). We did not observe a difference in serum levels of 
high sensitivity C-reactive protein (hsCRP) between the two groups. Also after adjustment for the 
potential confounders age, sex, body mass index and the use of lipid lowering agents, no 
difference in hsCRP levels was observed between the two groups (table1) 
 
Potentially, genetic variation could mask true differences in CRP levels between the two groups. 
To distinguish between constitutional and acquired levels of hsCRP, we performed a genetic 
analysis of haplotypes constructed from the common CRP variants rs1205, rs1800947 and 
rs1417938, that have previously been associated with serum CRP levels. For the present analyses 
we report the results of the four most common haplotypes (frequency>5%) that cumulatively 
account for 99.9% of the haplotypes. The relation between the four selected haplotypes and serum 
hsCRP levels is depicted in table 2. All haplotypes correlated significantly with hsCRP levels. An 
increasing number of haplotype 1 and 2 gave rise to higher hsCRP levels, whereas an increasing 
number of haplotype 3 and 4 was related to a decrease in hsCRP serum levels. The change in 












Table 1. Baseline characteristics of the study population 
 
Results for insulin and hsC-reactive protein (hsCRP) are presented as estimated geometric means with 95% 
confidence intervals. *Data on body mass was available for 1823 subjects (1266 offspring and 557 
partners). Results for body mass index were adjusted for age and sex. †Data on §current smoking status 
were available for 1819 subjects (1262 offspring and 557 partners). Results for insulin and glucose were 
adjusted for age, sex and body mass index. 95% CI: 95% confidence interval. 
 
Next we assessed if the distribution of CRP haplotypes was different between the two groups. In 
both the study groups haplotypes were in Hardy-Weinberg equilibrium. No difference in the 
frequencies of CRP haplotypes was observed between the group of offspring and the group of 









 Offspring Controls p-value 
Participants (N)  1479 635  
Male sex (N, %) 691 (46.7) 264 (41.6) 0.032 
Age in year (median (interquartile range) 59.1 (54.9 – 64.0) 58.7 (53.8 – 63.6) 0.078 
Body Mass Index  in kg/m2 (mean 95% CI)* 25.3 (25.0 – 25.5) 25.4 (25.1 – 25.7) 0.57 
Lipid-lowering agent (N, %) 87 (5.9) 45 (7.1) 0.33 
Currently smoking§ 167 (13.2) 78 (14.0) 0.66 
    
Insulin  in µIU/L (mean 95% CI) 15.7 (14.9 – 16.4) 16.6 (15.5 – 17.7) 0.16 
Glucose in mmol/L (mean 95% CI) 5.70 (5.64 – 5.77) 5.90 (5.81 – 5.99) 0.001 
    
HsCRP in mg/dL (mean 95% CI)    
Adjusted for sex and age (model 1) 1.21 (1.15 – 1.28) 1.25 (1.16 – 1.34) 0.54 
Model 1 and body mass index 1.20 (1.32 – 1.26) 1.23 (1.15 – 1.32) 0.56 
Model 1 and lipid lowering agents   1.06 (0.97 – 1.16) 1.10 (1.00 – 1.21) 0.48 
Model 1 and current smoking status† 1.30 (1.21 –  1.40) 1.34 (1.23 – 1.46)  0.53 
Model 1 and body mass index and lipid lowering 
agents and current smoking status 
1.11 (1.01 – 1.23) 1.14 (1.03 – 1.26) 0.54 
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Table 2. Association between CRP haplotypes and serum hsCRP levels 
Results for serum high-sensitivity C-reactive protein (hsCRP) are given as estimated geometric means and 
95% confidence intervals for number of haplotypes. Results were adjusted for sex, age and study group 
(controls and offspring). P for interaction was calculated for the difference between controls and offspring 
in the trend of hsCRP over increasing number of haplotypes.  
 
Table 3. CRP haplotype structure and frequencies 
Minor alleles are in bold. SNP=single nucleotide polymorphism 
 
Since high levels of CRP have been associated with insulin resistance, we examined the 
association between serum levels of hsCRP and serum levels of non-fasted insulin as well as 
glucose for the group of offspring and the group of controls. Higher levels of hsCRP were 
consistently related to higher levels of insulin in both groups (figure 1A). In the group of 
offspring one standard deviation increase in ln hsCRP was associated with an increase in levels of 
ln serum insulin of 0.08 (95% confidence interval: 0.04 – 0.13) µIU/L (p<0.001). In the group of 
controls one standard deviation increase in ln hsCRP was associated with an increase in levels of 
ln serum insulin of 0.11 (0.04 – 0.19) (p=0.004). The relation between hsCRP and insulin was not 
different between the two groups (p for interaction=0.28). Next we examined the relation between 
hsCRP and glucose in the two groups. Among offspring no significant relation was observed 
between one standard deviation increase in ln hsCRP and glucose (mmol/L): 0.01 (-0.05 – 0.08) 
Haplotype 0-copies (mean (95% CI)) 1-copy (mean (95% CI)) 2-copies (mean (95% CI)) P for trend P 
interaction 
HsCRP (mg/dL) 
1  1.17 (1.09 – 1.24) 1.25 (1.18 – 1.34) 1.35 (1.20 – 1.51) 0.015 0.87 
2 1.13 (1.06 – 1.20) 1.28 (1.20 – 1.36) 1.45 (1.28 – 1.65) <0.001 0.63 
3 1.32 (1.24 – 1.40) 1.14 (1.07 – 1.22) 1.04 (0.89 – 1.22) <0.001 0.18 
4 1.27 (1.21 – 1.34) 0.97 (0.87 – 1.09) 0.52 (0.29 – 0.93) <0.001 0.23 
  SNP allele    Frequency 
Haplotype rs1205 rs1800947 rs1417938   Offspring Controls p-value 
1 T G T  0.335 0.344 0.57 
2 T G A   0.336 0.315 0.17 
3 C G T   0.260 0.273 0.38 
4 C C T   0.069 0.068 0.94 
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(p=0.71). (figure 1B). In contrast, among controls one standard deviation increase in ln hsCRP 
was related with a 0.13 (0.02 – 0.24) mmol/L increase in serum glucose levels (p=0.017). The 
association between hsCRP and glucose was significantly different in the group of controls when 





Figure 1. Association between hsCRP levels and non-fasted serum insulin levels (A) and serum glucose 
levels (B) for offspring and controls. For the figure HsCRP levels were dichotomized into categories of 
low and high hsCRP levels based on the median value of CRP of the whole population (1.15 mg/dL). * 
denotes P-value lower than 0.05. 
 
If CRP haplotypes associate with CRP levels and CRP levels associate with markers of glucose 
metabolism, it could be expected that CRP haplotypes associate with markers of glucose 
metabolism. To tease out the causal relation between serum hsCRP and glucose metabolism we 
assessed the relationship between CRP haplotypes and serum levels of insulin as well as glucose. 
(table 4) In both groups, none of the haplotypes demonstrated an association with levels of serum 
insulin nor serum glucose.   
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Table 4. Association between CRP haplotypes and serum glucose parameters  
Results for serum insulin are given as estimated geometric means and 95% confidence intervals for number 
of haplotypes. Results for glucose are given as estimated means and 95% confidence intervals for number 
of haplotypes. Results were adjusted for sex, age and study group (controls and offspring). P for interaction 
was calculated for the difference between controls and offspring in the trend of insulin or glucose over 
increasing number of haplotypes. 
 
Discussion 
Earlier it has been demonstrated that the offspring from exceptionally long-lived families have a 
more favorable glucose metabolism when compared to population based controls.12;13 In the 
present study we show that this difference in glucose metabolism could not be explained by 
current differences in subclinical inflammation, as estimated from serum levels of hsCRP. We did 
not find a difference in the levels of hsCRP between the group of offspring from long-lived 
families and the group of environmentally matched controls, nor in the frequencies of the 
common genetic CRP variants and haplotypes. All CRP haplotypes correlated significantly with 
hsCRP levels, however no association was found between CRP haplotypes and insulin or glucose 
levels. We observed a distinct association between levels of hsCRP and levels of glucose in the 
Haplotype 0-copies (mean (95% CI)) 1-copy (mean (95% CI)) 2-copies (mean (95% CI)) P for trend P interaction 
Serum insulin ( µIU/L) 
1  16.1 (15.2 – 17.1) 16.2 (15.3 – 17.2) 16.9 (15.2 – 18.7) 0.54 0.68 
2 16.4 (15.5 – 17.4) 16.0 (15.1 – 17.0) 16.6 (14.8 – 18.7) 0.84 0.15 
3 16.4 (15.5 – 17.2) 16.5 (15.5 – 17.5) 14.4 (12.4 – 16.6) 0.09 0.23 
4 16.1 (15.5 – 16.9) 17.3 (15.6 – 19.2) 11.9 (6.57 – 21.6) 0.41 0.83 
      
Serum glucose (mmol/L) 
1  5.80 (5.72 – 5.87) 5.82 (5.74 – 5.89) 5.83 (5.68 – 5.97) 0.66 0.49 
2 5.80 (5.73 – 5.88) 5.79 (5.71 – 5.87) 5.92 (5.76 – 6.07) 0.42 0.39 
3 5.84 (5.77 – 5.91) 5.79 (5.71 – 5.87) 5.65 (5.46 – 5.85) 0.09 0.40 
4 5.80 (5.74 – 5.86) 5.88 (5.74 – 6.02) 5.39 (4.67 – 6.11) 0.57 0.18 
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two groups: in the group of controls increasing levels of hsCRP were associated with higher non-
fasted glucose levels, whereas in the group of offspring this relation was absent.  
The lack of difference between the group of offspring and controls in hsCRP levels as an 
approximate measure for low-grade inflammation is remarkable given the higher prevalence of 
metabolic syndrome in the group of controls 13. The metabolic syndrome is a combination of 
cardio-vascular risk factors for which the dominant underlying factor appears to be insulin 
resistance 15. A chronic subclinical inflammatory state is considered a crucial factor in the 
development of insulin resistance 5;5;16. In accordance, insulin resistance has been shown to 
correspond closely with elevated levels of inflammatory markers as CRP 17;18. The current study 
demonstrates that the offspring from long-lived families compared to controls are able to tightly 
regulate glucose levels despite elevated markers of low-grade inflammation. This suggests that 
the more favorable glucose metabolism reported earlier in offspring is sustained and even more 
manifest under challenging conditions as for example during low-grade inflammation. Subjects 
from long-lived families seem to be protected by their robust insulin sensitivity against the effects 
of low-grade inflammation and concomitant morbidity, as for example metabolic syndrome. 
Alternatively, CRP might be causal in the observed difference in insulin sensitivity in response to 
inflammation. However, the consistent lack in both groups of association between CRP 
haplotypes with glucose levels strongly argues against this explanation. 
 
During inflammation, acute phase reactants and pro-inflammatory cytokines are thought to induce 
a hypermetabolic state. This hypermetabolic state, which is aimed at mobilizing energy to support 
immune function and tissue repair, is characterized by an accelerated gluconeogenesis 19 as well 
as induced insulin resistance resulting in elevated glucose levels 20 (figure 2A). Preserved insulin 
action in the offspring presumably allows for disposal of the excess glucose and/or reduced 
hepatic gluconeogenesis, thereby abolishing the inflammatory induced hyperglycemia (figure 
2B). Hypothetically, a favorable balance between insulin-sensitizing and diabetogenic 
components underlies this phenomenon. Multiple endogenous diabetogenic components and 
insulin-sensitizing factors have been identified, as for example IL-6, TNF-α, PAI-1 and leptin on 
the one hand, and adiponectin on the other hand.21 Our future research will focus on unraveling 
the specific mechanisms of the robust glucose metabolism in offspring from long-lived families. 
 
In conclusion, we found that the previously observed favorable glucose metabolism in middle-
aged offspring from exceptionally long-lived families is unaffected by low-grade inflammation, 
as estimated by the inflammatory marker hsCRP, suggesting a resilience against the 
hyperglycemic effects of a chronic low-grade inflammatory state. 
 























Figure 2. Mechanism of inflammatory induced hyperglycemia. The state is characterized by an 
accelerated hepatic gluconeogenesis as well as induced peripheral insulin resistance leading to 
hyperglycemia (A). Preserved insulin action in the offspring from long-lived families presumably allows for 
disposal of excess glucose and/or reduced hepatic gluconeogenesis, thereby abolishing the inflammatory 
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Recently, we have shown that compared to controls, long-lived familial nonagenarians (mean 
age: 93.4 years) from the Leiden Longevity Study displayed a lower mortality rate, and their 
middle-aged offspring displayed a lower prevalence of cardio-metabolic diseases, including 
diabetes mellitus. The evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has been 
implicated in longevity in model organisms, but its relevance for human longevity has generated 
much controversy. Here, we show that compared to their partners, the offspring of familial 
nonagenarians displayed similar non-fasted serum levels of IGF-1, IGFBP3 and insulin but lower 
non-fasted serum levels of glucose, indicating that familial longevity is associated with 
differences in insulin sensitivity. 
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Introduction 
In Western societies, life expectancy has increased dramatically over the last century, but striking 
inter-individual differences in life expectancy remain 1. Ample evidence has shown that healthy 
longevity is determined by a mix of genetic, environmental and chance elements. Because, as the 
risk of developing common and rare diseases, the odds of exceptional longevity runs in families, 
we designed the Leiden Longevity Study.2 Recently, we have shown that the nonagenarian 
siblings included in the Leiden Longevity Study displayed a 41% lower risk of mortality 
compared to sporadic nonagenarians.3 Moreover, compared to their partners, the offspring of 
nonagenarian siblings displayed a significantly lower prevalence of myocardial infarction, 
hypertension and diabetes mellitus 3. The differences in clinical phenotype observed after 
selection for familial longevity are in line with the lower prevalence of cardio-metabolic disease 
previously detected when offspring from sporadic centenarians were compared to offspring of 
parents who had died at average age 4and when offspring from sporadic centenarians were 
compared to their partners 5. Moreover, the observed lower mortality rate at high ages and better 
preservation of health at middle age indicates that resilience against disease and death may have 
similar underlying biological mechanisms that are influenced by genetic or familial factors.  
 
Of the genetically determined pathways that have been implicated in longevity in a variety of 
different model organisms, the evolutionary conserved insulin/IGF-1 signaling (IIS) pathway 
clearly stands out in current literature (reviewed in 6. Mutations in IIS components were first 
found to affect reproduction, metabolism, stress response and life span in C. elegans (reviewed in 
7. The link between reduced IIS signaling and longevity was subsequently also observed in D. 
melanogaster. Mutants in the D. melanogaster insulin receptor InR  8 and in the insulin receptor 
substrate CHICO 9are both long-lived. Strikingly however, in both cases the long-lived phenotype 
was only observed for females. In addition to being long-lived, these D. melanogaster females are 
small, obese and infertile. In mice, selective disruption of the insulin receptor in the adipose tissue 
leads to a reduction in fat mass and extended longevity 10. Increases in lifespan were also reported 
in mice with deletion of insulin receptor substrate 1 (IRS1) in whole body11 or IRS2 only in the 
brain 12. Moreover, dwarf mice exhibiting GH deficiency or resistance, including Prop1df/d 13, 
Pit1
dw/dw 14, GHRHRlit/li 14 and GHR-/-  15 all display hypoinsulinemia and enhanced insulin 
sensitivity along with extended longevity. In mice heterozygous for igf1r deletion (Igf1r+/- 16 or 
containing a hypomorphic igf1r mutation (Midi mice 11), only females, but not males, exhibited 
the long-lived phenotype.  
 
Based on the similarities among the insulin/IGF-1 pathways in animals and humans the 
possibility that modifications in the insulin/IGF-I signaling system could also extend lifespan in 
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humans has been suggested. However, separating the roles of insulin and IGF-1 in mammals and 
their relevance for human healthy longevity has been difficult and generated much controversy. 
In humans, relatively low IGF-I levels have been associated with an increased risk of developing 
cardiovascular disease and diabetes, while relatively high IGF-I levels have been associated with 
an increased risk of developing cancer 17. Moreover, in humans, an age-related decline in IGF-1 
levels occurs 18, and at old age, low IGF-1 levels are associated with frailty 19, poor nutrition and 
cognitive decline 20 and an increased risk of death 21. On the other hand, genetic variation in genes 
associated with down-regulation of IIS pathway has been associated with human longevity in 
several instances, although, when moving up the evolutionary ladder, together with an increase in 
genome complexity, effect sizes became smaller 22. Two studies have shown evidence for a role 
for genetic variation in the IIS pathway in body height as well as human longevity. First, earlier 
we found an association between genetic variation associated with reduced IIS pathway activity 
and shorter stature as well as improved old age survival in sporadic female octogenarians 23. 
Second, offspring of sporadic female centenarians were shown to be smaller and display higher 
IGF-1 levels, indicative of IGF-1 insensitivity, while rare IGF-1R mutations associated with IGF-
1 insensitivity were found enriched in centenarians 24. Here, to investigate whether these results 
could be generalized to familial longevity, we have compared key anthropometric measures as 
well as serum parameters related to insulin/IGF-1 signaling in a group of middle-aged offspring 
of nonagenarian siblings and a control group of their partners of the Leiden Longevity Study.  
 
Materials and methods 
Leiden Longevity Study  
In the Leiden Longevity Study, 420 families were recruited consisting of long-lived Caucasian 
siblings together with their offspring and the partners thereof. 2. Families were recruited if at least 
two long lived siblings were alive and fulfilled the age-criterion of 89 years or older for males and 
91 year or older for females. There were no selection criteria on health or demographic 
characteristics. For 2465 of the offspring and their partners, non-fasted serum samples taken at 
baseline were available for the determination of endocrine and metabolic parameters. Between 
November 2006 and May 2008, for 2235 of the offspring and their partners, information on 
medical history was obtained from the participants’ general practitioner (response: 91%). For 
2255 of the offspring and their partners, information on the use of medication was obtained from 
the participants’ pharmacy (response: 92%). For 2184 of the offspring and partners a general 
questionnaire containing information on lifestyle and self-reported height and weight was 
obtained (response: 89%). For the present study, for a total of 1713 of the offspring and their 
partners, serum as well as information on medical history on diabetes and information on 
medication use and the general questionnaire were available (inclusion: 70%). After exclusion of 
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subjects with diabetes in medical history (n=87) and/or non-fasted glucose lower than 11 mmol/L 
(n=1) and/or use of glucose lowering medication (n=37), a sample of 1625 subjects was available 
for the current study. The Medical Ethical Committee of the Leiden University Medical Centre 
approved the study and informed consent was obtained from all subjects. 
 
Biochemical analysis 
All serum measurements were performed with fully automated equipment. For insulin-like 
growth factor-1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP3) and insulin, the 
Immulite 2500 from DPC (Los Angeles, CA, USA) was applied. CVs for these measurements 
were all below 8%. For glucose, total cholesterol, HDL-cholesterol, triglycerides, free fatty acids 
(FFA) the Hitachi Modular or the Cobas Integra 800, both from Roche, Almere, the Netherlands 
were applied. CVs of these measurements were all below 5 %.  
 
Medication use 
Lipid lowering agents were defined as fibrates, niacin, bile acid sequestrants, HMG-COA 
reductase inhibitors (ATC code C10).  
 
Calculations and statistical analysis 
For estimation of the level of LDL cholesterol the Friedewald formula was applied (LDL 
cholesterol [mmol/l] = total cholesterol - HDL cholesterol - [triglycerides/2.2]), whereby 
participants with a triglyceride concentration higher than 443 mg/dl (5 mmol/l) were excluded. 
For molar comparisons between IGF-1 and IGFBP3, the following molecular masses were used 
in the calculation: IGF-1: 7.5 kDa and IGFBP3: 28.5 kDa. 
Distributions of continuous variables were examined for normality and logarithmically 
transformed, when appropriate and used in all calculations. Geometric means (with 95% 
confidence intervals (CI)) are reported for transformed variables (insulin, triglycerides, and free 
fatty acids). All differences in mean serum levels and anthropometrics between the groups of 
offspring and partner were assessed with the use of linear regression, adjusted for sex, age and 
correlation of sibling data using robust standard errors in STATA. The relation between 
IGF1/IGFBP3 molar ratio (expressed in Z-scores and restricted to values within 3 standard 
deviations (SDs) from the mean) and glucose was assessed with the use of a linear mixed model, 
adjusted for sex, age and correlation of sibling data in SPSS. The cumulative distributions of IGF-
1, IGFBP3 and height were calculated in SPSS. The change in levels of IGF-1, IGFBP3 over 
chronological age as a continuous variable was assessed with the use of a linear mixed model, 
adjusted for age and correlation of sibling data in SPSS. The Statistical Package for the Social 
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Sciences (SPSS) program for Windows, version 14.0, and STATA version 10.0 were used for 
data analysis, and plots were drawn in Excel. 
 
Results 
Metabolic characteristics of offspring compared to partners 
Table 1 depicts the demographic and metabolic characteristics of the groups from the Leiden 
Longevity Study that were used for the present study. The group of offspring proportionately 
contained less diabetics than the group of partners (p = 0.001). After exclusion of diabetics, the 
group of offspring had lower non-fasted serum levels of glucose (p = 0.002) than the group of 
partners.  In addition, the group of offspring had a slightly more favorable lipid profile as 
compared to the group of partners.   
 
IGF-1/IFGBP3 and non-fasted glucose 
Next we assessed whether the lower glucose levels observed among the group of offspring 
relative to their partners could be driven by differences in IGF-1 axis parameters.  Therefore we 
determined the association between serum IGF-1 / IGFBP3 molar ratios and non-fasted serum 
glucose levels. Higher ratios of IGF-1/ IGFBP3 were associated with lower serum glucose levels. 
One standard deviation increase in IGF-1/IGFBP3 ratio was associated with a decrease of 0.10 
mmol/L serum glucose (SE: 0.05) among the group of partners (p = 0.05). The difference 
between partners and offspring in the change of glucose levels per standard deviation IGF-
1/IGFBP3 ratio was not significant: 0.02 (SE: 0.06) nmol/L per year (p for interaction = 0.70). 
 
Measures of the IGF-1 axis in offspring compared to partners 
Table 2 shows the comparison between offspring and their partners for various IGF-1 axis 
parameters for males and females separately. In order to detect the effect of possible genetic 
differences in IGF-1 signaling between offspring and their partners, we also determined 
anthropometrical characteristics in subjects of both study groups (table 2). With regard to serum 
IGF-1 axis parameters, no differences were observed between the group of offspring and the 
group of partners in both sexes. Likewise, the study groups showed no differences in terms of 
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Table 1. Comparison of demographics and serum parameters between offspring and partners for 
males and females combined 
 
 
Next, we determined whether the distribution of serum IGF-1 axis parameters and 
anthropometrical parameters were different between offspring and partners. Figure 1 displays the 
cumulative distributions of IGF-1, IGFBP3 and height among partners and offspring for both 
sexes separately. No differences in height were observed between offspring and partners in the 
lower tail of the IGF-1 and IGFBP3 distribution curves. Taken together, the cumulative 
distribution curves do not suggest enrichment of high or low IGF-1 axis parameters nor large or 
short statures among the offspring versus their partners.   
 
 Offspring Partners p-value 
Demographics    
   Participants - n 1171 542  
   Diabetics – n (%) 46 (3.9) 42 (7.7) 0.001 
   Females – n (%) 633 (54.1) 302 (55.7) 0.57 
   Age  (year) 59.2 (55.0 – 64.1) 58.8 (54.3 – 63.7) 0.15 
    
Serum parameters (non-diabetics)    
   Participants - n 1125 500  
   Glucose  (mmol/L)  5.69 (5.62 – 5.76) 5.87 (5.76 – 5.97) 0.002 
   Insulin  (mU/L )** 14.4 (13.6 - 15.4) 15.4 (14.0 -16.8) 0.21 
    
   Total cholesterol  (mmol/L)† 5.56 (5.47 – 5.65) 5.62 (5.52 - 5.72) 0.40 
   LDL cholesterol (mmol/L)† 3.32 (3.24 - 3.39) 3.37 (3.29 - 3.45) 0.33 
  HDL cholesterol  (mmol/L)† 1.46 (1.42 - 1.49) 1.43 (1.39 - 1.47) 0.24 
   Triglycerides (mmol/L) **,† 1.50 (1.44 – 1.55) 1.57 (1.50 – 1.65) 0.09 
   Free fatty acids (mmol/L) **,† 0.27 (0.26 – 0.28) 0.27 (0.26 – 0.29) 0.38 
*Mean values are presented with 95% confidence intervals.  Mean values, 95% confidence intervals 
and p-values were calculated using a linear regression model, adjusted for age and sex. LDL denotes 
low-density lipoprotein and HDL high-density lipoprotein. Age is presented as median with 
interquartile range. 
**Data are presented as geometric means and 95% confidence intervals.  
† Mean values, standard error of the mean and p-value for Total cholesterol , LDL cholesterol, HDL 
cholesterol, LDL cholesterol/ HDL cholesterol ratio, Triglycerides, Triglycerides/  HDL cholesterol 
ratio, Free Fatty Acids and High sensitivity C-reactive protein were adjusted for lipid lowering 
agents (niacin, bile acid sequestrants, HMG-COA reductase inhibitors). 
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Table 2. Comparison of anthropometrics and growth hormone axis parameters between offspring 
and partners for females separately 
 
Data are presented as means with 95% confidence intervals. All analyses were adjusted for age. *Diabetic 














Females (n) 610 286  
   IGF-1 axis serum parameters    
     IGF-1  (nmol/L)  17.1 (16.7 – 17.5) 17.1 (16.5 – 17.7) 0.99 
     IFGBP3 (mg/L)  4.44 (4.36 - 4.53) 4.47 (4.36 - 4.57) 0.72 
     IGF-1/ IGFBP3 (molar ratio)  0.11 (0.11 – 0.11)) 0.11 (0.11 – 0.11) 0.60 
    
   Anthropometrics    
     Height (m) 166.8 (166.2 – 167.3) 166.9 (166.1 – 167.7) 0.79 
     Weight (kg) 69.2 (68.2 – 70.3) 70.2 (68.9 – 71.6) 0.25 
     Body Mass Index (kg/m2) 24.9 (24.5 – 25.3) 25.2 (24.8 – 25.7) 0.25 
    
Males (n) 515 214  
   IGF-1 axis serum parameters    
     IGF-1  (nmol/L)  17.5 (17.0 - 17.9) 17.3 (16.6 - 18.0) 0.75 
     IGFBP3 (mg/L)  4.22 (4.13 - 4.30) 4.20 (4.08 - 4.32) 0.85 
     IGF-1/ IGFBP3 (molar ratio)  0.12 (0.12 – 0.12) 0.12 (0.12 – 0.12) 0.82 
    
   Anthropometrics    
     Height (m) 178.7 (178.1 – 179. 4) 179.1 (178.2 – 180.0) 0.44 
     Weight (kg) 82.0 (80.9 – 83.0) 82.4 (80.8 – 84.1) 0.61 
     Body Mass Index (kg/m2) 25.6 (25.4 – 25.9) 25.7 (25.2 – 26.1) 0.96 
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Figure 1. Cumulative distribution curves of serum IGF-1 levels, serum IGFBP3 and height. Cumulative 
distribution curves of IGF-1 levels for offspring and partners among females (A) and males (B); 
Cumulative distribution curves of IGFBP-3 levels for offspring and partners among females (C) and males 
(D); Cumulative distribution curves of height for offspring and partners among females (E) and males (F). 




IGF-1 levels have been consistently 
reported to progressively decline with age. 
To determine whether this observation 
applied to the groups that were used in the 
present study, we assessed the association 
between serum IGF-1 levels and serum 
IGFBP-3 levels with age. Figure 2 displays 
the sex-specific serum IGF-1 and IGFBP3 
levels for different age categories among 
offspring and partners.  Serum IGF-1 levels 
declined with age in both female partners (-
0.14 (SE: 0.04) nmol per year increase; 
p<0.001) and male partners (-0.16 (SE: 
0.05) nmol/L per year increase; p =0.001). 
The difference in annual change in serum 
IGF-1 levels between partners and offspring 
was not significant: 0.01 (SE: 0.05) nmol/L 
per year (p for interaction= 0.79) for 
females and 0.01 nmol/L (SE: 0.06) per year 
(p for interaction=0.83) for males. 
Similarly, no differences between partners 
and offspring were observed in terms of 
annual change in serum IGFBP3 levels: 
0.01 mg/L (SE: 0.01) (p for interaction = 
0.47) for females and 0.02 mg/L (SE: 0.01)  
(p for interaction =0.10) for males.  
 
Figure 2. Association between age categories 
and serum IGF-1 levels for offspring and 
partners among females (A) and males (B) and 
association between age categories and serum 
IGFBP-3 levels for offspring and partners among females (C) and males (D). Dark bars represent 
offspring, light bars represent partners. Number of participants per age category for females (offspring/ 
partners): category <55: 156/110; category 55-60: 194/83; category 60-65: 146/66; category >65: 
114/27.  Number of participants per age category for females (offspring/ partners): category <55: 133/42; 
category 55-60: 140/49; category 60-65: 140/57; category >65: 102/66. 
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Discussion 
The main findings of this study are twofold. First, consistent with the lower prevalence of 
diabetes observed earlier, non-fasted serum glucose levels were lower in the offspring of familial 
nonagenarians when compared to their partners. Second, we did not observe differences in non-
fasted serum levels of IGF-1, IGFBP3 or in height between the groups of offspring and their 
partners, nor in the rate of the decline of levels of IGF-1 or IGFBP3 over chronological age. 
Taken together, these data indicate that familial longevity is associated with differences in 
glucose handling, which are not explained by major differences in IGF-1 and/or IGFBP3 levels. 
 
The link between reduced IIS activity and longevity is evolutionary conserved from worms to 
rodents, with effects on longevity often being stronger in the female sex. However, separating the 
roles of insulin and IGF-1 in mammals has been very difficult and generated much controversy. 
Because the actions of GH, insulin and IGF-1 are largely interwoven, genetic modification of the 
GH/IGF-1 axis in mammals also entails differences in the regulation of glucose metabolism. 
Interestingly, the hallmark phenotype of all long-lived mouse models containing mutations that 
induce GH/IGF-1 deficiency or resistance, is their enhanced insulin sensitivity.6, 25 Here, we show 
that in non-diabetics, lower non-fasted glucose levels were observed in the offspring of familial 
nonagenarians as compared to their partners, which is consistent with our previous observation of 
a lower prevalence of diabetes in the offspring group 3. Moreover, the lower non-fasted glucose 
levels in offspring compared to partners are suggestive of a better glucose handling and/or higher 
insulin sensitivity in familial longevity, which is in line with the hallmark phenotype observed in 
the many long-lived mammalian IIS mutants. Other data also support a link between preserved 
insulin sensitivity and human longevity. While insulin sensitivity generally declines with age in 
humans 25, sporadic long-lived centenarians have been shown to exhibit an exquisite insulin 
sensitivity, comparable to that of young adults 26.  
 
The preserved insulin sensitivity observed in centenarians, occurred in relatively high levels of 
IGF-1/IGFBP3, which has lead to the suggestion of causal link between the preserved insulin 
sensitivity and levels of IGF-I/IGFBP-3 27. In rats, IGF-1 and IGFBP3 were shown to have 
opposing (centrally mediated) effects on glucose metabolism, with IGF-1 acting as an insulin 
sensitizer, and IGFBP3 as an insulin inhibitor 28. Similarly, in humans, IGF-1 administration was 
found to increase glucose uptake and inhibit hepatic glucose production in healthy subjects 29, and 
low serum IGF-1 levels were found associated with glucose intolerance 30. In line with these 
findings, we also observed a negative association between IGF-1/IGFBP3 levels and non-fasted 
glucose levels in both our study groups, but neither this association nor the mean levels of IGF-1 
and IGFBP3 were different between the offspring and partner group. Our observation of 
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improved glucose handling in the absence of major differences in IGF-1/IGFBP3 levels 
resembles the effects observed upon caloric restriction in humans. In contrast to model organisms, 
in humans, IGF-1 levels were not found to be decreased upon caloric restriction, while insulin 
sensitivity was increased upon caloric restriction in humans as in model organisms 31. The lack of 
differences in BMI, as well as preliminary data on food intake, indicate however that the observed 
difference in glucose handling between the offspring group and their partners can not be 
explained by a lower caloric intake in the offspring group. 
 
The observation of improved glucose handling in the absence of major differences in IGF-
1/IGFBP3 in familial longevity does not rule out the possibility that genetic variations affecting 
IGF-1/IGFBP3 levels do contribute to human longevity. Recently, it was shown that centenarians 
exhibited a relative enrichment for rare genetic variants in the IGF-1 receptor which resulted in 
high levels of IGF-1/IGFBP3 coexisting with low levels of IGF-1 signaling 24. Also, earlier we 
and others showed that common genetic variations affecting IGF-1 signaling might contribute to 
differences in mortality in the population at large 23, 32, but the phenotypic effects associated with 
such variants (smaller stature, differences in serum levels of IGF-1 and/or IGFBP3) do not form a 
distinctive part of the hallmark phenotype of preserved glucose handling which we found 
associated with familial longevity.  
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Reduced insulin/ IGF-1 signaling has been associated with life span extension in various model 
organisms. However, the role of insulin/ IGF-1 signaling in human longevity remains 
controversial. In this study we related serum IGF-1 levels in nonagenarian siblings from the 
Leiden Longevity Study to the family mortality history score of their parents. We found that a 
lower parental family mortality history score (less mortality) was associated with lower IGF-1 
serum levels in female but not in male nonagenarian siblings. These findings suggest that reduced 
IGF-1 activity is associated with exceptional familial longevity. 
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Introduction 
The role of the evolutionarily conserved insulin/ insulin-like growth factor (IGF-1) signaling (IIS) 
pathway in the regulation of lifespan is well documented in worms 1, flies 2, and rodents 3, 4. 
Genetic mutations that inhibit IIS activation prolong lifespan in these organisms, particularly in 
the female sex. The involvement of IIS modulation in human longevity is less clear. In agreement 
with the findings in model organisms, reduced IIS pathway activity was associated with old age 
survival in sporadic female octogenarians and different cohorts of nonagenarians 5, 6. 
Furthermore, centenarians were shown to be enriched for rare IGF-1R mutations associated with 
IGF-1 resistance 7. In contrast to these apparent beneficial effects, lower serum IGF-I levels in 
humans have been associated with an increased risk of developing cardiovascular disease and 
diabetes 8. 
  
In order to identify heritable determinants of longevity we set up the Leiden Longevity Study. 
This study includes nonagenarian siblings, recruited from 421 Caucasian families based on 
proband siblings that both exhibit exceptional longevity 9 and their offspring 10. Earlier we 
reported on the lack of differences in IGF-1 serum levels between middle-aged offspring of 
familial nonagenarians and controls 11. In the nonagenarian siblings however, comparative 
analysis IGF-1 axis parameters is hampered by their extreme age, precluding the use of age-
matched controls. Therefore we calculated a family mortality history score describing the 
mortality of the parents of the nonagenarian siblings 12. We reasoned that in nonagenarian siblings 
from parents with a lower family mortality history score (i.e. lower than expected mortality), 
characteristics associated with longevity are more prominent than in nonagenarian siblings from 
parents with a higher family mortality history score. In the current study we aim to examine the 
association between parental family mortality history score of the parents of the nonagenarian 
siblings and serum parameters related to insulin/IGF-1 signaling in the nonagenarian siblings.   
 
Materials and methods 
In the Leiden Longevity Study, 421 families were recruited consisting of long-lived Caucasian 
siblings together with their offspring and the partners thereof. For the current study, data on IGF-
1 and IGFBP3 levels were available for 859 of the 944 nonagenarian participants from the Leiden 
Longevity Study. The Medical Ethical Committee of the Leiden University Medical Centre 
approved the study and informed consent was obtained from all subjects.  For details on 
enrollment please see previous publications 10, 11. 
  
All serum measurements were performed with fully automated equipment. For IGF-1 and 
IGFBP3, the Modular E170 was used, for high sensitivity C-reactive protein (hsCRP) the Cobas 
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Integra 800 was used, both from Roche, Almere, the Netherlands. The coefficients of variation of 
these measurements were all below 5 %. ADL, IADL, MMSE and self perceived health was 
available for 779 participants. 
 
Data on body height were available for 77 participants. Body height was measured using a tape 
measure when standing upright without shoes. Disability was determined using the activities of 
daily living scale (ADL) and Instrumental Activities of Daily Living scale (IADL). 13 Global 
cognitive function was assessed with the Mini Mental State Examination (MMSE). Self perceived 
health was assessed by one question with five alternatives: 1 = `very good', to 5 = `very poor'. 
ADL, IADL, MMSE and self perceived health was available for 779 participants. 
 
For each parent we computed the sex and birth cohort cumulative hazards using the life tables of 
the Dutch population. Note that since both parents are deceased one minus the cumulative hazard 
equals the martingale residual. The martingale residual is defined as the difference between the 
event status (0 if alive, 1 if deceased) and the cumulative hazard at the observed age (current age 
or age at death). The sum of the martingale residuals measures the deviation of survival of the 
parents with respect to their birth cohort. Therefore negative values mean excess survival and 
positive values mean excess mortality. 
 
The association between family mortality history score and IGF-1 axis parameters was assessed 
using a linear mixed model with a random sibship effect to model correlation of sibling data. 
Distributions of continuous variables were examined for normality and logarithmically 
transformed when appropriate (high sensitivity C-reactive protein). 17 individuals with serum 
IGF-1 or IGFBP3 levels beyond 3 standard deviations from the mean were excluded from the 
analyses: thus, in total 842 individuals were included in the analyses. The Statistical Package for 
the Social Sciences (SPSS) program for Windows, version 14.0, was used for data analysis. 
Graphs were drawn using Graph Pad Prism version 5.   
 
Results 
The baseline features of the study population are displayed in table 1. The median age of the 
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Table 1. Baseline characteristics of the study population 
 
 Study population 
Number participants (N) 842 
Males (N, %) 518 (61.5) 
Age (year) 92.9 (91.4 – 94.8) 
  
IGF-1 (nmol/L) 10.0 (7.6 – 12.9)  
IGFBP3 (mg/L) 2.9 (2.4 – 3.4) 
IGF-1 IGFBP- Ratio 0.10 (0.08 – 0.12) 
  
High sensitivity C-reactive protein (mg/L) 2.8 (1.3 – 5.7) 
  
Disability (points)  
   ADLs 18 (15 - 20) 
   Instrumental ADLs 8 (4 - 11) 
   Mini Mental State Examination 26 (22 - 28) 
   Self perceived health 3 (3 - 4) 
Unless stated otherwise, all data are given as median values with interquartile range (25% - 75%). 
 
Table 2 shows the association between the family mortality history score and the different IGF-1 
axis parameters for males and females separately according to two models. Model 1 was adjusted 
for age only. As IGF-1 levels are known to be affected by illness, we repeated all analyses after 
adjustment for various parameters of physical disability in model 2. In both models a lower 
family mortality history score (lower than expected mortality) was associated with lower IGF-1 
levels in females, but not in males (figure 1). No significant relation was observed between the 
family mortality history score and levels of IGFBP3 or the ratio of IGF-1 over IGFBP3, although 
in females a higher family mortality history score tended to be associated with a higher IGF-1 
IGFBP3 molar ratio. 
Next we determined the relation between family mortality history score and height for females 
and males separately. Although far from significant, in figure 2 higher family mortality history 






Table 2. Association between Family Mortality History Score and IGF-1 axis parameters 
Data are presented as mean change per one unit increase in Family Mortality History Score and 95% 
confidence intervals. Results were adjusted for sex and age, MMSE, ADLs, instrumental ADLs, High 
sensitivity C - reactive protein and Self Perceived Health. 
 
 Change per Family History Score Unit p-value 
Model 1: adjusted for age 
Females   
IGF-1 (nmol/L) 0.19 (-0.004 – 0.38) 0.055 
IGFBP3 (mg/L) 0.02 (-0.02 – 0.07) 0.25 
IGF-1 IGFBP-3 Molar Ratio (*104) 9.3 (-3.0 – 21.6) 0.14 
   
Males   
IGF-1 (nmol/L) 0.003 (-0.24 – 0.25) 0.98 
IGFBP3 (mg/L) -0.01 (-0.06 – 0.04) 0.78 
IGF-1 IGFBP3  Molar Ratio (*104) 4.2 (-12.4 – 20.8) 0.62 
   
Model 2: as model 1 adjusted for ADLs, IADLs, MMSE, SPH and logCRP 
Females   
IGF-1 (nmol/L) 0.26 (0.05 – 0.46) 0.017 
IGFBP3 (mg/L) 0.04 (-0.01 – 0.08) 0.11 
IGF-1 IGFBP3  Molar Ratio (*104) 12.0 (-0.6 – 24.6) 0.061 
   
Males   
IGF-1 (nmol/L) 0.05 (-0.21 – 0.32) 0.70 
IGFBP-3 (mg/L) -0.01 (-0.06 – 0.04) 0.74 
IGF-1 IGFBP3  Molar Ratio (*104) 9.8 (8.0 – 27.6) 0.28 
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Figure 1. Association between family mortality history score and IGF-1 serum levels, for females (A) 
and males (B). Bars represent tertiles of family mortality history scores adjusted for age, ADLs, IADLs, 
MMSE, self perceived health and log serum high sensitivity C-reactive protein. Association between family 
mortality history score and height for females (C) and males (D). Bars represent tertiles of family mortality 
history scores. Results were adjusted for age. 
 
Discussion 
Our findings suggest that lower serum IGF-1 levels are a heritable determinant for exceptional 
longevity as observed in the Leiden Longevity Study. These results concur with the observed 
association between reduced IIS activity and longevity in various model organisms as well as in 
human studies showing life extending effects of reduced IGF-1 signaling 1-4, 6. In these studies 
lifespan extending effects were mostly confined to females, in agreement with the results 
presented here.  
 
Our findings are in contrast with the lack of difference in IGF-1 serum levels previously observed 
between middle-aged offspring of familial nonagenarians and controls. These contrasting results 
may be partly due to differences in age. The estimated contribution of genetic factors is modest 
(20-30%) but was shown to become more important and specific at higher ages 14, 15. Therefore it 
is possible that the effects of genetic variation in the IIS pathway only become detectable at 
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advanced ages. In line, the association between FOXO3A and longevity was for example found to 
be stronger in centenarians than in nonagenarians 16. Another possible explanation for these 
contrasting observations could be differences in imprinting of the IGF-1 gene, reflecting historical 
differences in maternal nutrition between the two generations 17. 
 
Several weaknesses of our study should be considered. First, anthropometric data were only 
available for a small subset of the studied population. The non-significant association between 
family mortality history scores and small stature could therefore well be due to lack of power 6.  
In conclusion, we present preliminary evidence that in females but not in males reduced IGF-1 
levels are associated with exceptional familial longevity.  
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The hypothalamo–pituitary–thyroid axis has been widely implicated in modulating the aging 
process. Life extension effects associated with low thyroid hormone levels have been reported in 
multiple animal models. In human populations, an association was observed between low thyroid 
function and longevity at old age, but the beneficial effects of low thyroid hormone metabolism at 
middle age remain elusive. We have compared serum thyroid hormone function parameters in a 
group of middle-aged offspring of long-living nonagenarian siblings and a control group of their 
partners, all participants of the Leiden Longevity Study. When compared to their partners the 
group of offspring of nonagenarian siblings showed a trend towards higher serum thyrotropin 
levels (1.65 vs.157 mU/L, p=0.11) in conjunction with lower free thyroxine levels (15.0 vs. 15.2 
pmol/L, p=0.045) and lower free triiodothyronine levels (4.08 vs 4.14 pmol/L, p=0.024). 
Compared to their partners, the group of offspring of nonagenarian siblings show a lower 
thyroidal sensitivity to thyrotropin. These findings suggest that the favorable role of low thyroid 
hormone metabolism on health and longevity in model organism is applicable to humans as well. 
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Introduction 
The hypothalamo–pituitary–thyroid axis has been widely implicated in modulating the aging 
process. Life extension effects associated with low thyroid hormone levels have been reported in 
multiple animal models. In neonatal rats, induction of hypothyroidism results in a moderate 
extension of lifespan 1. Similarly, low thyroid hormone levels are characteristic of murine 
pituitary mutants with delayed aging: long-lived Ames and Snell dwarf mice show traits that are 
hypothesized to be related to thyroid hormone deficiency, including hypothermia and delayed 
maturation 2, 3. Administration of thyroid hormone during adulthood partly diminishes longevity 
in Snell dwarf mice 4. Another very long-living mammal, the naked mole rat (Heterocephalus 
glaber) also has very low serum thyroxine levels 5.  
In agreement with the findings in animals, various studies have shown an association between 
low thyroid function and improved longevity in elderly humans. In the general population of the 
oldest old, high levels of thyrotropin are associated with a prolonged life span 6, 7. In contrast, low 
serum thyrotropin and higher serum free thyroxin levels are related to an increased risk of 
cardiovascular mortality 8. These findings suggest a favorable effect of thyroid hypofunction on 
healthy aging in humans.  
However, comparative cross-sectional studies involving long-lived subjects are hampered by the 
lack of proper controls. These studies remain inconclusive as to whether thyroid hypofunction in 
extreme old age represents an adaptive mechanism or is the result of selective survival of subjects 
with lifelong thyroid hypofunction. We designed the Leiden Longevity Study in order to identify 
familial determinants of healthy longevity in nonagenarian siblings and their offspring, who are 
enriched for heritable influences on morbidity and mortality.9 The aim of this study was to assess 
whether low thyroid function observed in extreme old age is already present in middle-aged 
individuals with higher than average life expectancy. To this end we have compared thyroid 
hormone function parameters in a group of middle-aged offspring of long-living nonagenarian 
siblings and a control group of their partners of the Leiden Longevity Study.  
Materials and methods 
Leiden Longevity Study  
In the Leiden Longevity Study, 420 families were recruited consisting of long-lived Caucasian 
siblings together with their offspring and the partners thereof. Families were recruited if at least 
two long lived siblings were alive and fulfilled the age-criterion of 89 years or older for males and 
91 year or older for females. There were no selection criteria on health or demographic 
characteristics. For 2465 of the offspring and their partners, non-fasted serum samples taken at 
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baseline were available for the determination of endocrine and metabolic parameters. Between 
November 2006 and May 2008, for 2235 of the offspring and their partners, information on 
medical history was obtained from the participants’ treating physicians (response: 90.7%). For 
2255 of the offspring and their partners, information on the use of medication was obtained from 
the participants’ pharmacist (response: 91.5%). For 2184 of the offspring and partners a general 
questionnaire containing information on lifestyle and self-reported height and weight was 
obtained (response: 89.0%). For the present study, for a total of 1738 of the offspring and their 
partners, serum as well as information on medical history and information on medication use and 
the general questionnaire were available (inclusion: 69.5%). The Medical Ethical Committee of 
the Leiden University Medical Centre approved the study and informed consent was obtained 
from all subjects. 
 
For the current study participants using thyroid medication were excluded from the analyses: 32 
(2.7%) offspring using thyroid medication were excluded and 11 (2.0%) partners were excluded 
from the analyses. Thyroid hormone medication was defined as thyroid or anti-thyroid 
preparations (ATC code H03). Outliers were defined as serum thyroid parameters (thyrotropin, 
thyroxine and triiodothyronine) beyond three standard deviations below or above the standard 
error of the mean. Outliers were excluded from the analyses. 34 offspring with serum thyroid 
parameters beyond 3 standard deviations from the mean were excluded from the analyses, of 
which one individual was clinically hyperthyroid (thyrotropin <0.3 mU/L and free thyroxine > 24 
pmol/L) and three individuals clinically hypothyroid (thyrotropin > 4.8 mU/L and free thyroxine 
< 10 pmol/L). 9 partners with serum thyroid parameters beyond 3 standard deviations from the 
mean were excluded from the analyses, of which 2 individuals were clinically hyperthyroid 
(thyrotropin <0.3 mU/L and free thyroxine > 24 pmol/L). In our laboratory, the reference values 




All serum measurements were performed with fully automated equipment. For thyrotropin, free 
thyroxine and free triiodothyronine, the Modular E170 was used from Roche, Almere, the 
Netherlands. The coefficients of variation of these measurements were all below 5 %.  
 
Statistical analysis 
Distributions of continuous variables were examined for normality and logarithmically 
transformed, when appropriate and used in all calculations. Geometric means (with 95% 
confidence intervals (CI)) are reported for thyrotropin. All differences between offspring and 
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partner categories were assessed with the use of linear mixed modeling, adjusted for age and 
correlation of sibling data. Differences in age and body mass index between the two groups of 
offspring and partners were tested using a Mann-Whitney rank sum test. Differences in smoking 
behavior and gender distribution between the group of offspring and the group of partners were 
calculated using a Chi-Square test. The Statistical Package for the Social Sciences (SPSS) 
program for Windows, version 16.0, was used for data analysis. 
 
Results 
Table 1 shows the baseline characteristics for the two study populations. In total, we used data on 
1119 middle-aged offspring of nonagenarian siblings and 533 of their middle-aged partners. The 
group of female offspring was slightly older than the group of female partners, whilst the group of 
male offspring was younger than the group of male partners. No significant differences between 
the two groups were observed with regard body mass index and current smoking status. 
 
Table 1. Baseline characteristics of study populations 
 
Age is presented as median age with interquartile range. Height, weight and body mass index are presented 
as estimated means with 95% confidence intervals. Results for weight, height and body mass index were 
adjusted for age. 
 
Table 2 displays the mean serum levels of various thyroid function parameters in the group of 
middle-aged offspring of nonagenarian siblings as compared to the group of their middle-aged 
partners adjusted for age and body mass index. A trend was observed towards higher serum 
 Offspring Partners P-value 
Females – (n) 596  293   
   Age (year) 58.9 (54.9 – 64.0) 57.4 (52.4 – 61.9) <0.001 
   Height (cm) 166.8 (166.2 – 167.3) 167.0 (166.2 – 167.7) 0.62 
   Weight (kg) 69.6 (68.6 – 70.7) 70.8 (69.4 – 72.2) 0.17 
   Body Mass Index (kg/m2) 25.0 (24.7 – 25.4) 25.4 (24.9 – 25.9) 0.20 
   Currently smoking (n, %) 75 (12.8%) 45 (15.4%) 0.30 
    
Males – (n) 523  240   
   Age (year) 59.4 (55.0 – 64.2) 61.4 (56.2 – 66.3) 0.001 
   Height (cm) 178.6 (178.0 – 179.3) 179.1 (178.3 – 180.0) 0.32 
   Weight (kg) 82.4 (81.3 – 83.4) 82.7 (81.1 – 84.2) 0.73 
   Body Mass Index (kg/m2) 25.8 (25.5 – 26.1) 25.7 (25.3 – 26.1) 0.76 
   Currently smoking (n, %) 78 (15.1%) 37 (15.5%) 0.91 
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thyrotropin levels in the group of offspring when compared to the group of partners (p=0.11).  
The free serum thyroxine levels were lower in the group of offspring than in the group of partners 
(p=0.045). Likewise, mean free serum triiodothyronine levels were lower in the group of 
offspring in comparison to the group of partners (p=0.024). Results were not materially different 
when analyses were adjusted for smoking behavior. 
 
Table 2. Serum levels of thyroid hormone axis parameters for offspring and partners 
 
Data are presented as estimated means with 95% confidence intervals. Results for all were adjusted for 
age, sex and body mass index. Results for males and females separately were adjusted for age and body 
mass index. Reference values are given between parentheses. 
 
Discussion 
The secretion of thyroid hormone from the thyroid gland is regulated by thyrotropin, which in 
turn is controlled by the hypothalamic derived thyroid-releasing-hormone. The main thyroid 
hormone produced in the thyroid gland is thyroxine (3,5,3',5'-tetraiodothyronine), which has a 
low affinity for thyroid hormone receptors in target tissues. Thyroxine can be converted 
peripherally to the more biologically active free 3,5,3'-triiodothyronine or the inactive reverse 
 Offspring Partners p-value 
All    
  Thyrotropin (0.3 - 4.8 mU/L) 1.65 (1.59 - 1.71) 1.57 (1.49 - 1.66) 0.11 
  Free thyroxine (10 - 24 pmol/L) 15.0 (14.9 - 15.2) 15.2 (15.0 - 15.4) 0.045 
  Free triiodothyronine (2.5 - 5.5 pmol/L) 4.08 (4.04 - 4.12) 4.14 (4.09 - 4.20) 0.024 
  Ratio triiodothyronine thyroxine   0.28 (0.27 - 0.28) 0.28 (0.27 - 0.28) 0.84 
     
Females    
  Thyrotropin (0.3 - 4.8 mU/L) 1.72 (1.63 - 1.80) 1.64 (1.52 - 1.76) 0.28 
  Free thyroxine (10 - 24 pmol/L) 14.8 (14.6 - 14.9) 15.1 (14.8 - 15.3) 0.034 
  Free triiodothyronine (2.5 - 5.5 pmol/L) 3.89 (3.84 - 3.94) 4.00 (3.93 - 4.07) 0.007 
  Ratio triiodothyronine thyroxine   0.27 (0.26 - 0.27) 0.27 (0.26 - 0.27) 0.48 
     
Males    
  Thyrotropin (0.3 - 4.8 mU/L) 1.60 (1.52 – 1.69) 1.53 (1.42 - 1.65 ) 0.26 
  Free thyroxine (10 - 24 pmol/L) 15.2 (15.0 - 15.4) 15.5 (15.2 - 15.7) 0.12 
  Free triiodothyronine (2.5 - 5.5 pmol/L) 4.26 (4.20 - 4.31) 4.34 (4.26 - 4.42) 0.048 
  Ratio triiodothyronine thyroxine   0.28 (0.28 - 0.29) 0.28 (0.28 - 0.29) 0.95 
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triiodothyronine (3,3′,5′-triiodothyronine). When compared to their partners the group of 
offspring of nonagenarian siblings showed a trend towards higher serum thyrotropin levels in 
conjunction with lower free thyroxine levels and lower free triiodothyronine levels. These 
findings indicate a lower thyroidal sensitivity to thyrotropin in the group of offspring of 
nonagenarian siblings.  
 
In middle aged human populations the effect of low thyroid hormone metabolism on health is 
unclear. At middle age, overt hypothyroidism is considered a risk factor for the development of 
atherosclerosis and myocardial infarction 10, 11. Paradoxically, in euthyroid middle-aged subjects, 
lower triiodothyronine serum levels are associated with a beneficial cardio-metabolic profile 12, 13. 
In the current study we demonstrate lower thyroid hormone levels in a middle-aged population 
which was previously shown to have a lower prevalence of cardiovascular disease 14.  These data 
suggest that selective survival of subjects with a lifelong thyroid hypofunction may contribute to 
the association between decreased thyroidal sensitivity to thyrotropin and a longer life span 6, 7.  
 
Our results agree with observations in several several animal studies showing that lower activity 
of the thyroid hormone axis is beneficial during the aging process 1, 3, 15. Active triiodothyronine 
primarily regulates the basal metabolic rate of cells, thereby increasing thermogenesis and the 
production of free radicals 16. Data from model organisms show that low triiodothyronine is 
associated with lower production of reactive oxygen species (ROS) and ROS inflicted genomic 
damage 17. The more efficient transport of electrons through the respiratory chain under 
conditions of low triiodothyronine might reduce the production of ROS and slow aging. 
Additionally, previous studies in euthyroid subjects have shown an association between higher 
levels of thyroid hormones and higher serum glucose levels, higher serum insulin levels as well as 
increased serum triglyceride levels in males 18, 19. Furthermore higher triiodothyronine levels have 
been associated higher blood pressure. Increases in heart rate, cardiac output, myocardial 
contractility, and blood volume possibly underlie this association between triiodothyronine levels 
and blood pressure 20.  
 
In conclusion, our data demonstrate that the middle-aged offspring of nonagenarian siblings have 
lower serum free triiodothyronine levels as compared to their middle-aged partners. These 
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A relation between low thyroid activity and prolonged lifespan in humans has been 
observed. Several studies have demonstrated hereditary and genetic influences on thyroid 
function. The aim of this study was to test whether low thyroid activity associated with 
extreme longevity constitutes a heritable phenotype which could contribute to the familial 
longevity observed in the Leiden Longevity Study. The Leiden Longevity Study 
comprises 859 nonagenarian siblings (median age 92.9 year) from 421 long-lived 
families. Families were recruited from the entire Dutch population if at least two long-
lived siblings were alive and fulfilled the age-criterion of 89 years or older for males and 
91 years or older for females. There were no selection criteria on health or demographic 
characteristics. In the present study we calculated the Family Mortality History score of 
the parents of the nonagenarian siblings and related this to thyroid function parameters in 
the nonagenarian siblings. We found that a lower family history score (less mortality) of 
the parents of nonagenarian siblings was associated with higher serum thyrotropin levels 
(p=0.005), lower free serum thyroxine levels (p=0.002) as well as lower free 
triiodothyronine levels (p=0.034) in the nonagenarian siblings. Our findings support the 
previous observation that low thyroid activity in humans constitutes a heritable phenotype 
which contributes to exceptional familial longevity observed in the Leiden 
Longevity Study.
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Introduction 
A relation between low thyroid function and prolonged lifespan in elderly humans has been noted 
1, 2. In the oldest old, higher concentrations of thyrotropin are associated with a survival benefit 
without detrimental effects on ability or mood. Contrastingly, at old age decreased serum 
thyrotropin and raised serum free thyroxin levels are related to an increased risk of mortality.3 
Hereditary and genetic influences on thyrotropin and serum thyroid hormone concentrations have 
been reported in multiple studies. The lower thyroid activity associated with extreme longevity 
might therefore constitute a heritable phenotype 4-8. 
In order to identify heritable determinants of longevity we designed the Leiden Longevity Study. 
This study comprises nonagenarian siblings, recruited from families based on proband siblings 
that both exhibit exceptional longevity 9. We also included the offspring of the nonagenarian 
siblings, which are enriched for heritable influences on morbidity and mortality 10. In line with the 
observed association between low thyroid function and longevity, we showed that the middle-
aged offspring of nonagenarian siblings indeed have lower thyroid hormone levels when 
compared to middle-aged controls 11. In the nonagenarian siblings however, comparative analysis 
of the association between low thyroid function and longevity is hampered by their extreme age, 
which precludes the use of proper age-matched controls. 
To examine the relation between low thyroid function and longevity in the nonagenarian siblings 
we calculated a family history score describing the mortality of the parents of the nonagenarian 
siblings 12. We reasoned that in nonagenarian siblings from parents with a lower family history 
score (i.e. lower than expected mortality), traits related to longevity would be more pronounced 
than in nonagenarian siblings from parents with a higher family history score. Therefore we 
hypothesized that lower family history score of the parents of the nonagenarian siblings is related 
to higher thyrotropin levels and lower serum thyroxine levels in the nonagenarian siblings.  
 
Materials and methods 
Leiden Longevity Study 
In the Leiden Longevity Study, 421 families were recruited consisting of long-lived Caucasian 
siblings together with their offspring and the partners thereof. Between 2002 and 2006 families 
were recruited if at least two long-lived siblings were alive and fulfilled the age-criterion of 89 
years or older for males and 91 years or older for females, representing less than 0.5 % of the 
Dutch population in 2001. There were no selection criteria on health or demographic 
characteristics. Blood samples were taken at baseline for extraction of DNA, RNA and the 
determination of non-fasted serum and plasma parameters. Blood samples were obtained 
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throughout the day between 9:30 a.m and 17:00 p.m Moreover, data on disability, global 
cognitive function and self perceived health were collected. The Medical Ethical Committee of 
the Leiden University Medical Centre approved the study and informed consent was obtained 
from all subjects. Of the 944 nonagenarians of the Leiden Longevity Study, data on thyrotropin, 
thyroxine and triiodothyronine levels and sampling time were available for 859 of the 
nonagenarian participants. Of the 421 families included in this study, 344 (81.7%) families 
contributed 2 nonagenarian siblings, 67 families have contributed 3 nonagenarian siblings 
(23.3%), 9 families have contributed 4 nonagenarian siblings (4.2%), 1 family has contributed 5 
nonagenarian siblings (0.6%). 
Chemical analyses 
All serum measurements were performed with fully automated equipment. For thyrotropin, free 
thyroxine and free triiodothyronine, the Modular E170 was used, for high sensitivity C-reactive 
protein (hsCRP) the Cobas Integra 800 was used, both from Roche, Almere, the Netherlands. The 
coefficients of variation of these measurements were all below 5 %. All chemical analyses were 
performed in a single batch at the Department of Clinical Chemistry, Leiden University Medical 
Center, the Netherlands, excluding the possibility of confounding by batch effects. In our 
laboratory, the reference values for thyrotropin were 0.3-4.8 mIU/L; free thyroxine: 10-24 
pmol/L; and free triiodothyronine, 2.5-5.5 pmol/L. Of the 859 participants, 746 participants 
(86.8%) were euthyroid; 5 had overt hyperthyroidism (0.6%); 43 (5.0%) had subclinical 
hyperthyroidism; 7 (0.8%) had overt hypothyroidism; 58 (6.8%) had subclinical hypothyroidism.  
Additionally, of the 746 euthyroid subjects, 6 subjects had isolated free thyroxine levels outside 
the reference values and 14 subjects had isolated free triiodothyronine levels outside the reference 
values. When analyses were restricted to subjects with thyroid function parameters within the 
reference range 726 subjects were included (that is: 746 euthyroid subjects minus 6 subjects 
having abnormal levels of thyroxine and 14 subjects having abnormal levels of triiodothyronine). 
 
Disability 
In the Leiden Longevity Study disability was determined using the activities of daily living scale 
(ADL) and Instrumental Activities of Daily Living scale (IADL) 13. Disability scores in ADLs 
range from 0 points (fully dependent in all activities) to 20 points (fully independent in all 
activities). Disability scores in IADLs range from 0 points (fully dependent in all activities) to 14 
points (fully independent in all activities). Global cognitive function was assessed with the Mini 
Mental State Examination (MMSE). Self perceived health was assessed by one question with five 
alternatives: 1 = “very good”, 2 = “rather good”, 3 = “moderate”, 4 = “rather poor”, 5 = “very 
poor”. The MMSE scores range from zero points (very severe cognitive impairment) to 30 points 
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(optimal cognitive function). ADL, IADL, MMSE and self perceived health was available for 779 
participants. 
Family History Score 
Each participating family has provided us with the genealogical information regarding the parents 
of the nonagenarian siblings, all siblings, and the offspring of the nonagenarian siblings. To 
reduce possible unreliability of questionnaires and participants’ memories, whenever possible, 
this information was verified by passport, or by birth or marriage certificate. Furthermore, all data 
were additionally verified with the personal record cards of the deceased family members in the 
national population registry located at the Central Bureau of Genealogy in The Hague, The 
Netherlands. For each parent we computed the sex and birth cohort cumulative hazards using the 
life tables of the Dutch population. A family history score for a family was defined as two minus 
the sum of the cumulative hazards of the two parents. Note that since both parents are deceased 
one minus the cumulative hazard equals the martingale residual. The martingale residual is 
defined as the difference between the event status (0 if alive, 1 if deceased) and the cumulative 
hazard at the observed age (current age or age at death). The sum of the martingale residuals 
measures the deviation of survival of the parents with respect to their birth cohort. Therefore 
negative values mean excess survival and positive values mean excess mortality. 
 
Statistical analyses 
The association between family history score and serum thyroid function parameters was assessed 
using a linear mixed model with a random sibship effect to model correlation of sibling data. 
Broad heritability of serum thyroid function parameters was estimated with the following 
formula: heritability = 2 * (between-families variance)/(between-families variance + within-
families variance). Distributions of continuous variables were examined for normality and 
logarithmically transformed when appropriate (thyrotropin and high sensitivity C-reactive 
protein). The Statistical Package for the Social Sciences (SPSS) program for Windows, version 
14.0, was used for data analysis. Graphs were drawn using Graph Pad Prism version 5.  
 
Results 
The principal features of the studied population (n=859) are displayed in table 1. The median age 
of the study population was 92.9 years and 38.4% of the study population was male.  
First, we examined the broad heritability of serum thyroid function parameters in the cohort of 
nonagenarian siblings, as shown in table 2. To determine to what extent the association between 
thyroid function and familial longevity was driven by subjects with thyroid function parameters 
beyond the normal range, we repeated all the analyses in subjects restricted to thyroid function 
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parameters within the euthyroid range (model 2). Moreover, it has been demonstrated that 
alterations in thyroid hormone levels can occur during acute or chronic critical illness. This 
condition, referred to as non-thyroidal illness syndrome is characterized by a variety of alterations 
in thyroid function parameters that commonly include low serum triiodothyronine along with 
normal or inappropriately low thyrotropin and serum free thyroxine levels 14. To exclude the 
possibility that physical illness played a major role in our findings, particularly regarding 
triiodothyronine levels, we repeated the analyses after adjustment for ADLs, IADLs and serum 
high sensitivity C-reactive protein levels. (model 3). Dependent on the used model, heritability of 
the serum thyrotropin levels varied between 0.41 and 0.49.  Heritability of serum levels of free 
thyroxine and free triiodothyronine ranged from 0.18 – 0.31 and 0.24 – 0.50 respectively.   
    Table 1. Baseline characteristics of the study population 
 
 Study population 
Number participants 859 
Males (n, %) 330 (38.4) 
Age (year) 92.9 (91.4 – 94.8) 
  
Thyrotropin (0.3 – 4.8 mU/L) 1.51 (0.95 – 2.40) 
Free thyroxine (10 – 24 pmol/L) 16.0 (14.4 – 17.6) 
Free triiodothyronine (2.5 – 5.5 pmol/L) 4.00 (3.70 – 4.40) 
  
Hyperthyroidism (n, %) 5 (0.6) 
Subclinical hyperthyroidism (n, %) 43 (5.0) 
Euthyroidism (n, %) 746 (86.8) 
Hypothyroidism (n, %) 7 (0.8) 
Subclinical hypothyroidism (n, %) 58 (6.8) 
  
High sensitivity C-reactive protein (<10 mg/L) 2.84 (1.28 – 5.95) 
  
Disability (points)  
   ADLs 18 (15 – 20) 
   Instrumental ADLs 8 (4 - 11) 
   Mini Mental State Examination 26 (22 - 28) 
   Self perceived health 3 (3 - 4) 
Data are presented as median values with interquartile range (25 – 75%). Reference values are given 
between parentheses. 
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Table 2. Broad heritability of thyroid function parameters within the study population 
 
 Broad heritability p-value 
Model 1: adjusted for sex and age. 
Thyrotropin  0.41 <0.001 
Free thyroxine  0.18 0.049 
Free triiodothyronine  0.24 0.009 
 
Model 2: as model 1, restricted to participants with levels within reference values. 
Thyrotropin  0.49 <0.001 
Free thyroxine  0.31 0.007 
Free triiodothyronine  0.50 <0.001 
 
Model 3: as model 2 adjusted for ADL, IADL, serum hsCRP levels. 
Thyrotropin  0.46 <0.001 
Free thyroxine  0.30 0.012 
Free triiodothyronine  0.45 <0.001 
Next, we assessed the relation between lower family history score of the parents of the 
nonagenarian siblings and thyroid hormone function parameters in the nonagenarian siblings. For 
this purpose we calculated the family history score of the parents of the nonagenarian siblings, as 
depicted in figure 1. A family history score of 0 represents the standardized mortality rate of the 
entire Dutch population. Values below 0 denote excess survival when compared to the Dutch 
population, while values above 0 denote relative excess mortality. Median family history score 
was -1.37 (interquartile range: -2.68 - -0.21), indicating that we have recruited families with a 
higher average survival than the general Dutch population.  
Figure 1. Frequency distribution of family 
history score of the parents of 
nonagenarian siblings. A family history 
score of 0 represents the standardized 
mortality rate of the entire Dutch 
population. Values below 0 denote excess 
survival when compared to the Dutch 
population, whilst values above 0 denote 





Table 3 and figure 2 show the association between family history score and thyroid function 
parameters. A lower family history score (lower than expected mortality) was associated with 
higher serum thyrotropin levels, lower free serum thyroxine levels as well as lower free serum 
triiodothyronine levels. Similar results were obtained after restriction of analyses to participants 
with thyroid hormone levels within reference values. We repeated the analyses after adjustment 
for ADLs, IADLs and serum high sensitivity C-reactive protein levels to exclude possible 
confounding by physical illness ( all p values <0.05). 
  
Table 3 Association between family history score and serum thyroid function parameters 
 Change per increase familial mortality 
history unit 
p-value 
Model 1: adjusted for sex and age. 
Log thyrotropin (mU/L) -0.05 (-0.09 - -0.004) 0.032 
Free thyroxine (pmol/L) 0.16 (0.05 – 0.26) 0.005 
Free triiodothyronine (pmol/L) 0.03 (0.002 – 0.06) 0.034 
   
Model 2: as model 1, restricted to participants with levels within reference values. 
Log thyrotropin (mU/L) -0.04 (-0.06 - -0.01) 0.005 
Free thyroxine (pmol/L) 0.13 (0.04 – 0.23) 0.005 
Free triiodothyronine (pmol/L) 0.01 (-0.01 – 0.04) 0.23 
   
Model 3: as model 2 adjusted ADL, IADL, serum hsCRP levels..  
Log thyrotropin (mU/L) -0.04 (-0.06 - -0.01) 0.005 
Free thyroxine (pmol/L) 0.15 (0.05 – 0.25) 0.002 
Free triiodothyronine (pmol/L) 0.02 (0.002 – 0.05) 0.034 
  Data are presented as mean change per unit increase in familial mortality history and 95% confidence intervals. 
 
Figure 2A-C. Association between family history score and serum thyroid hormone parameters. For 
thyrotropin (A), free thyroxine (B) and free triiodothyronine (C).  Bars represent tertiles of family history 
score scores adjusted for age, sex, ADLs, IADLS, and log serum high sensitivity C-reactive protein. Results 
were restricted to participants with serum thyroid hormone parameters within reference values. 
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Discussion  
We aimed to examine the association between lower thyroid function and longevity in our cohort 
of nonagenarian siblings.  We found that a lower family history score (less mortality) of the 
parents of nonagenarian siblings was associated with higher serum thyrotropin levels, lower free 
serum thyroxine levels as well as lower free triiodothyronine levels in the nonagenarian siblings. 
This observation was not explained by differences in physical disability.  
 
Our findings are an important extension of our previous observation of lower free thyroxine 
levels and lower free triiodothyronine levels along with a tendency towards higher serum free 
thyrotropin levels in the middle-aged offspring of nonagenarian siblings when compared to 
controls 11. Our results not only concur with the reported association between low thyroid 
hormone function and human longevity1 , but also support the recently reported observation of 
low thyroid function as a heritable phenotype contributing to exceptional longevity 2,15. Moreover, 
our results are in agreement with earlier studies showing a strong heritability of thyroid function 6-
8.  
The relation between lower family history score of the parents of the nonagenarian siblings and 
higher thyrotropin along with lower serum thyroxine levels in the nonagenarian siblings may 
indicate that lower activity of the thyroid hormone axis is a heritable phenotype which contributes 
to exceptional longevity. Lower activity of the thyroid hormone axis possibly serves as a 
mechanism to shift energy expenditure from growth and proliferation to protective maintenance. 
The phenotype of low thyroid hormone levels observed in our long-lived cohort is reminiscent of 
the phenotype of murine pituitary mutants with delayed aging, as for example the long-lived 
Ames and Snell dwarf mice 16, 17. These model organisms show traits that are hypothesized to be 
related to thyroid hormone deficiency, and supplementation of thyroid hormone during adulthood 
partly diminishes their enhanced lifespan.18 However, unlike our cohort of nonagenarian siblings 
in which downregulation of the thyroid axis is due to a lower thyroid activity, in these model 
organisms thyroid hormone deficiency is due to central hypothyroidism at the level of the 
pituitary.  
 
There are some limitations to our study. First, data on current medication use were not available 
for the nonagenarian siblings. Furthermore, we have no records of previous history of thyroidal 
disease, the prevalence of which increases with age. Therefore we could not determine to what 
extent our observations were affected by thyroid disease and/or its treatment. Thirdly, data on 
specific SNPs in the thyrotropin receptor which were shown to be associated with higher 
thyrotropin levels 15, were not available for our cohort. Future research will therefore focus on 
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unraveling the underlying genetic determinants. Another limitation is that samples were not all 
drawn fasted at 9:00 a.m. However, additional adjustment for time of blood sampling did not 
materially change any of the obtained results.  
 
In conclusion our results support the previous observation that low thyroid activity in humans 
constitutes a heritable phenotype which contributes to exceptional longevity.  
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Increasing evidence suggests that pro-inflammatory cytokines are at play in lowering peripheral 
thyroid hormone levels during critical illness. Conversely, thyroid hormones have been suggested 
to enhance production of inflammatory cytokines. In view of these considerations, we 
hypothesized a mutual association between triiodothyronine and pro-inflammatory cytokines. 
Therefore we evaluated the relation between both circulating and induced inflammatory markers 
and serum thyroid function parameters in the Leiden 85-plus Study. We found that higher 
circulating levels of inflammatory markers were associated with lower levels of free serum 
triiodothyronine. In turn, higher serum free triiodothyronine levels were related to higher 
production capacity of pro-inflammatory cytokines after stimulation with lipopolysaccharide. By 
combining in vivo en ex vivo data we were able to demonstrate for the first time the existence of 
a potential feedback mechanism between thyroid function and immune production capacity. We 
conclude that maintenance of normal thyroid function might be important for a preserved immune 
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Introduction 
During critical illness, major changes in serum thyroid hormone metabolism without primary 
involvement of the thyroid gland can occur 1;2. This altered thyroid metabolism, referred to as 
non-thyroidal illness syndrome, is characterized by low serum levels of triiodothyronine and 
thyroxine, without changes in thyrotropin levels. Although the pathogenesis of non-thyroidal 
illness syndrome remains poorly understood, the reduction of peripheral thyroid levels is most 
probably under the influence of pro-inflammatory cytokines, and interleukin-6 in particular 3-5.  
 
Conversely, it has been suggested that thyroid hormones induce production of inflammatory 
cytokines. Earlier studies have demonstrated higher circulating levels of pro-inflammatory 
cytokines in patients with hyperthyroidism 6;7. These elevated cytokine levels were independent 
of autoimmune inflammation usually associated with thyroid disease. Moreover, treatment of 
hyperthyroidism was associated with lowering of serum pro-inflammatory cytokine levels.8  
 
In view of these considerations, we postulated a mutual association between triiodothyronine and 
pro-inflammatory cytokines, in which serum free triiodothyronine has a stimulatory effect on the 
pro-inflammatory cytokine production capacity, whilst pro-inflammatory cytokines in turn temper 
this stimulatory effect of triiodothyronine by lowering peripheral thyroid hormone levels. To test 
this hypothesis we first assessed the relation between various circulating inflammatory markers 
and serum thyroid function parameters in the Leiden 85-plus Study, a prospective population 
based study among the oldest old. Next, we assessed the relation between serum thyroid function 
parameters and ex vivo cytokine production capacity. Physical illness was considered a potential 
confounder in the relation between serum thyroid function parameters and cytokine production 
capacity. 
 
Materials and methods 
The Leiden 85-plus Study 
We obtained data from the prospective population-based Leiden 85-plus Study involving 85-year 
old inhabitants of the city of Leiden, the Netherlands. A total of 599 subjects (397 women and 
202 men) participated (with a response rate of 87%). No selection criteria had been imposed for 
health status or demographic characteristics. A cytokine production capacity assay was performed 
for 555 subjects. For the present study subjects using thyroid medication were excluded from 
analyses (n = 21) as were participants with incomplete thyroid function parameters (n=22). For 
further details on enrollment we refer to previous publications.9;10 The Medical Ethical 
Committee of the Leiden University Medical Centre approved the study and informed consent 




All serum measurements were performed with fully automated equipment. For thyrotropin (TSH), 
free thyroxine (fT4) and free triiodothyronine (fT3), the Modular E170 was used and for C-
reactive protein (CRP), the Hitachi Modular or the Cobas Integra 800, both from Roche, Almere, 
the Netherlands were applied. Coefficients of variation (CV) of these measurements were below 5 
%. In our laboratory, the reference values for thyrotropin were 0.3-4.8 mIU/L; free thyroxine: 13-
23 pmol/L; and free triiodothyronine: 2.5-5.5 pmol/L. 
The production capacity of cytokines (ng/mL) was assessed by measuring the cytokine 
production capacity of whole blood samples upon ex vivo stimulation with lipopolysaccharide 
(LPS) as described elsewhere.11 In short, cytokine production peak levels were assessed with an 
ex vivo whole-blood assay. All venous blood samples were taken in the morning before 11.00 
a.m to preclude circadian variation. The blood was collected in heparinized tubes and samples 
were diluted two-fold with RPMI-1640 (Sigma, St. Louis, MO) and stored after addition of 
10 pg/ml E. coli-derived LPS (Difco Laboratories, Detroit) at 37 °C and 5% CO2 for 24 hours. 
After centrifugation, the supernatants were stored at −80 °C until assayed using standard ELISA 
techniques (Central Laboratory of the Blood Transfusion Service, Amsterdam, The Netherlands). 
The CV for the cytokine assays, influenced also by dilutions for high stimulated values, were 
below 6% for IL-1β and IL-10; below 8 % for TNF-α and IL-6; whereas IL-1 RA ranged up to 12 
%.  
Data on circulating interleukin-6 levels were not available for our study population. Therefore, we 
used the IL-6 levels in unstimulated whole blood as a surrogate measure for circulating IL-6 
levels.12 
Health status 
We considered physical illness a potential confounder in the relation between serum thyroid 
function parameters and cytokine production capacity. Indication of baseline health status was 
obtained by assessing plasma levels of C-reactive protein, Activities of Daily Living scores, 
Instrumental Activities of Daily Living scores and Mini Mental State Examination. Disability 
scores in ADLs and in IADLs range from 9 points, indicating complete independence in all 
activities, to 36 points indicating complete dependence in all activities. The MMSE scores range 
from zero points, indicating very severe cognitive impairment, to 30 points indicating optimal 
cognitive functioning. 
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Statistical analyses 
The association between serum inflammatory markers and thyroid function parameters was tested 
using a linear regression model adjusted for sex. For the association between thyroid axis 
parameters and cytokine production capacity we used a linear regression model adjusted for sex 
only and additionally adjusted for ADLs, IADLs, MMSE and CRP to take into account potential 
confounding by physical illness. Distributions of continuous variables were examined for 
normality and logarithmically transformed, when appropriate (Thyrotropin, CRP, unstimulated 
IL-6, and stimulated levels of IL-1β, IL-6, TNF-α, IL-1RA, and IL-10). The Statistical Package 
for the Social Sciences (SPSS) program for Windows, version 16.0 was used for data analysis. 
Sixteen subjects had serum thyroid parameters beyond three standard deviations from the 
geometric mean and were considered outliers. All but two of the sixteen outliers were euthyroid.  
 
Results 
The baseline characteristics of the 496 participants in the study are presented in table 1. All study 
participants were 85 years of age and 327 out of 496 participants (65.9%) were female.  
 
Table 2 shows the association between various serum inflammatory markers and different thyroid 
parameters. Neither CRP nor interleukin 6 were associated with serum thyrotropin or free 
thyroxine levels. Higher levels of circulating C-reactive protein were significantly related to 
lower serum levels of free triiodothyronine (p = 0.001). Likewise, higher levels of interleukin-6 
were associated with lower levels of triiodothyronine (p = 0.020). We repeated the analyses after 
excluding persons who on the basis of their CRP levels (higher than 10.0 mg/dL) may be 
experiencing an acute infection (n=75). Although after exclusion of subjects with CRP levels 
above 10 mg/dL the associations between free triiodothyronine levels and CRP and between free 
triiodothyronine levels and IL6 lost statistical significance, the effect sizes remained roughly 
similar, indicating that the observed associations are not completely driven by those with 
exceptionally high hsCRP. 
 
Next, we assessed the association between different thyroid function parameters and whole blood 
LPS-stimulated cytokine production capacity. The outcomes are given in Table 3. Serum 
thyrotropin levels and serum free thyroxine levels were not associated with cytokine production 
capacity. However, higher levels of serum free triiodothyronine concentrations were consistently 
associated with a higher production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) after 
whole blood stimulation with LPS. The relation between triiodothyronine levels and the pro-






























ata are given as median value with interquartile range, unless stated otherwise.  
* IL-6 levels in unstimulated whole blood were used as a surrogate measure for 











 Study Population 
N = 496 
Demographics  
   Age (year)  85 
   Females (N, %) 327 (65.9 %) 
   MMSE (points) 26 (22 – 28) 
   ADLs (points) 10 (9 – 15) 
   Instrumental ADLs (points) 18 (12 - 26) 
  
Serum parameters   
   Thyrotropin – mU/L 1.81 (1.20 – 2.74) 
   Free thyroxine  – pmol/L 14.3 (12.7 – 15.7) 
   Free triiodothyronine – pmol/L 3.41 (3.08 – 3.74) 
  
   C-reactive protein (mg/L) 4.0 (1.0 – 8.0) 
   Unstimulated IL-6 (ng/L)* 11.0 (1.0 – 50.5) 
  
LPS- induced cytokine production   
   IL-1β (ng/L) 3517 (2099 – 6502) 
   IL-6 (ng/L) 60750 (43406 - 84733) 
   TNF-α (ng/L) 10325 (7393 – 13418) 
   IL-1RA (ng/L) 37297 (28369 – 46016) 
   IL-10 (ng/L) 764 (490 - 1089) 
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Table 2. Association between serum inflammatory markers and thyroid function parameters 
 
Data are given as mean change (with standard error of the mean) in serum thyroid parameter per standard 
deviation increase in ln C-Reactive protein and Ln unstimulated IL-6. Analyses were adjusted for sex. LPS: 
lipopolysaccharide. 
 
We considered physical illness as a potential confounder of the relation between triiodothyronine 
levels and cytokine production capacity. Therefore we repeated the analyses after inclusion of 
parameters of physical disability: activities of daily living score (ADLs), instrumental activities of 
daily living score (ADLs), Mini Mental State Examination (MMSE) and serum C-reactive protein 
(CRP). As apparent from table 4, correction for these parameters did not substantially affect our 
results. Also exclusion of subjects with hsCRP levels higher than 10.0 mg/L (n=75) from the 
analyses did not materially affect the observed associations between thyroid function parameters 
and whole blood LPS-stimulated cytokine production (data not shown):  lower free 
triiodothyronine levels were associated with lower production capacity of pro-inflammatory 
cytokines after stimulation with LPS (all p values <0.006). No relation was observed between 
levels of serum thyrotropin and serum free thyroxine and cytokine production capacity. 
 
 
 Change per standard deviation increase 
 All subjects  Restricted to CRP levels ≤10 (mg/dL) 
Ln C-Reactive protein     
   ln thyrotropin (mU/L) 0.02 (0.03)  0.04 (0.05) 
   p-value 0.57  0.32 
   Free thyroxine (pmol/L) 0.07 (0.10)  -0.09 (0.13) 
   p-value 0.47  0.52 
   Free triiodothyronine (pmol/L) -0.07 (0.02)  -0.05 (0.03) 
   p-value 0.001  0.09 
    
Ln unstimulated IL-6    
   ln thyrotropin (mU/L) 0.02 (0.03)  0.03 (0.04) 
   p-value 0.57  0.40 
   Free thyroxine (pmol/L) 0.05 (0.10)  0.01 (0.11) 
   p-value 0.59  0.92 
   Free triiodothyronine (pmol/L) -0.05 (0.02)  -0.03 (0.02) 
   p-value 0.020  0.25 
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Table 3. Association between thyroid function parameters and whole blood LPS-stimulated cytokine 
production  
Data are given as mean change (with standard error of the mean) in LPS stimulated cytokine level per 




Figure 1. Relation between tertiles of serum free triiodothyronine levels and pro-inflammatory cytokine 
production capacity for A: Log Il-1β; B: Log IL-6; C: Log TNF-α. Results were adjusted for sex. 
 
 
 Change per standard deviation increase 
LPS -stimulated cytokine 
levels 





 Free triiodothyronine 
(pmol/L) 
   ln IL-1β (ng/ml) -0.06 (0.06)  0.02 (0.05)  0.13 (0.04) 
   p-value 0.25  0.61  0.002 
   ln IL-6 (ng/ml) -0.02 (0.04)  0.00 (0.03)  0.10 (0.03) 
   p-value 0.56  0.99  <0.001 
   ln TNF-α (ng/ml) -0.02 (0.03)  0.01 (0.03)  0.09 (0.02) 
   p-value 0.45  0.63  <0.001 
      
   ln IL1β RA (ng/ml) 0.01 (0.03)  0.02 (0.03)  0.02 (0.02) 
   p-value 0.96  0.36  0.39 
   ln IL-10 (ng/ml) -0.03 (0.05)  -0.03 (0.04)  0.07 (0.04) 
   p-value 0.47  0.49  0.052 
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Table 4. Association between thyroid axis parameters and whole blood LPS-stimulated  
cytokine production in subjects aged 85  
Data are given as mean change (with standard error of the mean) in LPS stimulated cytokine level per 
standard deviation increase in serum thyroid parameter.  All analyses were adjusted for sex, ADLs, 
instrumental ADLs, MMSE and log serum CRP levels. LPS: lipopolysaccharide. 
 
Discussion 
The purpose of this study was to investigate a mutual association between triiodothyronine and 
pro-inflammatory cytokines. Here, we show that higher circulating levels of inflammatory 
markers were associated with lower levels of free serum triiodothyronine. In turn, lower free 
triiodothyronine levels were related to lower production capacity of pro-inflammatory cytokines 
after stimulation with LPS. We did not observe such a relation for levels of serum thyrotropin and 
serum free thyroxine. Our findings were independent of measures of physical and cognitive 
impairment.  
 
The observed association between higher unstimulated interleukin-6 levels and lower free serum 
triiodothyronine in our study agrees with earlier reports which show an association between 
increased inflammatory cytokines and low triiodothyronine syndrome 3;4. Moreover, other studies 
have demonstrated higher circulating levels of pro-inflammatory cytokines in patients with 
hyperthyroidism, suggesting a stimulatory effect of thyroid hormones on inflammatory cytokine 
production 8. However, to our knowledge this is the first study to address a direct relation 
 Change per standard deviation increase 
LPS -stimulated cytokine 
levels 
ln Thyrotropin  
(mU/L) 
 Free thyroxine 
(pmol/L) 
 Free triiodothyronine 
(pmol/L) 
   ln IL-1β (ng/ml) -0.06 (0.05)  0.03 (0.05)  0.09 (0.04) 
   p-value 0.24  0.47  0.047 
   ln IL-6 (ng/ml) -0.02 (0.03)  0.01 (0.03)  0.06 (0.03) 
   p-value 0.48  0.82  0.017 
   ln TNF-α (ng/ml) -0.03 (0.03)  0.02 (0.03)  0.07 (0.03) 
   p-value 0.37  0.46  0.006 
      
   ln IL1β RA (ng/ml) 0.00 (0.03)  0.02 (0.03)  0.01 (0.02) 
   p-value 0.99  0.35  0.58 
   ln IL-10 (ng/ml) -0.03 (0.05)  -0.02 (0.04)  0.03 (0.04) 
   p-value 0.51  0.60  0.41 
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between serum thyroid hormone levels and inflammatory cytokine production capacity in blood 
cells.  
 
Our findings support the hypothesis of a mutual association between triiodothyronine and pro-
inflammatory cytokines. As depicted schematically in figure 2, in this proposed feedback system, 
serum free triiodothyronine stimulates the pro-inflammatory cytokine production capacity, while 
pro-inflammatory cytokines in turn blunt the stimulatory effect of triiodothyronine by lowering 
peripheral thyroid hormone levels. Lowering of peripheral triiodothyronine levels under the 
influence of cytokines possibly occurs through regulation of peripheral deiodinase activity, 
although this putative mechanism has been disputed. The stimulatory effect of triiodothyronine on 
the cytokine production capacity is likely mediated via nuclear receptors regulating genes 
involved in the cell-mediated immune response. In humans high affinity nuclear thyroid hormone 
receptors have been identified in mononuclear cells 13;14. Although these observations provide a 
tentative explanation for the mutual association between thyroid hormones and cytokines, the 








Figure 2. Schematic 









Another possible limitation of our investigation is the advanced age of our study population. We 
have however no reason to assume that our findings do not apply to younger age categories. 
Moreover, the fact that the prevalence of thyroid disorders increases with age 15, makes our 
observations done in a population of the oldest old all the more clinically relevant. The age-
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function with age. Maintenance of normal thyroid function could therefore contribute to a 
preserved immune response in elderly human populations.  
 
Our study has several strong points, particularly the large size of the study population and the 
variety of studied inflammatory markers, comprising both pro- as well as anti-inflammatory 
markers. In addition, our study is unique in that we were able to combine both in vivo en ex vivo 
information on our study population. Finally, the current study has been done in the general 
population composed of healthy to moderately healthy subjects, in contrast to most previous 
studies on the relation between thyroid hormones and immune response which have been done in 
clinical settings.  
 
In summary, by combining in vivo and ex vivo data we are the first to demonstrate a potential 
feedback mechanism between thyroid function and immune production capacity. These 
observations suggest that maintenance of normal thyroid function contributes to a preserved 
immune response in elderly human populations. Therefore our findings could have important 
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World life expectancy has rapidly increased over the last two centuries, however not all of the 
gained years of life are spent in good health. There is a strong need to identify candidate targets 
for interventions to prevent age-related loss of function and morbidity. Substantial evidence 
supports the familial clustering of exceptional longevity, suggesting a genetic etiology for 
longevity. In search for the biology of healthy longevity we therefore set off to study the 
phenotypes of exceptionally long-lived families in the Leiden Longevity Study. In this chapter, 
we give a summary of the endocrine and metabolic characteristics that appear to be pertinent for 
familial healthy longevity.  
 
Mortality and morbidity  
Previous studies have shown that familial factors contribute substantially to the ability to reach 
very old age 1. Indeed, families from the Leiden Longevity Study display a striking survival 
benefit of 30% when compared to the general population (chapter 2). This lower mortality risk is 
not only present in nonagenarian sibling pairs but extends to first-degree family members of the 
nonagenarian siblings as well 2;3. Persistence of a survival advantage in siblings up to the highest 
age ranges suggests the involvement of genetic factors since many environmental factors shared 
early in life are likely to diverge as the siblings grow older 4. 
 
Apart from a delay in mortality, another important indicator of aging retardation is a later onset of 
age-related diseases  5. The incidence of diseases declines with age and is an important 
contributor to mortality 6. We found that the offspring of nonagenarian siblings had a markedly 
reduced risk for age-related diseases as myocardial infarctions, hypertension and most notably 
type II diabetes (chapter 2) 2. Our outcomes are in accordance with prior studies which showed 
lower disease prevalence in children from parents who reached an exceptionally high age when 
compared to control subjects whose parents died at younger ages 7;8. However in these earlier 
studies significant differences in major cardiovascular risk factors were present between these 
groups, including years of education and smoking habits. Exact determination of the contribution 
of genetic, behavioural, and lifestyle factors therefore remained cumbersome. Moreover, since 
centenarians generally engage in healthy lifestyles, their offspring may have copied their 
behaviour 9. To rule out potential confounding by differences in environmental factors, we 
compared offspring from long-lived cases with their partners in the Leiden Longevity Study. We 
hypothesized that as the offspring and their partners by and large share the same environment, it 
is unlikely that any observed differences between the two groups are due to differences in 
environmental factors. Indeed, major indicators of lifestyle, including estimates for BMI, current 
smoking, and associated prevalence of chronic obstructive pulmonary disease were similar 
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between both groups, indicating that the difference in health status is more likely due to genetic 
than environmental factors 2;10.  
 
We did not find a difference in cancer prevalence nor deaths due to cancer when comparing 
offspring with controls. This finding is at odds with earlier research showing a relative lower risk 
of cancer mortality in offspring of centenarians as compared to controls 11. The discrepancy might 
be explained by a difference in age: the study groups from the Leiden Longevity Study are 
approximately 10 years younger than those in the reported study.  
 
IGF insulin signaling  
The role of the evolutionarily conserved insulin/ insulin-like growth factor (IGF-1) signaling (IIS) 
pathway in the regulation of lifespan is well documented in worms 12, flies 13, and rodents 14;15. 
Genetic mutations that partially blunt IIS activation prolong lifespan in these organisms, 
particularly in the female sex. Invertebrates have a single receptor that binds multiple ligands 
comparable to insulin/IGF-1, whereas in mammals distinct receptors have evolved for insulin and 
IGF-1, with different but overlapping functions. IGF-1 is involved in growth, while insulin 
primarily regulates metabolism 16. 
 
In mammals, a hallmark phenotype shared by many of the long-lived mutants 17 including those 
with genetically induced IGF-1 resistance is their preserved insulin sensitivity and low fasting 
blood glucose levels. Preserved insulin sensitivity is also closely linked to the lower mortality 
observed in mammals under dietary restriction conditions. Several findings in the Leiden 
Longevity Study imply that preserved insulin sensitivity is at play in human longevity as well.  
 
First, the middle-aged offspring of nonagenarian siblings had relatively lower blood glucose and 
insulin levels (chapter 7) 18 as well as a more favourable glucose tolerance as assessed by oral 
glucose tolerance tests (chapter 3) 10. Preliminary evidence suggests that this phenotype of lower 
blood glucose and insulin levels in families with exceptional longevity relative to the general 
population is present even up to the highest age ranges (figure 1). Remarkably, common 
determinants for insulin resistance such as physical activity, body composition, diet, low-grade 
inflammation (chapter 5) were similar between the middle-aged groups. Secondly, the group of 
offspring showed a lower prevalence of metabolic syndrome (chapter 3) 10, a combination of 
cardio-vascular risk factors for which the dominant underlying factor appears to be insulin 
resistance. When considering the individual components of the metabolic syndrome, the group of 
offspring contained fewer individuals with low HDL levels and a lower number of individuals 
with impaired fasting glucose. Obesity related criteria, including elevated waist circumference 
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and fasting triglyceride levels were equal between the two groups, centralizing the role of glucose 
metabolism in our findings. Finally, middle-aged offspring predisposed for healthy longevity 
showed higher whole-body insulin sensitivity, marked by enhanced peripheral glucose disposal as 
assessed by hyperinsulinaemic euglycaemic clamp (chapter 4)).  Using this technique, which is 
considered the gold standard for assessment of whole-body insulin sensitivity, we found that it is 
insulin action on glucose metabolism, and glucose disposal in particular, that distinguishes 
offspring of long-lived siblings from controls, rather than insulin mediated suppression of 
endogenous glucose production or lipolysis. The importance of sustained insulin action on 
glucose disposal is in agreement with prior studies on the pathophysiology of type II diabetes 
mellitus. Peripheral insulin resistance is regarded as one of the earliest steps in the 
pathophysiology of diabetes 19;20, and is already present several decades before onset of the 
disease 21;22. Insufficient suppression of hepatic glucose production, on the other hand, is a 
consequence of fat accumulation in the liver 23, and is considered an advanced phenomenon in the 
trajectory towards onset of diabetes 20.  
 
Figure 1. Non-fasted serum glucose (A) and log insulin (B) levels for familial nonagenarians (N=333) 
and sporadic nonagenarians (N=49) (not selected for having nonagenarian siblings). To decrease the 
possible influence of differences in health status between the two groups, nonagenarians from the highest 
tertile of performance on Instrumental Activities of Daily Living score were included. Bars represent mean 
levels with standard errors of the mean adjusted for sex and age.   
 
Our data agree with earlier studies which show that the offspring of exceptionally long-lived 
individuals are protected against development of cardio-vascular disease 11;24;25. Earlier, offspring 
from long-lived parents were shown to have favorable lipid profiles 26;27. However, while it was 
shown that offspring of exceptionally long-lived individuals are healthier in many respects 28, this 
has not been reported before for glucose regulation. While insulin sensitivity generally declines 
with age in humans, sporadic long-lived centenarians exhibit an extraordinary insulin sensitivity, 
comparable to that of young adults 29. Our findings add to these previous observations by 
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demonstrating that a beneficial glucose metabolism is already present at middle-age in offspring 
of familial nonagenarians.  
Apart from the preserved insulin sensitivity, exceptional human longevity is possibly associated 
with tempering of the IGF-1 signaling pathway. Recently, it was shown that centenarians 
exhibited a relative enrichment for rare genetic variants in the IGF-1 receptor which resulted in 
high levels of IGF-1/IGFBP3 coexisting with low levels of IGF-1 signaling 30. We and others 
demonstrated that common genetic variations affecting IGF-1 signaling might contribute to 
differences in mortality in the general population 30;31. In line with these studies and other studies 
in model organisms, we found preliminary evidence for the involvement of reduced IGF-1 
signaling in familial longevity. Most recently, we observed lower serum levels of IGF-1 in female 
nonagenarians whose parents reached an exceptionally high age when compared to nonagenarian 
subjects whose parents died at younger ages (chapter 8). Another important feature of (lifelong) 
blunted IGF-signalling in both humans and model organism is a relatively small stature. In 
agreement with this observation, nonagenarians from parents who reached an exceptionally high 
age tended to be shorter than nonagenarian subjects whose parents died younger.  
The findings in the group nonagenarians contrast with those in their middle-aged children. We did 
not observe differences in IGF-1 serum levels nor height between the offspring and their partners 
(chapter 7) 18. Moreover a single time-point measurement after overnight fast showed similar 
levels of serum growth hormone levels between the two generations (table 1). These disparate 
results may be explained by differences in age. The estimated contribution of genetic factors to 
longevity is modest (20-30%) but was shown to become more important and specific at higher 
ages. Therefore it is possible that the effects of genetic variation in the IIS pathway only become 
detectable at advanced ages. In line, the association between genetic variation in FOXO3A and 
longevity was found to be stronger in centenarians than in nonagenarians 32. Another possible 
explanation for these contrasting observations could be differences in imprinting of the IGF-1 
gene, reflecting historical differences in maternal nutrition between the two generations 30;33.  
  
Thyroid function 
The hypothalamo–pituitary–thyroid axis is widely implicated in modulating the aging process 34. 
Life prolonging effects related to decreased thyroid hormone levels have been reported in 
multiple animal models. In neonatal rats induction of hypothyroidism results in a moderate 
extension of lifespan 35. Similarly, low thyroid hormone levels are characteristic of murine 
pituitary mutants with postponed aging: long-lived Ames and Snell dwarf mice show features that 
are likely related to thyroid hormone deficiency 36. In humans a relation between low thyroid 
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function and extended lifespan has been observed as well. In the oldest old, higher concentrations 
of thyrotropin are associated with a survival advantage without apparent detrimental effects on 
ability or mood 37;38.  
Table 1. Serum levels of endocrine parameters under fasted conditions for offspring and partners 
Data are given as mean values with 95% confidence intervals. TSH, growth hormone and high-sensitivity 
C-reactive protein (hsCRP) are given as geometric means with 95% confidence intervals. Samples were 
taken between 9:00 – 9:30 a.m. data were adjusted for sex and age.  
 
The outcomes of the Leiden Longevity Study seem to support the relation between low thyroid 
function and extended life span. Nonagenarians from parents who reached an exceptionally high 
age had higher thyrotropin levels, lower free thyroxine and lower free triiodothyronine levels 
when compared to nonagenarian subjects whose parents died at younger ages (chapter 9) 39. The 
lower thyroid function in the nonagenarians was reflected in their middle-aged children, who 
showed lower peripheral thyroid hormone levels and a tendency towards elevated thyrotropin 
levels as compared to their partners during both non-fasted (chapter 8) 40 and fasted conditions 
(table 1). These observations imply that lower activity of the thyroid hormone axis is a heritable 
phenotype which contributes to exceptional longevity.  
 Offspring Partners P-value 
Participants (N) 121 113  
Females (N, %) 62 (51.2%) 59 (48.8%) 0.90 
    
TSH (mU/L) 2.41 (1.93 -  3.06) 1.69 (1.33 – 2.15) 0.029 
free T4(pmol/L) 16.2 (15.8 – 16.6) 16.4 (16.0 – 16.9) 0.49 
free T3 (pmol/L) 5.03 (4.87 – 5.20) 5.26 (5.09 – 5.44) 0.045 
    
Growth hormone (mU/L) 1.90 (1.50 – 2.40) 2.02 (1.58 – 2.57) 0.72 
IGF-1 (nmol/L) 15.3 (14.3 – 16.2) 15.0 (14.1 – 16.0) 0.71 
IGFBP3 (mg/L) 4.03 (3.85 – 4.21) 3.98 (3.79 – 4.16) 0.63 
    
Cortisol (µmol/L) 0.49 (0.47 – 0.52) 0.52 (0.49 – 0.55) 0.22 
    
Prolactin (U/L) 10.1 (9.28 – 10.9) 10.3 (9.51 – 11.2) 0.64 
    
HsCRP (mg/dL) 1.29 (1.17 – 1.60) 1.17 (0.93 – 1.46) 0.45 
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Lower activity of the thyroid hormone axis  possibly acts as a mechanism to reallocate energy 
expenditure from growth and proliferation to protective maintenance. Thyroid hormones 
primarily regulate the basal metabolic rate of cells, thereby inducing thermogenesis and free 
radical production 41. Data from model organisms show that low triiodothyronine is associated 
with lower production of reactive oxygen species (ROS) and ROS inflicted genomic damage 42. 
The more efficient transport of electrons through the respiratory chain under conditions of low 
thyroid hormone might decrease the production of ROS and postpone aging.  
Our study demonstrated lower thyroid function in subjects from extremely long-lived families. 
The prevalence of subclinical hypothyroidism and subclinical hyperthyroidism increase steeply 
with age 43 and the exact definition of subclinical thyroid dysfunction and the requirement for 
age-specific thyrotropin reference limits in clinical practice is currently a matter of intense debate. 
Thyrotropin levels are known to gradually increase with age, a shift that was recently shown to 
extend to advanced age 44. The higher thyrotropin levels observed at old age possibly result from 
selective survival of subjects with constitutionally low thyroid function 37. Furthermore, some of 
the changes in thyroid function that occur upon aging may be part of the age related pathology 
that is caused by accumulated damage, while others may actually occur in response to the 
accumulation of damage and may instead represent adaptive mechanisms aimed at delaying age-
related pathology. Although controversial, the prevailing recommendation is to treat elderly with 
subclinical hypothyroidism with thyroid hormone supplementation. In view of these 
considerations however, the issue of reversing the endocrine changes that occur during human 
aging by treatment of (subclinical) hypothyroidism, remains highly controversial. While 
pathological changes might benefit from treatment, constitutively low thyroid function or changes 
in thyroid function that are part of an adaptive response might not.  
Upon aging, other changes may occur in the thyroid axis beside an elevation of thyrotropin levels. 
In chapter 10, we demonstrate the existence of a mutual relationship between levels of free 
triiodothyronine and inflammatory cytokines. High levels of inflammatory cytokines are 
associated with reduced levels of free triiodothyronine, suggesting that under conditions of 
inflammation, the activity of the thyroid axis is dampened, possibly via reduced conversion of 








As average life span continues to increase, so does the number of years spent in ill health. There 
is an urgent need to identify candidate targets for interventions to prevent age-related loss of 
function and morbidity. Studies into the phenotype of humans predisposed for an exceptional 
long life may delineate the determinants for healthy life span extension. Presuming that the 
characteristics conducive to longevity are transmitted in long-lived families, the offspring from 
exceptionally long-lived parents may reveal the key to successful aging.  
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Introduction to Part B 
Senescence is quintessentially defined as an increased probability of dying with age. Already 180 
years ago Benjamin Gompertz noted that mortality rates of human populations increase 
exponentially for most age ranges. When the Gompertz equation is transformed semi-
logarithmically, it conforms to a straight line, the slope of which has classically been defined as 
the species-specific senescence rate. Classic inference from the Gompertz law has lead to the 
conclusion that the rate of senescence is unaffected by environmental conditions. The second part 
of this thesis offers a critical appraisal of the definition of the rate of senescence. In chapter 
twelve we propose an alternative approach for assessment of the rate of senescence. In chapter 
thirteen we will empirically test this novel method as compared to the common approach in a 
population of renal patients, a population known to experience accelerated aging.
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Chapter 12: Parallel lines: nothing has changed? 
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The exponential increase in mortality rate with age is a universal feature of aging and is described 
mathematically by the Gompertz equation. When this equation is transformed semi-
logarithmically, it conforms to a straight line, the slope of which is generally used to reflect the 
rate of senescence. Historical and contemporary data of human and non-human populations show 
that adverse environmental conditions do not always change the slope of the log mortality rate 
over age. From these latter observations it is sometimes mistakenly inferred that the rate of 
senescence is unaffected by environmental conditions. Current biological inference emphasizes 
that gene action is dependent on the environment in which it is expressed. Here, we propose using 
the tangent line of the Gompertz equation to assess whether the rate of senescence has altered. 
Such an approach unmasks different rates of senescence when parameter G has remained 
constant, an observation that is in line with the notion that a plastic life history trait such as the 
rate of senescence results from the interplay of both genes and environment.    
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Senescence is quintessentially defined as an increased probability of dying with age1. This 
probability is estimated when following populations with similar genetic background for 
mortality over time and is expressed as mortality rate per year. Already 180 years ago it was 
noted by Benjamin Gompertz that mortality rates of human populations increase exponentially for 
most age ranges 2. This exponential increase in mortality rate (m(t)) over age (t) is mathematically 
expressed by the equation: 
 
m(t) = A0 e 
G t  (Eq. 1) 
 
When the Gompertz equation is transformed semi-logarithmically, it conforms to a straight line 
described as:  
 
ln m(t) = ln A0 + Gt  (Eq. 2) 
 
The slope of this straight line is determined by the Gompertz coefficient (G) and equals the 
derivative of equation 2. 
 
The Gompertz coefficient (G) is commonly used as an estimate of the rate of senescence 3. It is 
generally interpreted as a measure of intrinsic susceptibility of a biological system to withstand 
stressors. This intrinsic susceptibility leads to an accumulation of permanent damage to cells and 
tissues, loss of function and ultimately death, the rate of which is specific for the various species. 
Current reasoning prevails that decreasing the Gompertz coefficient provides decisive evidence 
that the rate of senescence is positively influenced.  
 
The parameter A0 is generally referred to as the “initial mortality rate”, and is alternatively 
designated as “intrinsic vulnerability” 4 or “frailty” 5. The parameter A0 is commonly estimated at 
the age of puberty when development is completed and mortality from senescence is at its 
minimum. When A0 is estimated that way, it also includes mortality from extrinsic hazards, i.e. 
environmental mortality that is age independent 6. To account for this source of mortality 
separately, Makeham proposed a modification of the Gompertz’ law of mortality 7.  
 
m (t) = C0  + A0 e 
G t  (Eq. 3) 
 





As the rate of senescence is expressed as the acceleration of mortality rate over time, it can take 
all values. This acceleration can approach negligible values if population mortality rates remain 
equal over time, and it is inferred that such a population, e.g. hydra, does not undergo senescence 
8. The acceleration of mortality rates over time can also level off at advanced ages 9 or mortality 
rates can decelerate as seen during development. It must be emphasized, however, that even in the 
absence of senescence mortality rates are unlikely to be zero as there are remaining deaths from 
environmental causes. Immortality is difficult to achieve. 
 
The logic that mortality from intrinsic causes and environmental causes are two independent 
mechanisms leading to death follows from classic observations of which an example is illustrated 
in figure 1a. The figure shows on a semi-log scale age specific mortality rates of prisoners of war 
in a Japanese concentration camp. When it is compared to the mortality rates of the Australian 
civilian population over a similar calendar period, the two lines are parallel 10, 11. This parallelism 
of the mortality curves over age shows that the adverse environment has left the slope (G) 
unchanged. The general inference of these data is that the rate of senescence is unaffected by an 
increasingly adverse environment 3. If anything, the process of senescence occurs at an earlier age 
when exposed to adverse conditions.  
 
When the same data on age specific mortality data from the Australian populations are plotted on 
a linear scale, such a presentation sheds a different light on the interpretation of the parallel 
curves in the semi-log plot. From figure 1b it follows that, when plotted on a linear scale, the 
difference in age-specific mortality between the prisoners of war and the civilian population is 
manifold larger in old age when compared to young age. At age 21-25 the mortality rate is 2.3 
deaths / 1000/ year among the internees whereas it is 0.7 deaths / 1000/ year in the civilian 
population (estimated from Jones11). The difference in mortality rate between these populations is 
1.6 deaths / 1000/ year. As the two populations are assumed to have a similar genetic background, 
the extra number of 1.6 deaths/ 1000/ year must be attributable to the incremental environmental 
hazards to which the internees were exposed. Due to senescence, mortality rate in the civilian 
population at age 80 has increased to 145.0 deaths/ 1000/ year. When the intrinsic susceptibility 
and the environment do not interact, we would have expected mortality rate among the internees 
to be 146.6 deaths/ 1000/ year (145.0 plus 1.6 deaths/ 1000/ year). However, mortality rate among 
the prisoners of war at age 81-85 is 750.0 deaths/ 1000/ year. The excess number of deaths among 
1000 elders who were interned for one year can thus be calculated as 750.0 deaths minus 145.0 
deaths as expected from senescence, minus an extra 1.6 death due to the increased environmental 
hazards in the camp. In the prevailing logic this excess number of 603.4 deaths among the older 
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internees cannot be accounted for by environmental hazards and is unexplained when the rate of 
senescence is assumed to be constant.  
 
 
Figure 1. Mortality rates as a function of age for a human population under adverse and affluent 
conditions. POW: prisoners of war held in concentration camps by the Japanese army during 1945; Aus: 
Civilians in Australia, 1944-1945.  1a; Plot of the mortality rates as function of age for POW versus 
Australian civilians on a semi-logarithmic scale 1b; Plot of the mortality rates as a function of age for 
POW versus Australian civilians on a linear scale. The tangent lines at age of 60 for prisoners of war and 




When to mathematically describe a biological interaction of risk factors the use of additive 
models is recommended rather than using multiplicative models 12. It is generally ignored that 
using linear regression on log transformed data, it effectively has become a multiplicative model. 
When fitting the regression line, the coefficient presents the added value of log mortality when 
age increases with one unit (equation 2). However, when the equation is exponentiated, to arrive 
at describing actual mortality rates, it has become the factor with which the mortality rate should 
be multiplied when age increases with one unit. This phenomenon is illustrated when comparing 
figure 1a and 1b. When the mortality trajectories are plotted on a semi-log scale, visual inspection 
shows that the lines have shifted upwards but remain parallel. On a linear scale, however, the 
acceleration of mortality over age under adverse conditions is unmasked. This higher rate of 
senescence under adverse conditions explains the excess number of 603.4 deaths/ 1000 among the 
60 year old prisoners of war that is not accounted for when the rate of senescence is assumed 




It is a striking oddity that when parameter G is used to estimate the rate of senescence, the rate of 
senescence is not only invariant under different environmental conditions, but is even unaffected 
by the elapse of time. This would imply that the rate of senescence in a 20 year old civilian is 
equal to the rate of senescence in an 80 year old internee. This conclusion calls into question the 
validity of parameter G as an estimate for the rate of senescence. 
 
The enigma of biology is to explain phenotypic characteristics as the result of genes that are 
expressed in a specific environment. Phenotypic characteristics can be markedly dissimilar in 
different environments despite the genetic background of the organism being identical 13-15. Gene-
by-environmental interactions account for a large component of the variance in gene expression 
and there is no reason to assume that senescence should be exempt. It follows that the rate of 
senescence results from an interaction between intrinsic susceptibility and specific environmental 
conditions. Despite the constancy of parameter G in the Gompertz equation, the rate of 
senescence can vary widely under different conditions and in different age categories.  
 
Following the notion that genes interact with environmental cues and that the rate of senescence 
can best be studied using absolute figures, the slope of the Gompertz curve would be the most 
appropriate estimate of the rate of senescence. When mortality rates are expressed on an absolute 
scale (figure 1b) the slope of the tangent line at the age 60 years is much steeper among the 
prisoners of war when compared to the civilian population, indicating that the rate of senescence 
is far higher under adverse conditions. The slope of the Gompertz curve, i.e. the first derivative, 
can be expressed for every given age (t) as: 
 
m’(t) = A0  G  e 
G t  (Eq. 4) 
 
with the expression unit being (deaths/ 1000 persons/ year) per year, which is the derivative of 
equation 1. Whatever may be the biological substrate for the parameters A0 and G, it is apparent 
that the rate of senescence m’(t) results from a multiplication of both parameters and varies with 
age (t).  
 
When using equation 4, describing the slope of the tangent line to estimate the rate of senescence 
as the combined effect of genetic background and environmental cues, it becomes clear that the 
Gompertz equation may reasonably well describe the patterns of mortality over age, but does not 
line up with current biological knowledge. The Gompertz law of mortality was formulated long 
before molecular insights in the biology of aging were accrued. 
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Alternative to the Gompertz model, power functions like the Weibull model are also used to 
express the mortality rate in a population 16: 
 
W(t) = C0 + αt
β (Eq. 5) 
 
In equation 5 the age-dependent component αtβ is added to the initial mortality rate C0. The slope 
of the Weibull model, an estimate for the rate of senescence, is expressed by the first derivative of 
equation (5): 
 
    W’(t) = αβt(β-1) (Eq. 6) 
 
The rate of senescence described by equation (6), results from the interaction of two parameters, 
α and β. Similar to the derivative of the Gompertz model 4, the rate of senescence W’(t) is 
dependent on age (t). Over the adult range, curve fitting leads to no clear preference of one model 
over the other 17. Although, the derivatives of the Weibull and Gompertz models both adequately 
describe the rate of senescence in mathematical terms, the isolated parameters cannot be 
interpreted in biological terms.  
 
Classic inference from the Gompertz law may have lead to incorrect conclusions. In 
industrialized human societies worldwide, mortality rates have been declining steadily for over a 
century. These declines have been associated solely with a reduction in initial mortality rates, 
with no reduction in the slope of the mortality trajectory 18. This lowering of the mortality 
trajectory has been taken to indicate that overall health at all ages has improved, but that the 
underlying process of accumulation of permanent damage has not been ameliorated.19 Here, we 
argue that this conclusion may be mistaken.  
 
In model organisms, there are various examples of interventions which that have been shown to 
extend the average and maximum lifespan, and, some are reflected in a lower slope of the 
mortality trajectory 20, 21. Many of these experiments involve the restriction of calorie intake 4, 22. 
In contrast, various data on genetic manipulation of experimental models also show an increase of 
average and maximal lifespan, but when expressed on a semi-log scale the age specific mortality 
trajectories have shifted parallel when compared to the control strains23-26. For these latter 
examples, the nowadays interpretation is one of disappointment, as if the process of senescence 
had not be influenced positively. The correct interpretation of these data, however, is that the 
tangent line, i.e. the acceleration of mortality, is markedly different. Despite the fact that the 
tangent line better reflects the decreased rate of senescence, the mathematical formula however, 
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does not allow for testing biological plausible hypotheses.  There is an urgent need for new 
mathematical models that adequately fit the increase of mortality rate over age and at the same 
time enable studying the biology of senescence that lines up with current scientific insights.  
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The most frequently used model to describe the exponential increase in mortality rate over age is 
the Gompertz equation. Logarithmically transformed, the equation conforms to a straight line, of 
which the slope has been interpreted as the rate of senescence. Earlier, we proposed the derivative 
function of the Gompertz equation as a superior descriptor of senescence rate. Here, we tested 
both measures of the rate of senescence in a population of patients with end-stage renal disease. It 
is a clinical dogma that patients on dialysis experience accelerated senescence, whereas those 
with a functional kidney transplant have mortality rates comparable to the general population. 
Therefore, we calculated the age-specific mortality rates for European patients on dialysis 
(n=274,221; follow-up=594,767 person-years), for European patients with a functioning kidney 
transplant (n=61,286; follow-up=345,024 person-years), and for the general European population. 
We found higher mortality rates, but a smaller slope of logarithmical mortality curve for patients 
on dialysis compared to both patients with a functioning kidney transplant and the general 
population (p<0.001). A classical interpretation of the Gompertz model would imply that the rate 
of senescence in patients on dialysis is lower than in patients with a functioning transplant and 
lower than in the general population. In contrast, the derivative function of the Gompertz equation 
yielded highest senescence rates for patients on dialysis, whereas the rate was similar in patients 
with a functioning transplant and the general population. We conclude that the rate of senescence 
is better described by the derivative function of the Gompertz equation. 
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Introduction 
In 1825, Benjamin Gompertz observed that human mortality rates increase exponentially with age 
1. Since then, no other definition of senescence has gained so much common acceptance 2. 
Mathematically, the model is known as the Gompertz equation and has become the most 
frequently used model of senescence 3, 4. The model describes the mortality rate at a given age 
with parameters α and γ. When transformed semilogarithmically, the formula conforms to a 
straight curve, hereinafter referred to as the Gompertz curve. The slope of this straight curve is 
determined by parameter γ. 
 
The Gompertz model fits mortality data very firmly, but it is purely empirical. Still, many 
investigators have tried to attribute biological properties to the estimated parameters. Based on 
mortality data from animal experiments 5-8 and historical changes in human mortality patterns 9-12, 
the slope of the logarithmically transformed Gompertz curve has classically been defined as the 
species-specific senescence rate 2, 13. However, based on theoretical considerations, the validity of 
the slope of the Gompertz curve as a measure of the senescence rate has been criticized 14-16. We 
have previously proposed to use the tangent of the mortality curve instead, as described by the 
derivative of the Gompertz equation 17. 
 
This work aims to empirically test both the classical and the newly proposed measure of 
senescence rate in end-stage renal disease patients. Hereto, we have calculated the age-specific 
mortality rates of a very large population of European patients with end-stage renal disease, 
comprising both patients on dialysis and with a functioning kidney transplant, using the general 
European population as a reference. It has been widely recognized that renal disease patients on 
dialysis show accelerated senescence when compared to the general population 18, 19. 
Furthermore, after transplantation, the mortality pattern of these patients converts toward the 
mortality pattern of the general population 20, 21, although this effect might also partly be due to 
selection of healthy subjects for transplantation. Therefore, these populations provide an excellent 
opportunity to assess different measures of the rate of senescence, as a valid measure of 
senescence rate should reflect these differences in senescence rates by attributing the highest 
senescence rate to patients on dialysis, and a lower senescence rate to patients with a functioning 
kidney transplant and the general population. 
 
Materials and methods 
The study population of patients with end-stage renal disease was derived from the Registry of 
the European Renal Association – European Dialysis and Transplant Association 22(ERA-EDTA 
Registry), which records European patients who receive renal replacement therapy, either dialysis 
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or kidney transplantation. Via national and regional registries individual patient data were derived 
from Austria, the Flemish speaking region of Belgium, the French speaking region of Belgium, 
Denmark, Finland, Greece, Iceland, the Netherlands, Norway, Romania, Sweden, the United 
Kingdom, and from several regions in Italy and Spain. Data were gathered during a period 
beginning between 1985 and 2007, and ending at 1 January 2008 for four regions in Spain and 
Italy and 1 January 2009 for the other regions and countries. For each individual patient the 
following parameters were collected at baseline: country or region of origin, date of birth, sex, 
primary cause of renal failure, and date and modality of first renal replacement therapy. History 
of renal replacement therapy with dates and changes of modality and date were collected during 
follow-up. Primary renal diseases were classified according to the ERA-EDTA coding system 
(ERA-EDTA Registry Annual Report 2008, 2010). 
 
Mortality rates were calculated based on the follow-up data contributed by each individual 
patient, separated for follow-up on dialysis treatment and follow-up with a functioning kidney 
transplant. In case of the dialysis group, follow-up began six months after initiation of dialysis 
treatment, to account for acute treatment-related mortality 23, and lasted until death, 
transplantation, recovery of renal function, loss to follow-up, or censoring at 1 January 2008 or 
2009. In case of the patients with a functioning transplant, follow-up began six months after 
transplantation, to account for acute surgery-related mortality 20, 24, and lasted until death, transfer 
to dialysis due to transplant failure, loss to follow-up, or censoring at 1 January 2008 or 2009. For 
both treatment groups, per five-year age group the number of deaths was divided by the years of 
follow-up, yielding the age-specific mortality rates. 
 
The application of the Gompertz model is limited to mortality data between the ages of 
approximately 20 and 80 to 90 years 3. Moreover, after the age of 85 years, available mortality 
data was scarce. Follow-up after this age comprised 15,638 person-years (2.52%) and 8,360 
deaths (5.83%) for the patient group on dialysis and 175 person-years (0.05%) and 25 deaths 
(0.26%) for the patient group with a functioning kidney transplant. Therefore, data on patients 
below the age of 20 years and from the age of 85 years onward were excluded from this study. 
 
Mortality data of the general European population were available through the Human Mortality 
Database 25 and Eurostat 26. For the countries in our study, the population and death figures were 
retrieved from the HMD for each five-year age category and for the years of data contribution. 
For Greece, Romania, and Spain these mortality data were downloaded from Eurostat, as they 
were not available through the HMD. For the calculation of age-specific mortality rates of the 
Senescence rates in end-stage renal disease 
 173 
general European population, per five-year age groups and years of participation, the sum of all 
deaths was divided by the sum of all inhabitants of the participating countries. 
 
The Gompertz curves were characterized by estimating the values of the parameters of the 
Gompertz model on the age-specific mortality data as well as the statistical significance of the 
differences in the model parameters between the treatment groups. The parameters α and γ are 
mathematically described by the Gompertz model as m(t) = α eγt, where m(t) is the mortality rate 
and t is the age in years. The calculations were performed by fitting the parametric proportional 
hazards Gompertz model 27 on the individual patient data and by linear regression on the 
aggregated data of the general European population. 
 
The classical senescence rates were given by γ, of which the values were derived by the 
aforementioned determination of the model parameters. In addition, according to the newly 
proposed analytical method that we have described earlier 17, the derivative function of the 
Gompertz equation was applied to the mortality curves of this study to determine the senescence 
rates. Hereto, the values of the model parameters, determined as described above, were 
incorporated in the derivative equation: m(t) = α γ eγt. 
 
The management of the ERA-EDTA Registry database, the calculations of the age-group-specific 
mortality rates of the patient population, and the linear regression analyses were carried out using 
PASW Statistics 17.0 (IBM SPSS Statistics). Linear regression was performed by the linear 
mixed model with the natural logarithms of the mortality rates as dependent variable, treatment 
group as factor, and age as covariate. All these calculations were repeated using Stata/SE 10.1 
(StataCorp LP). The fitting of the Gompertz model was performed using Stata/SE 10.1. 
 
Results 
Table 1 shows the basic characteristics of the patient population, both presented as the total 
number of patients and by the number of years of follow-up. As starting dialysis treatment or 
receiving kidney transplantation occured more than once in some patients, part of the population 
(n=58,387 or 20.1%) contributed follow-up to both treatment modalities. The number of these 
consecutive treatment modalities ranged between 1 and 11 per patient. 
 
Figure 1a shows the mortality rates per five-year age groups for patients on dialysis, for patients 
with a functioning kidney transplant, and for the general population. In all groups, mortality rates 
increased exponentially over age from adolescence onward. For each age group, the mortality rate 
of the dialysis patients was highest, whereas the mortality rate of patients with a functioning 
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transplant was higher than that of the general population. After transformation of the mortality 
rates to a semilogarithmical scale, the mortality curves of all three groups conformed to straight 
Gompertz curves from the age of 20 years and onward (figure 1b). The r2 values of these straight 
curves, indicating the fit of the Gompertz model, were 0.998 for patients on dialysis, 0.992 for 
patients with a functioning transplant, and 0.986 for the general population. Again, for each age 
group, the mortality rate of the patients on dialysis was highest, the mortality rate of the group 
with a functioning transplant was intermediate, and the mortality rate of the general population 
was lowest. 
 
Table 1. General characteristics of the end-stage renal disease patient population 
Characteristic Total On dialysis With a functioning transplant 
By number of patients    
Total amount of patients  n 290,510 274,221 61,286 
Sex  % male 61.1 61.2 62.7 
Age  median (iqr)    
- at first treatment 64.6 (52.0-73.3) 65.0 (52.7-73.5) 49.2 (38.3-58.6) 
- at death 71.0 (62.7-77.1) 71.1 (62.8-77.1) 60.5 (51.5-68.2) 
Follow-up per patient  median years (iqr) 1.8 (0.3-4.7) 1.3 (0.2-3.1) 4.5 (1.4-8.7) 
    
By contributed years of follow-up    
Total years of follow-up  person-years (%) 942,458 594,767 (63.1) 345,024 (36.6) 
Sex  % male 60.4 59.3 62.2 
General characteristics of the patients with end-stage renal disease, presented by the number of patients and 
by contributed years of follow-up. iqr: interquartile range. 
 
The quantitative description of the Gompertz curves by the model parameters is presented in 
table 2. The intercept or basal mortality rate α of the Gompertz curve of patients with a 
functioning kidney transplant was higher than that of the general population (p<0.001), while α 
for the patients on dialysis was higher than that of both other groups (p<0.001). The slope γ of the 
Gompertz curve of the patients with a functioning transplant was lowest for the patients on 
dialysis, intermediate for the patients with a functioning transplant, and highest for the general 
Senescence rates in end-stage renal disease 
 175 
population (p<0.001). The corresponding 
mortality rate doubling time was highest for 
the dialysis patients, intermediate for the 
patients with a functioning transplant, and 
lowest for the general population. We 
performed various additional analyses. 
Stratification of the mortality rates of 
patients on renal replacement therapy by 
sex, primary renal disease, and country of 
origin yielded similar results. Stratification 
by calendar year, for which the data were 
divided in two periods from 1985 through 
1996 and from 1997 through 2008, yielded 
similar results. Inclusion of only the first 
treatment period on dialysis or with a 
functioning transplant, did not affect the 
outcome. Furthermore, adjustment for 
duration of follow-up for different treatment 
modalities did not substantially influence the 
results (data not shown). 
 
 
Next, we estimated the tangent of the mortality 
curve as described by the derivative of the 
Gompertz equation to determine the senescence 
rates for the various groups. The derivative 
function yielded estimates for the age-specific 
senescence rates as depicted in figure 2. At every 
age, the senescence rate was highest in patients on 
dialysis when compared to patients with a 
functioning kidney transplant and to the general 
population. Contrary to a fixed senescence rate as 
determined by parameter γ in the Gompertz 
equation, senescence rates accelerated over age. 
This acceleration was fastest in patients on 
Figure 1. Age-specific mortality rates of patients on 
dialysis, patients with a functioning kidney transplant, 
and the general population on a linear scale (a) and 
on a semilogarithmical scale (b). Logarithmical 
transformation of the mortality curves yields straight 
Gompertz curves, of which the slopes have classically 
been interpreted as the senescence rate. For the 
mortality rates of the patients on dialysis and with a 
functioning transplant, the estimates are given with 
95% confidence intervals. The follow-up in person-
years for each treatment modality is shown in the table 




dialysis. Senescence rates estimated by the derivative of the Gompertz equation became similar to 
those of the general population when the patients with end-stage renal disease had a functioning 
kidney transplant (figure 2). These estimates do not preclude that age-specific mortality rates are 
higher in patients with a functioning transplant than in the general population for every age 
category. 
 
Table 2. Quantitative description of the Gompertz model parameters 
Parameter On dialysis With a functioning transplant General pop. 
ln α -4.75 (-4.71; -4.79) -7.71 (-7.58; -7.83) -9.55 
α ×10-2 0.86 (0.83; 0.90) 0.04 (0.04; 0.05) 0.01 
γ ×10-2 4.29 (4.23; 4.35) 6.70 (6.49; 6.90) 8.50 
MRDT 16.17 (15.95; 16.40) 10.35 (10.05; 10.68) 8.16 
Estimated values of the Gompertz model parameters for the mortality curves of patients on dialysis, 
patients with a functioning kidney transplant, and the general population. The mortality rate doubling times 
(MRDT) are given in years, derived from γ by MRDT = ln 2 / γ (Ricklefs and Scheuerlein, 2002). The 
values for α were derived from those for ln α. The estimates are given with 95% confidence intervals. All 
estimates of the parameters were significantly different between the three groups and from zero (p<0.001). 
 
 
Figure 2. Age-specific senescence 
rates of patients on dialysis, 
patients with a functioning kidney 
transplant, and the general 
population. It is emphasized that, 
in contrast to the mortality rates in 
Figure 1, these curves depict 
senescence rates. According to the 
newly proposed method, these 
senescence rates were calculated 
using the derivative of the 
Gompertz equation. Values of the 
Gompertz model parameters, as 
presented in Table 2, were 
incorporated into this equation. 
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Discussion 
In this work, we have tested two estimates of senescence rate using a population of end-stage 
renal disease patients as a model of accelerated senescence. When compared to the general 
population, patients on dialysis have higher mortality rates19, 28. Moreover, they suffer from age-
related diseases with a higher frequency and more rapid progression, among which there are 
cardiovascular diseases 21, 28, 29, cognitive impairment and dementia 29, metabolic bone disease 30, 
and dysfunction of the immune system. After successful kidney transplantation, the accelerated 
rate of senescence in the end-stage renal disease patients approaches the senescence rate of the 
general population 20, 21. These populations therefore provide an excellent opportunity to assess 
different measures of the rate of senescence. 
 
The commonly used Gompertz model describes the mortality rate m(t) at a given age t with 
parameters α and γ as: 
 
m(t) = α eγt (Eq. 1) 
 
The parameter α determines the intercept of the curve, also referred to as the basal mortality rate, 
and is usually set at adolescence. The parameter γ determines the extent of the age-dependent 
increase in the mortality rate 3, 31. On a semilogarithmical scale, the curve conforms to a straight 
line, the Gompertz curve, which is described as: 
 
ln m(t) = ln α + γt (Eq. 2) 
 
On the semilogarithmical scale, variation in α results in a parallel shift of the Gompertz curve, 
whereas variation in γ results in a different slope. The slope of the Gompertz curve has classically 
been regarded as the best estimate of the senescence rate 2, 13. As an alternative estimate of the 
senescence rate, we have proposed to use the derivative of the Gompertz equation 17, described 
as: 
 
  m’(t) = α γ eγt  (Eq. 3) 
 
Using the mortality data of a unique and unprecedented large population of patients with end-
stage renal disease, both the classical measure of the senescence rate, based on the slope γ of the 
Gompertz curve and the newly proposed measure of the senescence rate, estimated by the 
derivative of the Gompertz equation, we have obtained the following results. We showed that the 
mortality rates of patients on dialysis were highest and the slope of their Gompertz curve was 
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lowest when compared to patients with a functioning kidney transplant and the general 
population. In patients with a functioning transplant the mortality rates and the slope were 
intermediate. In the general population, the mortality rates were lowest, but the slope was highest 
compared to both patient groups. The classical interpretation of the parameters of the Gompertz 
model should lead to the conclusion that the senescence rate in patients on dialysis is lower than 
the senescence rate in patients with a functioning transplant as well as the general population. 
Moreover, a successful kidney transplantation lowers the mortality rates, but would increase the 
senescence rate. This interpretation of the parameter estimates is in sharp contrast to the clinical 
notion that patients on dialysis experience an accelerated senescence, whereas after 
transplantation the mortality pattern of patients shifts toward the mortality pattern of the general 
population. We have presented the first derivative of the Gompertz equation as an alternative 
measure of the senescence rate. This measure yields senescence rates that are highest for patients 
on dialysis compared to patients with a functioning transplant and the general population. The 
senescence rates of the group with a functioning transplant and the general population are similar, 
although the age-specific mortality rates are higher in patients with a functional transplant than in 
the general population for every age category. Only at the highest ages, the senescence rates of 
patients with a functioning transplant slightly lag behind those of the general population. In 
contrast to the classical interpretation of parameter γ as a measure of the rate of senescence, this 
result is consistent with the higher senescence rates observed in patients on dialysis compared 
with the general population and with the presumed return to normal mortality patterns after 
successful kidney transplantation. It should be noted however that the post transplant mortality 
conversion might partly be due selection bias of the transplanted cohort rather than a conversion 
in the mortality rate.  
 
While Benjamin Gompertz was the first to introduce a mortality model, many alternative models 
that fit human mortality data have since been proposed that fit human mortality data even better 4, 
32-34. The quest here is not to arrive at the best statistical fit of the data, but to obtain parameters 
that can be estimated empirically and represent biological phenomena. The approach that is 
presented here, to estimate the senescence rate using the derivative function of the Gompertz 
equation is such an attempt. This model is likely to be applicable to any model that fits mortality 
patterns. The approach presented here is solely based on the definition of senescence as an 
increase in mortality rate over age and is independent of any biological interpretation of the 
model from which it is derived, as long as the model fits the mortality data. Other models may 
even be preferred over the Gompertz model, as the Gompertz model is limited to fit mortality data 
between adolescence and the age of 80 to 90 years 3. It would, therefore, be worthwhile to 
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empirically test the validity of this interpretation of the derivative for alternative models as well 
35. 
In conclusion, this study shows that empirically testing of parameter γ of the Gompertz curve as a 
measure of senescence rate, failed to identify the high senescence rate in patients with end-stage 
renal disease on dialysis and did not identify the improvement when these patients undergo 
kidney transplantation. In contrast, the recently proposed alternative measure of senescence rate, 
determined by the derivative function of the Gompertz equation, estimates the highest senescence 
rates for dialysis patients and recognizes the improved prognosis of patients with a functioning 
kidney transplant. Thus, we propose to use the derivative of the Gompertz equation to estimate 
the rate of senescence. 
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General discussion and synopsis Part B 
In model organisms, there are various examples of interventions which extend average and 
maximal lifespan, but when expressed on a semi-log scale the age specific mortality trajectories 
have shifted parallel when compared to the control strains. The classical interpretation of the 
parameters of the Gompertz model is that the senescence rate in these model organisms has not 
been influenced positively. In chapter 12 we have proposed the tangent line of the Gompertz 
equation as an alternative method for assessment of the rate of senescence. Such an approach 
unmasks different rates of senescence when parameter G has remained constant. In chapter 13 
we have empirically tested this new approach in a population of renal patients, a population 
known to experience accelerated aging. This study showed that using the derivative function of 
the Gompertz curve identifies different rates of senenscence under various conditions. In contrast 
to the parameter G of the Gompertz curve which failed to detect these differences. To estimate the 
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Deel A: Over de hormonale en metabole kenmerken van familiare langlevendheid: 
de Leiden Lang Leven Studie 
De afgelopen twee eeuwen is de levensverwachting wereldwijd sterk toegenomen. Echter niet alle 
gewonnen levensjaren worden in goede gezondheid doorgebracht. Het vinden van eventuele 
aanknopingspunten voor interventies is nodig om ouderdomsziekten en achteruitgang in het 
functioneren te voorkomen. Er bestaat overtuigend bewijs dat langlevendheid vaker voorkomt in 
bepaalde families. Dit suggereert een genetische basis voor langlevendheid. Op zoek naar de 
biologie achter gezonde veroudering bestuderen wij daarom in de Leiden Langleven Studie de 
fenotypes van uitzonderlijk langlevende families. In dit hoofdstuk geven we een samenvatting 
van de belangrijkste hormonale en metabole kenmerken van familiare langlevendheid. 
   
Ziekte en sterfte 
Eerdere studies hebben laten zien dat familiare factoren een belangrijke rol spelen bij het bereiken 
van een hoge leeftijd 1. Ook in Leiden Langleven Studie hebben langlevende families een 
opmerkelijk overlevingsvoordeel van 30% in vergelijking met de algemene bevolking (hoofdstuk 
2). Het lagere sterfterisico is niet alleen aanwezig in broer- of zusparen van negentig jaar of 
ouder, maar ook in de eerstegraads familieleden van deze paren 2;3. Het feit dat dit 
overlevingsvoordeel aantoonbaar is tot in de hoogste leeftijdscategorieën, suggereert de 
betrokkenheid van genetische factoren. De omgevingsfactoren die op jonge leeftijd gelijk zijn 
voor de leden van een broer- en zuspaar, zullen met het ouder worden immers sterk gaan 
verschillen 4. 
 
Een andere belangrijke indicator van uitgestelde veroudering is, behalve sterfte, de hogere leeftijd 
waarop verouderingsziekten optreden 5. De incidentie van ziekten neemt toe met de leeftijd en 
ziekten zijn een belangrijke oorzaak voor sterfte 6. Wij hebben gevonden dat de kinderen van 
deelnemers van negentig jaar en ouder een aanzienlijk kleinere kans hebben op een myoinfarct, 
hypertensie en vooral diabetes mellitus type II (hoofdstuk 2) 2. Onze uitkomsten komen overeen 
met eerdere studies waarin werd aangetoond dat kinderen van ouders die een uitzonderlijke hoge 
leeftijd hebben bereikt een lagere ziekte prevalentie hadden dan kinderen van ouders die op 
jongere leeftijd waren overleden 7;8. Echter, in deze eerdere studies waren er significante 
verschillen in cardiovasculaire risicofactoren tussen de groepen, waaronder aantal jaren educatie 
en rookgedrag. Het exacte aandeel van genetica, gedrag en leefstijl bleef daarom lastig te bepalen. 
Aangezien honderdjarigen er over het algemeen gezonde levenswijzen op na houden, kunnen hun 
kinderen dit gedrag hebben overgenomen 9. Om mogelijke confounding door verschillen in 
omgevingsfactoren uit te sluiten, hebben wij de kinderen van langlevende personen vergeleken 
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met hun partners in de Leiden Langleven Studie. Aangezien kinderen en hun partners merendeels 
blootstaan aan de zelfde omgevingsfactoren, namen wij aan dat eventuele verschillen tussen beide 
groepen niet konden worden verklaard door verschillen in omgevingsfactoren. Inderdaad waren 
de belangrijkste maten voor leefstijl gelijk voor beide groepen, zoals de geschatte BMI, huidige 
rookgedrag en het daaraan gerelateerde vóórkomen van COPD. Hieruit volgt dat eventuele 
verschillen in gezondheidstoestand tussen beide groepen eerder verklaard moeten worden uit 
(epi)genetische factoren dan uit omgevingsfactoren 2;10.  
  
Wij hebben geen verschil gevonden in het vóórkomen van kanker noch de sterfte door kanker 
tussen de kinderen en hun partners. Deze uitkomst komt niet overeen met eerder onderzoek 
waaruit bleek dat kinderen van honderdjarigen een lagere kans hadden om te sterven aan kanker 
in vergelijking met controles 11. Dit verschil kan misschien verklaard worden door een 
leeftijdsverschil: de deelnemers in de Leiden Langleven Studie zijn gemiddeld ongeveer tien jaar 
jonger dan de deelnemers uit voornoemde studie. 
 
IGF/ insuline signaaltransductie   
De invloed van de evolutionair geconserveerde insuline/ insulin-like growth factor (IGF-1) 
signaaltransductie (IIS) route op veroudering is uitvoerig beschreven in wormen 12, fruitvliegen 13 
en knaagdieren 14;15. Genetische mutaties die de IIS gedeeltelijk remmen, verlengen de levensduur 
van deze organismen en vooral bij het vrouwelijk geslacht. Ongewervelde organismen hebben 
een enkele insuline/IGF-1 receptor,  waaraan verscheidene liganden binden. Zoogdieren hebben 
aparte receptoren ontwikkeld voor insuline en IGF-1 met gedeeltelijk overlappende functies. IGF- 
is betrokken bij groei terwijl insuline de stofwisseling stuurt 16. 
Het belangrijkste kenmerk dat langlevende zoogdieren delen met langlevende mutanten 17 
waaronder de mutanten met geïnduceerde IGF resistentie, is insuline gevoeligheid en lage 
nuchtere bloedsuikerspiegels. Insuline gevoeligheid is ook nauw gerelateerd met een lager sterfte 
risico in zoogdieren tijdens caloriebeperking. De bevindingen in de Leiden Langleven Studie 
suggereren dat insuline gevoeligheid ook een rol speelt bij langlevendheid in de mens. 
Ten eerste hebben de kinderen van negentigjarigen relatief lagere bloedsuikergehaltes en 
bloedinsulinegehaltes (hoofdstuk 7) 18. Daarnaast hebben zij een gunstiger glucose tolerantie 
zoals blijkt uit de orale glucose tolerantietest (hoofdstuk 3) 10. Voorlopige gegevens suggereren 
dat dit fenotype ook aanwezig is in de hoogste leeftijdscategorieën (figuur 1). Opmerkelijk 
genoeg, vonden wij tussen de studiepopulaties geen verschillen in de klassieke risicofactoren voor 
insuline-resistentie zoals lichaamsbeweging, voedingsgewoontes, subklinische ontsteking 
(hoofdstuk 5). Ten tweede, kwam in de groep kinderen van negentigjarigen minder vaak het 
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metabool syndroom voor (hoofdstuk 3) 10, een combinatie van cardiovasculaire risicofactoren 
waaraan mogelijk insulineresistentie ten grondslag ligt. Als we kijken naar de verschillende 
onderdelen van het metabool syndroom, bevatte de groep kinderen van de negentigjarigen minder 
personen met een laag HDL en minder personen met een gestoorde nuchtere bloedsuikergehalte. 
Het aantal personen dat voldeed aan obesitas gerelateerde criteria, waaronder buikomtrek en 
nuchtere triglyceridewaarde, verschilde niet tussen de twee groepen. Ten slotte, waren de 
kinderen van negentigjarigen gevoeliger voor insuline. Deze insulinegevoeligheid uitte zich in 
een versnelde perifere glucoseopname zoals gemeten tijdens een hyperinsulinemische 
euglycemische clampstudie (hoofdstuk 4). De hyperinsulinemische euglycemische clampstudie 
geldt als de gouden standaard voor het bepalen van insuline gevoeligheid. Aan de hand van deze 
methode stelden wij vast dat het effect van insuline op de suikerstofwisseling en met name de 
glucoseopname kinderen van langlevende ouders onderscheidt van controles. Het effect van 
insuline op de onderdrukking van glucoseproductie of lipolyse speelt hierbij een ondergeschikte 
rol. Het gevonden effect van insuline op de perifere glucoseopname strookt met eerdere 
onderzoeken naar de pathofysiologie van diabetes mellitus II. Perifere insuline ongevoeligheid 
wordt beschouwd als één van de eerste stadia in de ontwikkeling van diabetes 19;20, en is al 
tientallen jaren aanwezig voordat de ziekte zich openbaart 21;22. onderdrukking van de 
glucoseproductie in de lever is een gevolg van vetopstapeling in de lever 23, en betreft een laat 
stadium in de ontwikkeling van diabetes 20.  
 
Figuur 1. Niet nuchter bloedsuikergehalte (A) en logaritmische bloedinsulinegehaltes (B) in familiaire 
negentigjarigen (N=333) en sporadische negentigjarigen (N=49), negentigjarigen zonder negentigjarige 
zus of broer.  Om eventuele verschillen in gezondheidstoestand tussen de twee groepen uit te sluiten, zijn 
alleen negentigjarigen uit het hoogste tertiel van ADL scores (Activiteiten van het Dagelijks Leven) 
geïncludeerd. De staven stellen de gemiddelde bloedgehaltes voor met de standaardfout van het 
gemiddelde gecorrigeerd voor leeftijd en geslacht.  
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Onze bevindingen komen overeen met eerdere onderzoeken die aantoonden dat  kinderen van 
uitzonderlijk langlevende ouders beschermd zijn tegen cardiovasculaire aandoeningen 11;24;25. 
Eerder werd al aangetoond dat kinderen van langlevende ouders in veel opzichten gezonder zijn: 
kinderen van langlevende ouders hadden bijvoorbeeld een gunstiger lipidenprofiel 26;27;28. Wat 
betreft de suikerstofwisseling was dit nog niet aangetoond. Terwijl insuline gevoeligheid 
gewoonlijk afneemt met de leeftijd, blijken honderdjarigen een insuline gevoeligheid te hebben 
die vergelijkbaar is met die van jong volwassenen 29. Onze resultaten vormen een aanvulling op 
deze eerdere observaties door te laten zien dat in langlevende families de gunstige 
suikerstofwisseling al op middelbare leeftijd aanwezig is.  
Behalve behoud van insulinegevoeligheid is uitzonderlijke langlevendheid bij mensen 
waarschijnlijk ook geassocieerd met een onderdrukking van de IGF-1 signaal transductie. 
Onlangs is aangetoond dat in honderdjarigen vaker bepaalde zeldzame genetische varianten van 
de IGF-1 receptor voorkomen die gepaard gaan met een hogere IGF-1/IGFBP-3 ratio en met een 
lagere IGF-1 signaal transductie 30. Eerder is al aangetoond dat veelvoorkomende genetische 
variaties met betrekking tot de IGF-1 signaal transductie mogelijk bijdragen aan de verschillen in 
sterfte in de algemene bevolking 30;31. Wij vonden ook voorlopige aanwijzingen dat verminderde 
IGF-1 signaal transductie betrokken is bij familiare langlevendheid. Wij maten lagere IGF-1 
gehaltes bij negentigjarige vrouwen wier ouders een uitzonderlijk hoge leeftijd hebben bereikt in 
vergelijking met negentigjarigen wier ouders op jongere leeftijd waren overleden (hoofdstuk 7). 
Een ander belangrijk kenmerk van een levenslang onderdrukte IGF-1 signaal transductie in zowel 
mensen als modelorganismes is de relatief kleinere lengte. In overeenstemming hiermee waren 
negentigjarigen wier ouders uitzonderlijk oud werden doorgaans kleiner dan controles wier 
ouders jonger overleden. 
De resultaten in de groep negentigjarigen wijken af van de bevindingen in de groep kinderen 
(hoofdstuk 6). Wij vonden geen significante verschillen in IGF-1 bloedspiegels noch verschillen 
in lengte tussen de kinderen en hun partners 18. Daarnaast waren de groeihormoon gehaltes in het 
bloed na één nacht vasten gelijk tussen de twee groepen (tabel 1).  Deze tegenstrijdige resultaten 
kunnen misschien verklaard worden door een leeftijdsverschil. De geschatte bijdrage van 
genetische factoren aan langlevendheid is bescheiden (20-30%) maar neemt toe met de leeftijd. 
Daarom is het mogelijk dat het effect van genetische variabiliteit in de IIS pas op latere leeftijd 
merkbaar wordt. De associatie tussen FOXO3A en langlevendheid was bijvoorbeeld sterker in 
honderdjarigen dan in negentigjarigen 32. Een andere mogelijke verklaring zijn verschillen in 
imprinting van het IGF-1 gen, mogelijk ten gevolge  van historische verschillen in voeding tussen 
de twee generaties 30;33.  
Appendix A: General discussion and synopsis in Dutch Part A 
 191 
Tabel 1. Nuchtere, hormonale serum waarden voor kinderen en partners 
Data zijn weergegeven als gemiddelde waarden met een 95% betrouwbaarheidsinterval. TSH, 
groeihormoon and high-sensitivity C-reactive protein (hsCRP)  zijn weergegeven als geometrisch 
gemiddelde met een 95% betrouwbaarheidsinterval. Serum is afgenomen om 9:00 – 09:30 in de 
ochtend. Data zijn gecorrigeerd voor leeftijd en geslacht. 
Schildklierfunctie 
De hypothalamus-hypofyse-schildklier-as speelt waarschijnlijk een zeer belangrijke rol in het 
verouderingsproces 34. Het levensverlengend effect van een lager schildklierhormoongehalte is 
beschreven in verschillende diermodellen. Het veroorzaken van hypothyreoïdie bij neonatale 
ratten heeft een lichte toename van de levensduur tot gevolg 35. Lage schildklierhormoonspiegels 
zijn bovendien kenmerkend voor langlevende muismodellen met mutaties in de hypofyse. De 
langlevende Ames- en Snelldwergmuizen vertonen kenmerken die waarschijnlijk te maken 
hebben met schildklierhormoon tekort 36. In proefpersonen van vijfentachtig jaar en ouder zijn 
hogere thyrotropinespiegels gerelateerd met een overlevingsvoordeel zonder gevolgen voor het 
functioneren of de stemming 37;38.  
 
Ook in de Leiden Langleven Studie vonden we een relatie tussen vertraagde schildklierfunctie en 
toegenomen levensduur. Negentigjarige kinderen van ouders die een uitzonderlijk hoge leeftijd 
hebben bereikt, hadden hogere thyrotropinespiegels, lagere thyroxinespiegels en lagere 
 Kinderen Partners P-waarde 
Deelnemers (N) 121 113  
Vrouwen (N, %) 62 (51.2%) 59 (48.8%) 0.90 
    
TSH (mU/L) 2.41 (1.93 -  3.06) 1.69 (1.33 – 2.15) 0.029 
Vrij T4(pmol/L) 16.2 (15.8 – 16.6) 16.4 (16.0 – 16.9) 0.49 
Vrij T3 (pmol/L) 5.03 (4.87 – 5.20) 5.26 (5.09 – 5.44) 0.045 
    
Groei hormoon (mU/L) 1.90 (1.50 – 2.40) 2.02 (1.58 – 2.57) 0.72 
IGF-1 (nmol/L) 15.3 (14.3 – 16.2) 15.0 (14.1 – 16.0) 0.71 
IGFBP3 (mg/L) 4.03 (3.85 – 4.21) 3.98 (3.79 – 4.16) 0.63 
    
Cortisol (µmol/L) 0.49 (0.47 – 0.52) 0.52 (0.49 – 0.55) 0.22 
    
Prolactine (U/L) 10.1 (9.28 – 10.9) 10.3 (9.51 – 11.2) 0.64 
    
HsCRP (mg/dL) 1.29 (1.17 – 1.60) 1.17 (0.93 – 1.46) 0.45 
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triiodothyroninespiegels in vergelijking met negentigjarigen wier ouders op jongere leeftijd 
overleden (hoofdstuk 9) 39. De tragere schildklierfunctie in negentigjarigen was ook aantoonbaar 
in de kinderen van middelbare leeftijd. De kinderen van middelbare leeftijd hadden lagere 
perifere schilklhormoonspiegels en neigden tot hogere thyrotropinespiegels in vergelijking met 
hun partners onder nuchtere (hoofdstuk 8) 40 en niet-nuchtere omstandigheden (tabe1 1). Deze 
observaties suggereren dat een verminderde activiteit van schildklieras een overerfbaar fenotype 
is dat bijdraagt aan buitengewone langlevendheid. 
 
Verminderde activiteit van de schildklieras is mogelijk een manier om energiebesteding  te 
herverdelen van groei en proliferatie naar onderhoud. Schildklierhormonen regelen in de eerste 
plaats het basaal metabolisme van cellen en zodoende de aanmaak van warmte en vrije radicalen 
41. Studies in modelorganismen laten zien dat lagere triiodothyroninespiegels geassocieerd zijn 
met verminderde aanmaak van zuurstofradicalen 42. Efficiënter transport van elektronen via het 
mitochondrieel membraan bij een lager schildklierhormoongehalte vermindert mogelijk de 
aanmaak van zuurstofradicalen en vertraagt zo het verouderingsproces.  
 
Onze studie liet lagere schildklierspiegels zien in personen uit langlevende families. Het 
vóórkomen van subklinische hypothyreoïdie en subklinische hyperthyreoïdie neemt snel toe met 
de leeftijd 43. De precieze definitie van subklinische hypothyreoïdie en de noodzaak om 
leeftijdspecifieke normaalwaarden te ontwikkelen voor thyrotropine is momenteel punt van 
discussie.  
 
Thyrotropinespiegels stijgen geleidelijk met de leeftijd. Recentelijk is aangetoond dat deze 
stijging zich voortzet tot in de hoogste leeftijdscategorieën 44. De hogere thyrotropinespiegels op 
oudere leeftijd zijn mogelijk het resultaat van selectieve overleving van individuen met een 
aangeboren tragere schildklierfunctie 37. Daarnaast kan een verandering in de schildklierfunctie 
met de leeftijd enerzijds het gevolg zijn van een opeenstapeling van schade. Anderzijds kunnen 
afwijkingen in de schildklierfunctie onderdeel zijn van een adaptief mechanisme in weerwoord op 
verzamelde schade om zo verdere pathologie te beperken. De huidige aanbeveling luidt om bij 
ouderen met subklinische hypothyreoïdie schildklierhormoon te suppleren. In het licht van 
voorgaande overwegingen blijft de behandeling van de leeftijdsgerelateerde hormonale 
afwijkingen echter omstreden. Hoewel pathologische afwijkingen baat zouden hebben bij 
behandeling, geldt dit niet voor een aangeboren vertraagde schildklierfunctie of voor afwijkingen 
die onderdeel uitmaken van een adaptieve respons.  
Appendix A: General discussion and synopsis in Dutch Part A 
 193 
Behalve een stijging in de thyrotropinewaardes doen zich met de leeftijd andere veranderingen 
voor in de schildklieras. In hoofdstuk 10 laten wij een wederzijds verband zien tussen serum 
triiodothyroninespiegels en serum inflammatoire cytokines. Hoge spiegels van inflammatoire 
cytokines zijn geassocieerd met lagere vrije triiodothyroninespiegels. Dit suggereert dat bij  
inflammatie, de activiteit van de schildklieras wordt geremd. Dit gebeurt mogelijk door een 
verminderde conversie van thyroxine naar triiodothyronine. 
 
Conclusie 
Terwijl de gemiddelde levensverwachting blijft stijgen, nemen ook het aantal jaren dat in slechte 
gezondheid wordt doorgebracht toe. Het vinden van mogelijke aangrijpingspunten voor 
interventies is noodzakelijk om leeftijdsgerelateerde aandoeningen en achteruitgang van 
functioneren tegen te gaan. Bestudering van het fenotype bij mensen die gepredisponeerd zijn 
voor een langer leven kan hiervoor aanwijzingen bieden. Als we aannemen dat de eigenschappen 
die leiden tot een langer leven overerfbaar zijn, dan kunnen de kinderen van uitzonderlijk 
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Deel B: over het bepalen van de snelheid van veroudering 
Verschillende experimenten in modelorganismen laten een verlenging in de gemiddelde en 
maximale levensduur zien. Wanneer de overlevingscurve echter wordt weergegeven op een 
semilogaritmische schaal, blijkt deze parallel te zijn verschoven ten opzichte van de 
overlevingscurve van de controlegroep. De gangbare interpretatie van de Gompertz parameters is 
dat de snelheid van veroudering hiermee niet positief is beïnvloed. In hoofdstuk 12 stellen wij de 
raaklijn aan de overlevingscurve voor als een alternatief voor het bepalen van de snelheid van 
veroudering. Deze benadering levert verschillende snelheden van veroudering op bij een 
constante parameter G. In hoofdstuk 13 hebben wij de deze benadering empirisch getoetst in een 
populatie van nierpatiënten, een populatie patiënten die versneld verouderen. Afschatting van de 
snelheid van veroudering aan de hand van de eerste afgeleide van de Gompertz curve, laat onder 
wisselende omstandigheden verschillende snelheden van veroudering zien, in tegenstelling tot 
gebruik van parameter G als benadering voor de verouderingsnelheid, waarbij de snelheid van 
veroudering constant blijft. Bij bepaling van de snelheid van veroudering raden wij daarom de 
eerste afgeleide van de Gompertz curve aan.
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